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 V 
RIASSUNTO 
 
TRAP1 è uno chaperone molecolare con funzione antiapoptotica, 
identificato in seguito ad analisi di mRNA-differential display effettuate in 
cellule adattate allo stress ossidativo. L’obiettivo principale della mia tesi di 
dottorato è stato quello di caratterizzare l’interazione fra TRAP1 e 
TBP7/Rpt3, una ATPasi appartenente alla subunità regolatoria 19S del 
proteasoma, identificata come putativo ligando di TRAP1 in seguito ad 
analisi di spettrometria di massa. Esperimenti di coimmunoprecipitazione ed 
analisi di FRET (trasferimento di energia fluorescente in risonanza) 
dimostrano che TRAP1 e TBP7 sono localizzati sul versante citoplasmatico 
del reticolo endoplasmatico (ER), e che proprio in tale compartimento 
interagiscono; questa è la prima dimostrazione della localizzazione 
reticolare di TRAP1. La presenza di queste due proteine nell’ER lascia 
presupporre un loro ruolo nell’omeostasi di tale organello; il silenziamento 
di TRAP1  e di TBP7, infatti, sensibilizza le cellule HCT116 allo stress del 
reticolo indotto da tapsigargina, causando un incremento dell’espressione 
dello chaperone stress- indotto Bip/Grp78, e causa un notevole aumento 
dell’ubiquitinazione cellulare, specialmente nei compartimenti extra- 
mitocondriali. L’azione sul controllo di qualità esercitato da TRAP1 e TBP7 
è particolarmente evidente su specifiche proteine destinate al mitocondrio, 
Sorcina 18 e la subunità ß del complesso F1ATPasi, i cui livelli sono 
diminuiti in assenza di TRAP1 a causa del loro aumentato livello di 
ubiquitinazione. Questo meccanismo assume un impatto ancora più 
rilevante dal momento che la co-regolazione TRAP1-dipendente di substrati 
specifici è ritrovata anche in campioni di tessuti tumorali prelevati da 
carcinomi colon-rettali, in cui TRAP1 risulta iperespresso rispetto alle 
relative mucose sane. 
L’interazione TRAP1/TBP7 sull’ER apre nuovi scenari relativi al controllo 
di qualità delle proteine destinate al mitocondrio, e suggerisce che tale 
controllo possa avvenire all’interfaccia tra i due organelli; se le proteine 
neo-sintetizzate  sono non correttamente ripiegate, danneggiate o mis-
localizzate, vengono riconosciute dal complesso TRAP1/TBP7, ubiquitinate 
ed indirizzate al proteasoma per la degradazione. 
 
 
 
 
 VI 
SUMMARY 
TRAP1 is an antiapoptotic heat shock protein, identified through an mRNA-
differential display analysis in oxidants- adapted osteosarcoma cells. The 
main objective of my PhD thesis has been the characterization of the 
interaction between TRAP1 and TBP7 (S6-ATPase 4/Rpt3), a component of 
the 19S proteasome regulatory subunit, one of the putative TRAP1 
“partners” identified by our LC-MS/MS analysis. I demonstrated that 
TRAP1 and TBP7 are located in the endoplasmic reticulum (ER), on the 
outer side of this compartment; they directly interact in the ER, as 
demonstrated by coimmunoprecipitation experiments and by FRET 
analysis. The information available on the TRAP1 pathway describes just a 
few well-characterized functions of this protein in mitochondria. This is the 
first demonstration of TRAP1’s presence in this cellular compartment. 
Given the ER localization of TRAP1 and TBP7,  the involvement of these 
two proteins in ER homeostasis has been investigated. TRAP1silencing by 
short-hairpin RNAs, in cells exposed to thapsigargin-induced ER stress, 
correlates with upregulation of BiP/Grp78, thus suggesting a role of TRAP1 
in the refolding of damaged proteins and in ER stress protection. 
Consistently, TRAP1 and/or TBP7 interference enhanced stress-induced cell 
death and increased intracellular protein ubiquitination. These experiments 
led us to hypothesize an involvement of TRAP1 in protein quality control 
for mistargeted/misfolded mitochondria-destined proteins, through 
interaction with the regulatory proteasome protein TBP7. Remarkably, 
expression of specific MITO proteins decreased upon TRAP1 interference 
as a consequence of increased ubiquitination. The proposed TRAP1 network 
has an impact in vivo, as it is conserved in human colorectal cancers, is 
controlled by ER-localized TRAP1 interacting with TBP7 and provides a 
novel model of the ER–mitochondria crosstalk. 
The data described in my thesis on the functional characterization of 
TRAP1/TBP7 interaction allowed us to draw the following hypopthesis: 
when neo-synthesized proteins are damaged, they are not imported into 
mitochondria, but sequestered by TRAP1 to be  refolded/ repaired; if this 
attempt fails, these substrates are ubiquitinated, recognised by the regulatory 
subunits of proteasome to which TBP7 belongs, and delivered to the 
proteolytic core for degradation.  
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1 INTRODUCTION 
1.1  TRAP1 
The cellular chaperone machinery consists of several protein families 
that facilitate polypeptide folding in vivo and prevent misfolding and 
aggregation. Members of these protein families are often known as stress 
proteins or heat-shock proteins (HSPs), as they are upregulated under 
conditions of stress in which the concentrations of aggregation-prone 
folding intermediates increase. Chaperones are usually classified according 
to their molecular weight (HSP40, HSP60, HSP70, HSP90, HSP100 and the 
small HSPs). They are involved in a multitude of proteome-maintenance 
functions, not only de novo folding, or refolding of stress-denatured 
proteins, but even oligomeric assembly, protein trafficking and assistance in 
proteolytic degradation.  
Among these, TRAP1 was first identified as an Hsp90-like chaperone by 
screening for proteins associated with the cytoplasmic domain of the type 1 
Tumor Necrosis Factor Receptor-1 (TNFR1) using the yeast two-hybrid 
system (1). In an independent yeast two hybrid screen, an Hsp90-like 
protein of ~75 kD, designated as Hsp75, was also identified that bound the 
Retinoblastoma (Rb) protein (2). Sequence analysis later determined that 
TRAP1 and Hsp75 were identical molecules. Through a mRNA-differential 
display analysis between oxidant-adapted and control osteosarcoma cells, 
our group identified, among other proteins, TRAP1 whose expression was 
highly induced upon oxidant adaptation (3).  
Interestingly, our group recently demonstrated that stable and transient 
transfectants containing high TRAP1 levels: (i) are more resistant to both 
H2O2-induced DNA damage and to the apoptosis induced by cisplatin 
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(CDDP) and other apoptotic stressors; (ii) don’t release apoptosis-inducing 
factors from mitochondria upon CDDP treatment; (iii) show decreased  
caspase 3 activation; (iv) contain higher reduced glutathione levels than 
control cells, which probably contributed to their oxidant-resistant 
phenotype (4).  
Furthermore, TRAP1 exhibited antiapoptotic functions (4), while an 
involvement of this chaperone in the multi-drug resistance of human 
colorectal carcinoma (CRC) cells was also established (5), according to the 
observation that adaptation to oxidative stress is a phenomenon deeply 
linked to  drug resistance to antitumor agents. Moreover, recent data identify 
TRAP1 as a novel mitochondrial survival factor differentially expressed in 
localized and metastatic prostate cancer compared with normal prostate, 
suggesting that TRAP1 could be a novel therapeutic target to enhance tumor 
cell apoptosis (6).  Indeed, TRAP1 and HSP90 were recently described as 
components of a mitochondrial pathway selectively up-regulated in tumor 
cells which antagonizes the proapoptotic activity of cyclophilin D (CypD), a 
regulator of the mitochondrial permeability transition pore (PTP) and 
responsible for the maintenance of mitochondrial integrity, thus favoring 
cell survival (7).  
A major objective of our research group is the investigation of the molecular 
mechanisms responsible for TRAP1 protection from apoptosis and its role 
in drug resistance, with the attempt to characterize TRAP1 pathway as a 
novel molecular target for cancer therapy. In such a perspective, among 
several TRAP1 “ligands”, recently identified by mass spectrometry analysis, 
we selected two proteins for further studies, whose interaction with TRAP1 
is involved in chemioresistance, endoplasmic stress (ER) stress protection 
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and regulation of protein quality control, functions all proposed as  novel 
approaches for cancer therapy.  
A “fishing for partners” strategy combined with liquid chromatography- 
mass spectrometry analysis (LC-MS/MS) was carried out to identify TRAP1 
protein partners specifically interacting with the bait. Among all the putative 
ligands, our group selected two proteins for further investigation: the first 
one is a protein of ∼18 kDa identified as Sorcin by LC-MS/MS, a Calcium 
(Ca2+) binding protein involved in the regulation of intracellular Ca2+ 
homeostasis (8). It was identified as overexpressed in a proteomic screening 
in gastric cancer cell lines and in chemioresistant tumor cells  (9, 10). The 
involvement of Sorcin in chemioresistance and cell survival and the 
importance played by calcium in the regulation of PTP opening in 
mitochondria as well as in global cellular homeostasis prompted us to 
investigate the functional role of TRAP1-Sorcin interaction in colon cancer 
cells. 
As previously anticipated research activity during my PhD course also 
focused on the study of a second TRAP1 ligand identified by mass 
spectrometry, the Tat- binding protein 7 TBP7, a component of 19S 
regulatory proteasomal subunit (11).  The identification of novel pathways 
for protein quality control, likely altered in tumor cells, in which 
TRAP1/TBP7 could be involved moved our interest in investigating this 
interaction. 
 
1.2 CHAPERONES AND PROTEIN QUALITY CONTROL  
Eukaryotic cells must face with a continuous stream of misfolded 
proteins that compromise the balance of cellular protein homeostasis and 
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cell viability. An elaborate network of molecular chaperones and protein 
degradation factors continually monitors and maintains the integrity of the 
proteome. Cellular protein quality control relies on distinct yet 
interconnected strategies whereby misfolded proteins can either be refolded, 
degraded, or delivered to distinct quality control compartments that 
sequester potentially harmful misfolded species. Molecular chaperones play 
a critical role in determining the fate of misfolded proteins in the cell (12).  
Mammalian cells typically express in excess of 10,000 different protein 
species, which are synthesized on ribosomes as linear chains of up to several 
thousands amino acids. To function, these chains must generally fold into 
their “native state”, an ensemble of a few closely related three-dimensional 
structures. How this is accomplished and how cells ensure the 
conformational integrity of their proteome in the face of acute and chronic 
challenges constitute one of the most fundamental and medically relevant 
problems in biology. Central to this problem is that proteins must retain 
conformational flexibility to function, and thus are only marginally 
thermodynamically stable in their physiological environment. A substantial 
fraction of all proteins in eukaryotic cells (20–30% of the total in 
mammalian cells) even seems to be inherently devoid of any ordered three-
dimensional structure and adopt folded conformations only after interaction 
with binding partners. Aberrant behaviour of some of these metastable 
proteins, such as τ and α-synuclein, can give rise to the formation of fibrillar 
aggregates that are associated with dementia and Parkinson’s disease (12).  
Since the number of possible conformations that a protein chain can adopt is 
very large, folding reactions are highly complex and heterogeneous (Fig.1); 
partially folded or misfolded states are problematic because they tend to 
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aggregate in a concentration-dependent manner. The formation of these 
aggregates in vivo is strongly restricted by the chaperone machinery, 
suggesting that they may become more widespread under stress or when 
protein quality control fails; molecular chaperones typically recognize 
hydrophobic amino-acid side chains exposed by non-native proteins and 
may functionally cooperate with other co-chaperones, such as the small 
HSPs, which function as ‘holdases’, buffering aggregation (12). The 
translation process is the first step in which proteins are exposed to the risk 
of misfolding or aggregation, because an incomplete nascent polypeptide is 
unable to fold into a stable native conformation and the local concentration 
of nascent chains in the context of polyribosomes is very high; since 
partially synthesized nascent chains are particularly prone to aggregation, 
the presence of molecular chaperones that interact directly with the 
ribosome near the exit tunnel provides an important link between translation 
and protein folding. Mistranslated and misfolded proteins may be 
detrimental for the cell and need to be removed at an early stage, but, to 
date, the mechanisms and coordination between translation and quality 
control remain poorly understood, except for the observation that members 
of HSP70 family seem to be involved even in higher eukaryotes (13).  
 
Figure 1: Role  of molecular chaperones in the balance of folding, degradation and 
aggregation.  Molecular chaperones facilitate folding of newly synthesized polypeptides to 
the native state. Chaperones also bind to non-native intermediates that are generated when 
native proteins are denatured, for example by stress. Cellular surveillance results in either 
refolding or degradation. Under some circumstances, such as stress or aging, quality control 
efforts may fail; in these cases, misfolded proteins may form small soluble aggregates, 
which, if unresolved by refolding or degradation, go on to form heat- and detergent- 
resistant amyloidogenic aggregates. 
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1.3 UBIQUITIN-PROTEASOME SYSTEM (UPS) IN PROTEIN 
QUALIY CONTROL 
The elimination of misfolded proteins represents an important 
mechanism to maintain cell viability. This protein quality control involves 
the binding of a chaperone to the misfolded protein and its presentation to 
the ubiquitin-proteasome degradation pathway (14). Linking of ubiquitin to 
a protein is a highly controlled process that involves the sequential action of 
a ubiquitin- activating enzyme (E1), a ubiquitin conjugating enzyme (E2), 
and a ubiquitin ligase (E3). This enzymatic cascade results in the attachment 
of polyubiquitin chains onto specific lysine residues on the substrate; 
although several types of polyubiquitin chains have been reported, chains 
that are built on lysine 48 of ubiquitin serve as signal for recognition and 
degradation by 26S proteasome (Fig. 2). The 26S proteasome comprises two 
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main particles: the 20S core proteasome, in which proteins are cleaved and 
digested into short peptides,  and the 19S regulatory complex, that is 
responsible of recognition of ubiquitinated substrates. The 20S proteolytic 
core particle (CP) has a cylinder-like structure composed of a stack of two α 
and two β rings, whereas the 19S regulatory particle (RP) comprises a “lid” 
of eight non-ATPases and a “base” of six ATPases (Rpt1-Rpt6) and three 
non-ATPases. 19S ATPases provide the molecular chaperonin activity to 
the 19S RP; furthermore, 19S ATPase activity is essential for the assembly 
of the 26S proteasome complex and participates in the degradation of the 
proteins marked by a chain of more than four Lys-48-linked ubiquitin 
molecules. The lid of the 26S proteasome associates with the polyubiquitin 
chain, and subsequently the base unfolds the substrate protein in an ATP-
dependent manner, finally translocating it to the central chamber of the 20S 
CP for proteolysis (15).  
 
 
 
The UPS system is involved not only in degradation of yet translated 
damaged proteins, but even in quality control of nascent polypeptides 
emerging from ribosomes and not yet folded that can present signals similar 
Figure 2: The Ubiquitin- Proteasome 
System (UPS). After an ATP-dependent 
activation of an ubiquitin-molecule by 
E1 and binding of Ub to a cysteine 
residue of E1, Ub is transferred to E2,  
binding to a cysteine residue again,  
while E1 is released. After binding of 
E2-Ub to the E3-substrate complex, the 
Ub is transferred to a lysine-residue on 
the substrate protein. After many cicles, 
the substrate becomes polyubiquitinated, 
while both E2 and E3 are released.  
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to those recognized by the ubiquitin system in misfolded proteins or 
ubiquitin moieties; in fact, it has been estimated that up to 50% of newly 
synthesized proteins are cotranslationally degraded by the ubiquitin- 
proteasome system (16, 17), implying that efficient quality control 
mechanisms must exist that couple protein translation, protein folding and 
proteasomal degradation.  Moreover, it has been demonstrated that these 
nascent damaged proteins can be ubiquitinated while bound to ribosome, 
this indicating that exists a close coupling between protein synthesis and 
protein degradation (18). 
Furthermore, very recent findings suggest an association between the 
ribosomal apparatus, the eukaryotic elongation factor EF1A and the 
proteasome subunits Rpn10 and Rpt1, supporting the idea that proteasome 
plays an important role in cotranslational protein quality control (19); 
moreover, recent data obtained in yeast demonstrate the existence of a 
mechanism  that coordinates translation initiation, elongation, and quality 
control through the formation of an RNA independent supercomplex with 
eIFs, MSC, eEFs, ribosomes, and the proteasome, called “translasome” (20) 
(Fig. 3).  
 
Figure 3: The “translasome”. Eukaryotic initation factors, elongation factors, ribosomes, 
chaperones and proteasome associate with the nascent polypeptide to control its stability 
during translation, before the translated protein is released to reach the final destination. 
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1.4 QUALITY CONTROL AT ENDOPLASMIC RETICULUM (ERAD) 
The ER is an extensive network of cisternae and microtubules, which 
stretches from the nuclear envelope to the cell surface in all eukaryotic cells; 
it’s the largest organelle, with endomembrane accounting for more than 
50% of all the cellular membranes, and occupies a substantial part (> 10%) 
of the cell volume. The ER plays several vital functions. Firstly, the ER is 
the site of protein synthesis in the rough ER and correct post-translational 
“folding” of these proteins. Secondly, the ER serves as a common transport 
route by which numerous proteins are delivered to their destination. Thirdly, 
the ER acts as an indispensable source for fast physiological signaling being 
a dynamic calcium ions reservoir, which can be activated by both electrical 
and chemical cell stimulation (21).  
The ER provides an environment that is optimized for protein folding and 
maturation. It harbours three groups of molecular chaperones and folding 
enzymes: chaperones of the heat shock protein family, including Grp78/ BiP 
and its co-chaperone partners, chaperone lectins such as calnexin and 
calreticulin, and thiol oxidoreductases of the protein disulfide isomerase 
(PDI) family. Many of these chaperones interact with translocating nascent 
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polypeptide chains soon after their entry into the ER lumen and facilitate 
protein folding, oligomerization, maturation, and post-translational 
modifications, which may include glycosylation and disulfide bond 
formation (22). 
Substrate proteins are released from ER chaperones once their native 
structures are attained, and correctly folded and assembled proteins are 
transported from the ER. However, prolonged interactions of non-native 
proteins with ER chaperones and folding enzymes during chaperone-
mediated folding may well contribute to the retention of non-native proteins 
in the ER. When mis-folded proteins accumulate in the ER, ER chaperone 
binding reduces the concentration of free chaperones. To cope with the 
resulting ER stress, cells elicit an unfolded protein response (UPR). The 
UPR induces the transcription of gene products that facilitate the processing 
of aberrant proteins and that attenuate protein translation, which reduces the 
amount of newly imported proteins into the ER (23, 24).  One of the main 
responses elicited by ER stress is the overexpression of ER-resident 
chaperones, the Grp proteins (glucose- responsive proteins), like Grp78/ BiP 
and Grp94, that can be induced by stress conditions like perturbation of ER- 
calcium stores or inhibition of glycosylation. As these stress conditions 
generally lead to the accumulation of misfolded proteins in the ER, 
induction of Grp gene expression has been extensively used as a marker for 
the unfolded protein response (UPR)  (25). Pathological conditions such as 
tumor growth correlate with Grp78 and Grp94 overexpression (26, 27). This 
could be partly caused by the activation of Grp gene expression through 
glucose starvation, acidosis and hypoxia, which are hallmarks of the 
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microenvironment of poorly vascularized solid tumors and seem to 
represent the physiological stresses for Grp activation in vivo (28). 
In eukaryotes, endoplasmic reticulum-associated degradation (ERAD) 
functions in cellular quality control and regulation of normal ER-resident 
proteins (29). Protein folding in endoplasmic reticulum is monitored by 
UPS: in fact, when misfolded proteins are recognized as aberrant by luminal 
chaperone BiP and the repair fails, they are retrotranslocated, ubiquitinated 
and recognized by proteasome to be degraded (Fig. 4); this hypotesis is 
supported by the fact that polyubiquitination is necessary for the 
retrotranslocation process, and by the association of proteasome to the 
endoplasmic reticulum and by accumulation of ubiquitinated proteins on the 
cytoplasmic side of ER when the proteasome is blocked (30, 31).  
 
 
1.5 QUALITY CONTROL OF MITOCHONDRIAL PROTEINS 
Protein quality control in mitochondria is a still unclear issue because 
of the complexity of the organelle. The mitochondrion contains two 
membranes, the outer membrane (OM) and the inner membrane (IM); the 
later forms invaginations called cristae and contains the matrix where 
mitochondrial DNA resides. The space between the inner and outer 
Figure 4: Ubiquitin Proteasome 
System at ER. Damaged proteins in 
the ER are retrotranslocated, 
ubiquitinated and degraded via UPS. 
Failure in this quality control leads 
to ER stress, activating Unfolded 
Protein Response (UPR). 
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membranes is referred to as the intermembrane space (IMS) and contains 
several proteins, most of them are best known for their roles in the initiation 
of apoptosis upon their release from the mitochondria like cytochrome c, 
smac, HtrA2/Omi, and endonuclease-G. Protein quality control (PQC) 
inside mitochondria seems to exclude UPS, because it is mainly exherted by 
AAA-ATPases, the mitochondrial proteases that are responsible of 
degradation of misfolded-damaged proteins; furthermore, no evidences of 
the presence of proteasome have been reported in mitochondria (32). Recent 
findings suggest that ubiquitination may be involved in degradation of many 
OMM proteins (33) and of the IMM protein UCP3 (34) with a mechanism 
of ubiquitination and retrotranslocation that reminds ERAD pathways; in 
fact, upon inhibition of the proteasome, proteins accumulate in the 
mitochondria. Furthermore, these results raised the possibility that a 
proteasome-dependent PQC, exerted in concert with chaperones, normally 
acts to limit the import of excess or misfolded mitochondrial proteins. In 
agreement with this possibility, the accumulation of mitochondrial proteins 
and the appearance of electron-dense mitochondria was also reported 
following treatment with an inhibitor of the chaperone HSP90 (35). 
Interestingly, a quality control for one of the nuclear-encoded mitochondrial 
proteins, that have to be imported to the final destination, requires the 
ubiquitin-proteasome system outside the mitochondria. Data presented by 
Radtke et al (36) support the hypotesis that misfolded IMS proteins, like the 
IMS protein endoG, are ubiquitinated and eliminated in the cytoplasm prior 
to their import into the mitochondria, indicating presence of a PQC that 
monitors the folding state of proteins targeted to the IMS of the 
mitochondria. This PQC appears to act prior to the import into the IMS 
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based on the observation that deletion of the mitochondrial targeting signal 
did not abolish the ubiquitination of mutant endoG (Fig. 5). Is still unclear if 
this pre-import quality control happens at MAMs (mitochondrial associated 
membranes), points of contact between ER and mitochondria that could 
couple synthesis, import and quality control of mitochondria destined 
proteins. 
Figure  5 :The emerging role of UPS in quality control of mitochondrial proteins. 
Proteins of OMM are retrotranslocated, than ubiquitinated and degraded by UPS in an 
ERAD- like mechanism. For other mitochondrial proteins, a pre- import quality control via 
ubiquitin has been  recently suggested. 
 
 
 
1.6 AIM OF THE PROJECT  
Disorders of protein folding and degradation are emerging as 
fundamental mechanisms in the pathogenesis of many diseases. Many 
studies raise the intriguing possibility that quality-control pathways may 
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unexpectedly have a role in tumour progression (37). In this context the 
identification of TBP7, a regulatory proteasome subunit particle, as TRAP1-
interacting protein, appears a very suitable tool to further analyze a novel 
pathway contributing to cancer biology. 
The aim of my PhD research is a structural and functional  characterization 
of the interaction between TRAP1 and its putative ligand TBP7. Given the 
well known role exerted by TRAP1 in the protection against stress and 
apoptosis, and the involvement of TBP7 and the proteasome in the 
cleareance of misfolded proteins, the characterization of this interaction in 
the endoplasmic reticulum could elucidate the molecular pathways that link 
PQC, UPR and cell survival (Fig. 6). This novel TRAP1 regulatory function 
may be relevant for its antiapoptotic activity and involvement in drug 
resistance in human malignancies. Indeed, the proteotoxic stress generated 
by accumulation of misfolded proteins and the consequent heat shock 
response is currently under evaluation as a potential anticancer treatment 
target (38), since many tumor cells display constitutive proteotoxic stress 
and dependence on heat shock response due to their rapid rates of 
proliferation and translation. 
 
Figure 6: Protein quality 
control, UPR and cell survival  
An unbalance between 
synthesis and degradation could 
lead to accumulation of 
misfolded proteins:  a cell can 
responde and return to a 
physiological situation,  or can 
activate apoptotic pathways , or 
can overwhelm misfolding thus 
becoming tumorigenic. 
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2 MATERIALS AND METHODS 
2.1 Cell culture, plasmids generation and  transfections procedures 
HCT116 cells were cultured in DMEM supplemented with 10% fetal 
bovine serum (FBS) in standard conditions. Full-length TRAP1 and Sorcin 
expression vectors were obtained as described elsewhere (39). Mutant Δ1-
59-Myc was generated with the following primers: 
Δ59-myc Fw: 
5' - ATTAGAATTCATGAGCACGCAGACCGCCGAGG - 3'; 
Δ59-myc Rv: 
3' - ATTACTCGAGGTGTCGCTCCAGGGCCTTGA - 5'. 
PCR-amplified fragments were gel-purified and cloned in frame into 
pCDNA 3.1 plasmid (INVITROGEN) at the Eco-RI and XhoI restriction 
sites. 
Mutant Δ101-221- HA was generated using the following primers: 
TRAP1-HA fw: 
5’-atta GCGGCCGCGCAGCCAACATGGCGCGCGAGCCTGCGGG-3’; 
TRAP1-HA  rev:  
5’attaTCTAGATTAAGCGTAATCTGGAACATCATATGGGTATCAGT
GTCGCTCCAGGGCCTTGA-3’; 
ΔATPase-HA fw 221: 5‘-atta CCGCGGTCGGCAGCCCCGGGGAGCCT-
3’; 
ΔATPase-HA 110 rev: 5’-atta CCGCGGAAACACCTCTTTTTCTGAGT-
3’. 
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The PCR products obtained with the primers TRAP1-HA fw and ΔATPase-
HA rev were cloned in pRc-CMV vector (INVITROGEN); the PCR product 
obtained with the primers ΔATPase-HA fw and TRAP1-HA rev was 
subcloned in the same plasmid. All clones were sequenced to confirm 
identity and PCR fidelity. 
 The plasmid pCMV5L/S6 (TBP7-HA) was a kind gift of Dr. Simon 
Dawson, University of Nottingham. Transient transfection of DNA plasmids 
was performed with Polyfect Transfection reagent (Qiagen, Milan, Italy). 
siRNAs of TRAP1 and TBP7 were purchased from Qiagen, Milan, Italy 
(Cat. No. S100301469 for TBP7, SI00115150 for TRAP1). For knockdown 
experiments, siRNAs were diluted to a final concentration of 20 nmol/L and 
transfected according to the manufacturer's protocol. For control 
experiments, cells were transfected with a similar amount of scrambled 
RNA (Qiagen, Milan, Italy, Cat. No. SI03650318). Transient transfections 
of siRNAs were performed by using HiPerFect Transfection Reagent 
(Qiagen, Milan, Italy). TRAP1-stable interference was achieved by 
transfecting HCT116 cells with TRAP1 
(TGCTGTTGACAGTGAGCGACCCGGTCCCTGTACTCAGAAATAGT
GAAGCCACAGATGTATTTCTGAGTACAGGGACCGGGCTGCCTAC
TGCCTCGGA) or scrambled (sequence containing no homology to known 
mammalian genes) short hairpin RNAs (shRNA) (Open Biosystems, 
Huntsville, AL, USA). 
 
2.2 Cell extracts and treatments 
Total cell lysates were obtained by homogenization of cell pellets and 
tumor specimens in cold lysis buffer (20mM Tris, pH 7.5 containing 
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300mM sucrose, 60mM KC1, 15mM NaC1, 5% (v/v) glycerol, 2mM 
EDTA, 1% (v/v) Triton X-100, 1mM PMSF, 2 mg/ml aprotinin, 2 mg/ml 
leupeptin and 0.2% (w/v) deoxycholate) for 1 min at 4°C and further 
sonication for 30 sec at 4°C. Cytosolic, microsomal  and mitochondrial 
fractions were prepared with the Qproteome Mitochondria Isolation Kit 
(Qiagen, Milan, Italy). For ER stress induction, cells were treated overnight 
with 1µM thapsigargin (Sigma-Aldrich, Milan, Italy) before harvesting. 
 
2.3 Western blot analysis and antibodies 
Equal amounts of protein from cell lysates and tumor specimens were 
subjected to 10% (v/v) SDS-PAGE and transferred to a PVDF membrane 
(Millipore, Temecula, CA, USA). The membrane was blocked with 5% 
(w/v) skim milk and incubated with primary antibody, followed by 
incubation with an HRP-conjugated secondary antibody. Proteins were 
visualized with an ECL detection system (GE Healthcare, Waukesha, 
Wisconsin, USA). The following antibodies from Santa Cruz 
Biotechnology, Segrate, Italy were used for WB analysis and 
immunoprecipitation: anti-TRAP1 (sc-13557), anti-Sorcin (sc-100859), 
anti-TBP7 (sc-166003), anti-cMyc (sc-40),CypD, VDAC,  HSP60, anti-
ubiquitin (sc-8017), anti-COX4 (sc-58348), anti-F1ATPase (ATP5B 
subunit, sc-58619), anti-tubulin (sc-8035), anti-HA (sc-805), and anti–
glyceraldehyde-3-phosphate dehydrogenase (GAPDH; sc-69778). Rabbit 
polyclonal anti-calnexin antibody (BD Biosciences, Milan, Italy), mouse 
monoclonal anti- FLAG antibody (SIGMA ALDRICH, Milan, Italy) and 
mouse monoclonal anti-BiP antibody (StressGen, Milan, Italy) were also 
used. 
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2.4 Membrane fractionation , proteinase K digestion  and alkaline 
treatment 
Mitochondria and ER were purified using the Q- proteome 
Mitochondria Isolation Kit (Qiagen, Milan, Italy) according to the 
manufacturer’s protocol and as elsewhere described . Briefly, HCT116 cells 
were washed and suspended in lysis buffer, which selectively disrupts the 
plasma membrane without solubilizing it, resulting in the isolation of 
cytosolic proteins. Plasma membranes and compartmentalized organelles, 
such as nuclei, mitochondria, and ER, remained intact and were pelleted by 
centrifugation. The resulting pellet was resuspended in disruption buffer, 
repeatedly passed through a narrow-gauge needle (to ensure complete cell 
disruption), and centrifuged to pellet nuclei, cell debris, and unbroken cells. 
The supernatant (containing mitochondria and the microsomal fraction) was 
recentrifuged to pellet mitochondria. The resulting supernatant (microsomal 
fraction) was treated with proteinase K for 20 min on ice ± NP40 (Igepal, 
Sigma-Aldrich, Milan, Italy) according to Hassink et al. (40) or with 0.1 M 
Na2CO3 pH  11.3 for 30 min to remove peripheral ER membrane  proteins 
as described in  (41). Ribosomes were purified on a sucrose cushion as 
described in (42). 
 
2.5 RNA extraction and Real Time RT-PCR analysis.  
Total RNA from cell pellets and tumor specimens was extracted using 
the TRIzol Reagent (Invitrogen, Italy). For the first strand synthesis of 
cDNA, 3µg of RNA were used in a 20 µl reaction mixture utilizing a cDNA 
Superscript II (Invitrogen, San Giuliano Milanese, Italy). For Real Time 
PCR analysis, 1 µl of cDNA sample was amplified using the Platinum 
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SYBR Green qPCR Supermix UDG (Invitrogen, San Giuliano Milanese, 
Italy) in an iCycler iQ Real Time Detection System (BioRad Laboratories 
GmbH, Segrate, Italy). The following primers were utilized: GRP78/BiP 
forward 5’-CGTGGATGACCCGTCTGTG-3’, reverse 5’-
CTGCCGTAGGCTCGTTGATG-3’ (PCR product 308  bp); GAPDH, 
forward 5’-CAAGGCTGAGAACGGGAA-3’, reverse 5’-
GCATCGCCCCACTTGATTTT-3’ (PCR product 90 bp). Primers were 
designed to be intron spanning. Reaction conditions were 50° C for 2 min, 
95°C for 2 min, followed by 45 cycles of 15 s at 95°C, 30 s at 60°C, 30 s at 
72°C. GAPDH was chosen as an internal control. 
 
2.6 Cytotoxicity assay 
HCT116 cells were subjected to downregulation of TRAP1 and TBP7 
expression by siRNA transfection Apoptosis was evaluated by 
cytofluorimetric analysis of annexin V and 7-amino-actinomycin D (7-
AAD) positive cells using the FITC-Annexin V/7-AAD Kit (Beckman 
Coulter, Cassina De' Pecchi – Milan, Italy). Stained cells were analyzed by 
the “EPICS XL” Flow Cytometer (Beckman Coulter, Cassina De' Pecchi – 
Milan, Italy). Ten thousand events were collected per sample. Positive 
staining for annexin V, as well as double staining for annexin V and 7-AAD 
were interpreted as signs of, respectively, early and late phases of apoptosis. 
Experiments were performed three times using three replicates for each 
experimental condition. 
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2.7 Immunofluorescence, confocal-microcopy and EM analysis 
HCT116 cells were fixed with 0.1M phosphate buffer containing 4% 
(w/v) paraformaldehyde for 15 minutes, then blocked and permeabilized 
with 5% (w/v) BSA, 0.1% (v/v) Triton X-100, 10% (v/v) FBS in PBS for 20 
min at RT before staining with primary antibodies (for TRAP1, 
CALNEXIN and TBP7) and corresponding secondary TEXAS RED/FITC-
conjugated antibodies. The analysis of immunofluorescence was performed 
with a confocal laser scanner microscopy Zeiss 510 LSM (Carl Zeiss 
Microimaging, Göttingen, Germany), equipped with Argon ionic laser (Carl 
Zeiss Microimaging, Göttingen, Germany) whose λ was set up to 488 nm, a 
HeNe laser whose λ was set up to 546 nm, and an immersion oil objective, 
63 ×/1.4 f. For the immuno-EM analysis, cells were fixed with a mixture of 
4% (v/v) paraformaldehyde and 0.05% (v/v) glutaraldehyde, labeled with a 
monoclonal antibody against HA using the gold-enhance protocol, 
embedded in Epon-812, and cut as described previously (43). EM images 
were acquired from thin sections using an FEI Tecnai-12 electron 
microscope equipped with an ULTRA VIEW CCD digital camera (FEI, 
Eindhoven, The Netherlands). Thin sections were also used for 
quantification of gold particles residing within mitochondria using the 
AnalySIS software (Soft Imaging Systems GmbH, Munster, Germany). 
 
2.8 FRET experiments 
FRET was measured by using the acceptor photo-bleaching technique 
(44), where, upon irreversible photo-bleaching, the donor fluorescence 
increase was recorded. Cells on coverslips were fixed; immunostained with 
specific anti-TBP7 and anti-TRAP1 antibodies, and secondary antibodies 
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conjugated, respectively, to Cy3 and Cy5; and mounted in PBS/glycerol 
(1 : 1). Images were collected using a laser-scanning confocal microscope 
(Zeiss LSM 510 Meta) equipped with a planapo × 63 oil-immersion (NA 
1.4) objective lens. Laser lines at 543 and 633 nm were used to excite, 
respectively, the fluorophores Cy3 and Cy5. For Cy5 bleaching, the 633-nm 
He–Ne laser light with 100% output power was used and pinhole diameters 
were set to have 1.0-µm optical slices. 
FRET measurements were performed by using the LSM software (LSM 
Zeiss, Göttingen, Germany) after photo-bleaching of a selected squared ROI 
of 6 µm2. We calculated the FRET efficiency on the basis of the following 
equation: E=(Fluorescence intensity of Cy3 after bleaching−Fluorescence 
intensity of Cy3 before bleaching)/Fluorescence intensity of Cy3 after 
bleaching. 
As control we measured FRET on cells expressing TBP7 alone labeled with 
Cy3 in order to ensure that photo-bleaching per se does not affect the 
fluorescence of the donor and that photo-conversion does not occur during 
the photo-bleaching analysis. We calculated the background raised by the 
photo-bleaching per se by bleaching Cy5 in cells negative for this 
fluorophore. The background value was subtracted from all samples. 
 
2.9 Pulse-chase assay 
Pulse-chase analysis was performed as described elsewhere (45). In 
brief, HCT116 cells were incubated in cysteine/methionine-free media 
(Sigma-Aldrich, Milan, Italy) for 1 h followed by incubation in 
cysteine/methionine-free media containing 50 mCi/mL 35S-labeled 
cysteine/methionine (GE-Healthcare, Waukesha, Wisconsin, USA) for 1 h. 
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After labelling, cells were washed once with culture media containing 10-
fold excess of unlabeled methionine and cysteine (5mM each) and incubated 
further in the same medium for the indicated times. Cells were collected at 
the indicated time points, and separated on 10% SDS–PAGE. Proteins were 
transferred onto a PVDF membrane (Millipore, Temecula, CA, USA) and 
probed by WB analysis. 
 
2.10 Patients 
Between May 2008 and November 2010, specimens from both tumor 
and normal, non-infiltrated peritumoral mucosa were obtained from 51 
patients with CRC during surgical removal of the neoplasm. Samples were 
divided into 125 mm3 pieces, one specimen was fixed in formalin and used 
for the histopathological diagnosis, while the others were immediately 
frozen in liquid nitrogen and stored at –80°C for immunoblot analysis. 
Samples were analyzed within 30 days after collection and were thawed 
only once. Express written informed consent to use biological specimens for 
investigational procedures was obtained from all patients. 
 
2.11 Statistical Analysis.  
Chi-square test was used to establish the statistical correlation 
between the expression levels of TRAP1 and those of Sorcin, F1ATPase 
and TBP7 in human colorectal carcinomas. Statistically significant values 
(p<0.05) are reported in the Results.  
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RESULTS 
3.1 TRAP1/SORCIN INTERACTION: PROTECTION AGAINST 
ANTIBLASTIC AGENTS 
A proteomic analysis of TRAP1 co-immunoprecipitation complexes 
was performed in our laboratory, in order to further characterize the TRAP1 
network and evaluate protein interactors relevant for its roles. The first 
putative ligand analyzed by our group is Sorcin. Sorcin is a 21.6-kDa Ca2+-
binding protein that is a member of the penta EF-hand protein family and is 
widely distributed among mammalian tissues such as skeletal muscle, 
kidney, and brain, but most abundantly in cardiac muscle (8, 9, 10). Our 
group is involved in the study of molecular mechanisms responsible of 
chemoresistance in colorectal cancers, and the role played by Sorcin in the 
development of these mechanisms led us to investigate the functional role of 
the interaction between TRAP1 and Sorcin. 
Mass spectrometry analysis revealed interaction of TRAP1 with a smaller 
isoform of Sorcin, of about 18 kDa, generated by alternative splicing, whose 
function has never been identified. Coimmunoprecipitation experiments 
showed that TRAP1 and Sorcin interact in HCT116 and HT29 colon 
carcinoma cells and, in particular, TRAP1 seems to interact with the Sorcin 
band with a lower electrophoretic mobility. Considering the abundance of 
TRAP1 in mitochondria and given the cytosolic localization previously 
attributed to this protein, to further define the subcellular localization of 
sorcin isoforms detected by antibodies, cellular subfractionations were 
performed, and the result showed that the 18 kDa isoform localizes in 
mitochondria (Fig.7, panel A); the mitochondrial localization of the lower 
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band of Sorcin was confirmed by immunofluorescence experiments,  that 
showed colocalization between 18-Sorcin and a red fluorescent protein 
targeted to mitochondria (MITO-RFP). Coimmunoprecipitates from 
mitochocondrial lysates allowed us to detect the interaction between the two 
proteins specifically in this compartment; this interaction is highly sensitive 
to calcium concentration, in fact it was abolished after exposure to calcium 
chelators (data not shown). 
Once demostrated the interaction, our aim was to functionally characterize 
the binding between TRAP1 and Sorcin; first, we tested if a regulation 
between the levels of the two proteins occurs and indeed demonstrated that 
in TRAP1 stable interfered clones the levels of Sorcin 18 were dramatically 
decreased, while upon readdition of TRAP1 this phenotype was rescued. 
Finally, to study the functional effects of TRAP1/Sorcin interaction on the 
protection from apoptosis, we evaluated the rates of apoptotic cell death in 
colorectal carcinoma HCT-116 cells treated with anticancer compounds 
upon transient (siRNA) or stable (shRNA) downregulation of TRAP1 and/or 
Sorcin gene expression, and we found that silencing of either TRAP1 or 
Sorcin by siRNA enhanced drug-induced apoptosis. However, 
TRAP1/Sorcin double knockdown did not induce any additional effect on 
cell death, thus suggesting that the two proteins concomitantly contribute to 
cytoprotection and to development of a multi-drug resistant phenotype in 
colon cancer cells by interacting and working together in a common 
pathway (Table 1). This functional link is demonstrated even in human 
colorectal cancer tissues, where TRAP1 and Sorcin are co-upregulated (Fig. 
7, panel B); these findings suggest that TRAP1/Sorcin network in 
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mitochondria may represent a novel therapeutic strategy for colorectal 
tumors  (39).  
 
Figure 7: TRAP1 and Sorcin interact in mitochondria and are co-upregulated in 
colorectal carcinomas specimens. A) HCT116 cells were sufractionated in the cytosolic 
(CYTO) and mitochondrial (MITO) fractions, separated by SDS-PAGE and immunoblotted  
with the indicated antibodies. No Ab, total cellular extracts incubated with protein A/G-
Sepharose without antibodies; IP, immunoprecipitation with the corresponding antibodies. 
B) TRAP1 and Sorcin levels in colorectal carcinomas specimens (T) respect to the 
corresponding non infiltrated peritumoral mucosas (M) 
 
 
 
 
Table 1: Rates of apoptotic 
cell death in colorectal 
carcinomas HCT116 cells. 
Cells treated with I- OHP 
upon transient silencing of 
TRAP1 (siTRAP1), or Sorcin 
(si Sorcin), or both. The 
statistical analysis were 
performed as described in 
Materials and Methods. 
B 
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Our findings are in agreement with data obtained by Altieri’s group. They 
found that differential expression of TRAP1 in cancer, as opposed to normal 
tissues, has been implicated in inhibition of mitochondrial apoptosis, 
suppression of ROS production, and acquisition of resistance to standard 
chemotherapeutics. Effective cytoprotection under these conditions may 
require TRAP1 phosphorylation by the mitochondrial-localized kinase 
PINK1, which associates with TRAP1. The Ca2+ binding protein, Sorcin is 
also a TRAP1-associated molecule, which collaborates with TRAP1 in 
maintaining the cytoprotective network in mitochondria through the 
regulation of the activity of the PTP (46). 
 
3.2 TRAP1/TBP7 INTERACTION: IMPLICATIONS IN PROTEIN 
QUALITY CONTROL AND CELL SURVIVAL 
3.2.1. TRAP1 and TBP7  colocalize and directly interact in the 
endoplasmic  reticulum (ER) 
The main aim of my PhD project has been the characterization of the 
interaction between TRAP1 and TBP7 (S6-ATPase 4/Rpt3), a component of 
the 19S proteasome regulatory subunit (11, 47, 48), another putative partner 
identified by our LC-MS/MS analysis. I’ve performed western blot (WB) 
and co-immunoprecipitation (co-IP) analyses from total extracts of HCT116 
colon carcinoma cells to verify the effective interaction between TRAP1 and 
TBP7 in my experimental model (Fig. 8, panel A). To understand the 
subcellular compartment in which this interaction could occur, I performed 
cellular subfractionation of HCT116 cells; in fact, a prevalent mitochondrial 
localization has been previously reported for TRAP1 (5). WB analysis of 
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the fractions showed that: i) TBP7 is absent from mitochondria, but 
expressed both in the cytosol and microsomal (ER) fractions; ii) TRAP1 is 
present  in mitochondria and, surprisingly, also in ER (Fig. 8, panel B). This 
observation lead us to speculate that this interaction could happen 
specifically in endoplasmic reticulum; the hypothesis was confirmed by Co-
IP analyses from microsomal fraction, that confirmed TRAP1/TBP7 
interaction in the ER (Fig. 8, panel C). The TRAP1/TBP7 molecular 
interaction was further investigated by using a fluorescence resonance 
energy transfer (FRET) approach in fixed cells (Fig. 9, panel A). In cells 
coexpressing wild-type TRAP1 and TBP7 about 12% of FRET efficiency 
was found, indicating that TRAP1 and TBP7 are close enough to allow 
energy transfer. Interestingly, FRET was found exclusively after bleaching 
of ER regions, selected on the basis of their morphological features (one 
example in Fig. 9D, a–f). Thus, these data indicate that TRAP1 and TBP7 
directly interact with each other and this interaction occurs specifically in 
the ER compartments.  
 
Figure 8 : TRAP1 and TBP7 interact and colocalize in the ER. A) Total HCT116 
lysates were harvested and immunoprecipitated using anti-TRAP1 and anti-TBP7 
antibodies as described under Materials and Methods, separated by SDS-PAGE and 
immunoblotted using the indicated antibodies. B) Total HCT116 lysates were fractionated 
into mitochondrial (MITO), cytosolic (CYTO) and microsomal (ER) fractions as described 
under Materials and Methods, separated by SDS-PAGE and immunoblotted using the 
indicated antibodies to verify TRAP1 and TBP7 localization and to assess the purity of the 
fractions. C) TRAP1 and TBP7 co-IP analysis on the microsomal fraction (ER), obtained as 
described under Materials and Methods. WB of immunoprecipitates was performed by 
using the indicated antibodies.                                                                              
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To demonstrate the new finding of the ER localization of TRAP1, confocal 
and electron microscopy were used. First, HCT116 cells stably-
iperexpressing a plasmid for TRAP1-HA were fixed and analyzed for 
immuno- electron microscopy (EM). Labeling with gold particles revealed a 
main staining in mitochondria, as expected, but also a signal associated to 
elongated membranes  that on the basis of their ultrastructural features (such 
as attached ribosomes) can be attributed to the rough ER compartment; 
moreover, signals for TRAP1 were found even in corrispondence to nuclear 
envelope, that can be considered a part of ER network (Fig.9, panel B). 
Densitometric analysis (in arbitrary units, A.U.) of the labeling associated to 
TRAP1 confirmed the enrichment of this protein in mitochondria 
(2.53±0.34), but revealed the association of  a consistent fraction of TRAP1 
to endoplasmic reticulum (1.02±0.22).  Confocal microscopy confirmed the 
reticular localization of TRAP1 and TBP7; in fact, the two proteins 
colocalize with calnexin, an ER resident protein, and the signals given by 
anti-TRAP1 and anti-TBP7 antibody show a significant merge (Fig. 9, panel 
C: 1, 2, 3). 
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Even if these findings demonstrate that the interaction between TRAP1 and 
TBP7 occurs in endoplasmic reticulum, there is no indication about the 
topology of these two proteins; to reveal a more detailed localization for 
TRAP1 and TBP7, biochemical assays were performed. First, protease 
digestion of microsomal fractions shows that, in contrast to calnexin, that is 
tightly inserted into ER membranes, both TRAP1 and TBP7 are sensitive to 
proteinase K treatments (Fig. 9, panel D),  thus indicating that they are 
located on the outer side of ER, facing the cytoplasm. Moreover, alkaline 
treatment of ER fractions to remove peripheral membrane proteins 
demonstrates that both TRAP1 and TBP7 are loosely associated to ER 
membranes (Fig. 9, panel E). 
 
Figure 9  : TRAP1/TBP7 direct interaction and topology in ER. A) FRET was 
measured by using the acceptor photo-bleaching technique as described under Materials 
and Methods. The images show the signal of TBP7 (red) and TRAP1 (green) before (a–c) 
and after photo-bleaching (d–f). Error bars:±S.D. B) ER Distribution of TRAP1 in HCT116 
cells (EM). Cells expressing TRAP-HA vector were fixed and prepared for immuno-EM 
and labeled with the anti-HA antibody as described in Materials and Methods. The density 
of immuno-gold labeling (in arbitrary units; average±S.D.) in mitochondria (MITO), ER 
and endosomes (as a negative control) is reported in the lower histogram. C) ER 
TRAP1/TBP7 colocalization (confocal microscopy). Immunofluorescence shows 
colocalization of TBP7 with TRAP1 and with the ER protein calnexin. Panel-1: double 
immunofluorescent staining for TRAP1 (green) and TBP7 (red). Panel-2:double 
immunofluorescent for calnexin (green) and TBP7 (red). Panel-3: in cells expressing the 
Myc-tagged TRAP1 construct (red) the protein co-distributes to a great extent with 
endogenous calnexin (green). D and E) TRAP1/TBP7 ‘topology’ in the ER. WB of 
HCT116 microsomal fractions treated with 0.4 µg/ml or 4 µg/ml proteinase-K (pt K) ±1% 
NP-40 for 20 min on ice (D) or with 100mM Na2CO3 (pH 11.3) for 30 min (E) as described 
under Materials and Methods. Specific proteins were revealed using the indicated 
antibodies. E): S, supernatant; P, pellet. 
 
RESULTS 
 30 
 
 
  
 
3.2.2 TRAP1 and TBP7 interference sensitizes HCT116 cells to 
thapsigargin- induced ER stress 
Given the ER localization of TRAP1 and TBP7, I decided to 
investigate the involvement of these two proteins in ER homeostasis. 
Although oxidative stress can disrupt protein folding, how protein 
misfolding and oxidative stress impact each other has not been explored, but 
it is well known that antioxidant treatment reduces UPR activation, 
C 
A B 
D 
E 
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oxidative stress, and apoptosis, and that ROS concentration in ER is 
controlled by networks of molecular chaperones (49). Given the well 
characterized antioxidant role of TRAP1, we hypothezised that 
TRAP1/TBP7 interaction could constitute an additional check point to 
monitor the state/folding of proteins damaged in ER. To induce protein 
misfolding, HCT116 colon carcinoma cells were treated with thapsigargin 
(TG), an agent that induces ER stress through mobilization of calcium stores 
from the ER lumen (50); as a marker of ER stress induction we analyzed for 
REAL-TIME PCR (RT-PCR) the expression of the luminal chaperone 
BiP/Grp78, a central regulator of the UPR that is highly induced by 
thapsigargin (25). Upon TG treatment, shTRAP1 stable clones show an 
increased BiP expression compared to control cells (Fig.10, panels a, b); a 
rescue of the phenotype (decreased BiP iperexpression upon TG) is 
observed upon transfection of TRAP1 expression vector. These results show 
that TRAP1 sensitizes cells to ER and is involved in stress responses upon 
TG treatment, as recently indicated by  Takemoto et al (51). 
It has been previously demonstrated that ER stressors induce apoptosis after 
prolonged treatments (52); TRAP1 is well characterized as an anti-apoptotic 
protein, so we asked if TRAP1, in concert with TBP7, could sensitize 
HCT116 cells to apoptosis induced by reticular stress. As expected, 48 
hours TG treatments make TRAP1 and TBP7 interfered cells more sensitive 
to apoptosis induced by ER stress, and the same results were obtained after 
treaments with genotoxic agents (e.g. oxaliplatin, data not shown). Taken 
togheter, these results confirm the antiapoptotic function of TRAP1, 
demonstrating, in particular, that TRAP1 sensitizes cells to apoptosis 
induced by ER stressors and that TBP7 could be involved in this 
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cytoprotective mechanisms, highlighting a new role for proteasomal 
regulatory proteins in apoptotic control.  
Figure 10: BiP mRNA levels in sh-TRAP1 stable clones. a) Semi-quantitative RT-PCR 
analysis of BiP/Grp78 mRNA expression in sh-TRAP1 stable clones with respect to 
scrambled transfectants after 12 hours (h) treatment with 1 µM TG. As control, the levels of 
GAPDH transcript were analyzed. b) RT-PCR analysis of BiP/Grp78 mRNA expression in 
scrambled and sh-TRAP1 HCT116 cells exposed to 1 µM TG for 12 h and in sh-TRAP1 
HCT116 cells transfected with TRAP1 cDNA before treatment with TG. The P-values 
indicate the statistical significance between different BiP/Grp78 levels under the indicated 
conditions. 
   
 
3.2.3 TRAP1 and TBP7 are involved in control of cellular ubiquitination 
acting on ER . 
Ubiquitin modification irreversibly or reversibly changes the fate of a 
target protein. Not much is known about the regulation of ubiquitination in 
cellular processes like apoptosis and cell proliferation; the involvement of 
the UPS system in cellular processes like proliferation and apoptosis is well 
estabilished, but less is known about the cause-effect relashionships in 
cellular homeostasis or in stress responses. Several molecular chaperones 
have been reported to regulate cellular ubiquitination, in physiological 
conditions or in stress responses (53); given the interaction of TRAP1 with 
the proteasomal subunit TBP7, I tested if these two proteins could 
collaborate in regulation of cellular ubiquitination. Analysis of cellular 
lysates of TRAP1 stably interfered clones (sh-RNAs) shows an increased 
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amount of ubiquitinated proteins respect to control cells; this phenotype 
could be reverted by readdition of TRAP1 expression vector (Fig. 11, panel 
a). Cellular subfractions revealed additional details about TRAP1 control: in 
fact, proteins contained in post-mitochondrial (PM) fraction (microsomes+ 
cytosol) were found  more ubiquitinated in absence of TRAP1, accordingly 
with the fact that protein quality control via ubiquitin is more requested in 
compartments assigned to protein synthesis and folding, where the 
proteasome is present and active. Mitochondrial lysates, on the other hand, 
don’t show a TRAP1-dependent regulation of protein ubiquitination, 
according to the fact that TBP7 and the proteasome are absent in 
mitochondria (Fig.11, panel b). The interference of TBP7 with specific 
siRNAs mimics the effect of TRAP1 interference, while in cells interfered 
for both TRAP1 and TBP7 the phenotype does not seem to be additional, 
confirming the idea that TRAP1 and TBP7 could work in concert in 
regulation of protein ubiquitination (Fig.11, panel c). These effects seem to 
be independent from proteasome inhibition (MG132 treatments), and, 
according to this observation, TRAP1 and TBP7 interference does not affect 
proteasome activity, as demonstrated by in vitro proteasomal activity assays 
(Fig.11, panel d). These data support the hypothesis that TRAP1 and TBP7 
act upstream the proteasome function and that these two proteins don’t 
compromise the proteasomal catalytic activity, but may decide if a substrate 
can be ubiquitinated and then destined to proteasome. 
Since the endoplasmic reticulum, the extramitochondrial compartment in 
which TRAP1 is enriched, is the main site of protein quality control (after or 
during translation), I wanted to test the hypothesis that TRAP1 could exhert 
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the control of cellular ubiquitination outside from mitochondria, through its 
ER location, and that this control requires TRAP1/ TBP7 interaction.  
 
Figure 11  : Ub levels and proteasomal activity in HCT116 cells. a) Total cell lysates 
from sh-TRAP1 and scrambled HCT116 stable clones obtained as described in Materials 
and Methods were analyzed with the indicated antibodies to detect ubiquitin levels. b) Sub-
cellular fractions: PM fraction (microsomes +CYTO fraction) and mitochondria (MITO, 
see Materials and Methods) were obtained from sh-TRAP1 and scrambled HCT116 stable 
transfectants and analyzed using the indicated antibodies. c) HCT116 cells were co-
transfected with a Ub-HA vector and an siRNA negative control (scramble), or with 
siRNAs specific for TRAP1, TBP7, or both (as indicated) as described in Materials and 
Metohds, and the lysates were analyzed with the indicated antibodies. d) Proteasome 
activity is not affected by TRAP1 and TBP7 silencing. Total cellular extracts were prepared 
after 48 h of transfection with specific siRNA for TRAP1, TBP7 or Sorcin, as control, or 
with an siRNA negative control (scramble), and incubated in the presence of assay buffer 
and the fluorogenic substrate Suc-LLVY-AMC, as described under Materials and Methods. 
Samples were analyzed in triplicate using an excitation wavelength of 360 nm and an 
emission wavelength of 450 nm to detect chymotryptic proteasome activity. The data 
represent the mean of three independent experiments. 
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To demonstrate this, I generated the Δ1-59 mutant of TRAP1 (in which the 
first 59 aminoacids containing the mitochondrial targeting sequence (54) 
were removed from the N-terminus, yielding TRAP1 mutant defective for 
mitochondrial import but still able to bind TBP7),  and the TRAP1 mutant 
Δ101-221 able to localize into mitochondria but unable to bind TBP7 which, 
as previously shown, is absent in the mitochondrial fraction (Fig. 12, Panels 
A-B-C-E-F).   
Transfection of Δ1-59 mutant in sh-TRAP stable clones rescues the high 
amount of ubiquitinated proteins accumulated in absence of TRAP1, while 
the Δ101-221 mutant does not (Fig.12, panels D-G).  
A TBP7 deletion mutant, lacking a portion of one ATPase domain (ΔΤΒP7-
Flag, Fig.12, panel A), was generated to confirm that TRAP1/TBP7 
interaction was necessary in ubiquitination control; this mutant disrupts 
TRAP1/TBP7 interaction, probably acting like a dominant-negative mutant, 
and, as a consequence of this, increases the cellular ubiquitin levels in 
scramble control cells , inducing  a phenotype very similar to sh-TRAP cells 
(Fig. 12, panels I- J). Moreover,  the transfection of TRAP1 Δ1-59 mutant 
decreased Grp78/BiP mRNA levels present in sh-TRAP1 clones upon 
thapsigargin-induced ER stress (Figure 12, Panel H), while the 
mitochondrial TRAP1 mutant Δ101-221 is not only unable to counteract ER 
stress, but even further increased BiP levels. Taken together, these 
observations demonstrate that the mitochondrial localization of TRAP1 is 
not necessary for cellular ubiquitination control, and that ER TRAP1  
localization is required for this check point; furthermore, these results show 
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that TRAP1/ TBP7 interaction in ER is crucial and essential for protein 
quality control via ubiquitin-proteasome system. 
  
Figure 12: TRAP1/ TBP7 interaction is required in ER to control cellular 
ubiquitination. A) Scheme of TRAP1 mutants Δ1-59 and Δ101-221, and of TBP7 mutant 
ΔTBP7-Flag. For details about the generation of mutants, see Materials and Methods. B) 
and E) Subcellular localization of TRAP1 deletion mutants; the cellular subfractions were 
probed with the indicated antibody to detect the expression of mutants and assess the purity 
of fractions. C) and F) The indicated TRAP1 mutants were transfected, immunoprecipitated 
and immunoblotted with the indicated antibodies to verify the interaction with TBP7.  
D) and G) Ubiquitination levels upon transfection of TRAP1 mutants were analyzed as 
described in Materials and Methods. H) Real-time (RT-PCR) analysis of BiP/Grp78 mRNA 
expression was peformed as described in Materials and Methods. I) TRAP1/ TBP7 
interaction in presence of Δ TBP7 deletion mutant. Immunoprecipitation analysis were 
performed in presence of the Δ TBP7 mutant respect to mock- transfected cells; the  
indicated antibodies were used to verify the interaction. The arrow indicates TBP7-Flag 
mutant. J) Ubiquitination levels upon transfection of the Δ TBP7-Flag deletion mutant.  All 
the indicated data are representative of three independent experiments with similar results.  
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3.2.4 TRAP1 and TBP7 are responsible of quality control for specific 
mitochondrial-destined proteins 
The control of ubiquitination performed by TRAP1 and TBP7 could 
be exherted at different levels; the ubiquitin is the first signal that leads the 
proteins to degradation, recognizing their misfolding, therefore affecting 
their stability. I tested the hypothesis that  TRAP1 could influence the 
overall protein half-life performing pulse–chase experiments on total lysates 
of sh-TRAP1 stable clones and the respective scrambled controls. 
Surprisingly, the total rate of degradation seems unchanged between 
scrambled and sh-TRAP1 cells (data not shown), indicating that TRAP1 
doesn’t affect total protein stability, although influencing total 
ubiquitination; this observation led us to investigate the expression of 
specific proteins, in particular TRAP1 “substrates”. We analyzed the 
expression levels of F1ATPase βsubunit, a nuclear-encoded mitochondrial 
protein and a potential TRAP1 interactor as suggested by MS analysis, and 
the amount of 18 Sorcin, the mitochondrial TRAP1 interactor previously 
described (39). In sh-TRAP1 stable clones the levels of both 18 sorcin and 
F1ATPase are significantly reduced respect to control cells (Fig.13, panel 
A) and, interestingly, the basal levels of these proteins were rescued upon 
transfection of Δ1-59 mutant of TRAP1, and not by expression of the 
“mitochondrial” mutant Δ101-221 (data not shown); these data demonstrate 
that TRAP1 is responsible for the control of the levels of the two analyzed 
substrates and, more importantly, the mitochondrial localization of TRAP1 
is not required for this specific function. In agreement with these data, 
quantification of relative levels of TRAP1 and the above mentioned 
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substrates in tissue specimens of colorectal carcinomas confirmed a 
significant correlation between TRAP1 overexpression and upregulation of 
levels of 18 Sorcin and F1ATPase ß subunit (Fig.13, panel E). Again, pulse-
chase analysis  performed by immunoprecipitation of 18 Sorcin and 
F1ATPase in scrambled and shTRAP1 cells demonstrated that the 
stability/half-life of these substrates is not affected  by TRAP1 interference 
(data not shown).  Therefore, the more probable case was that the decreased 
expression of F1ATPase and p18 Sorcin in mitochondria of TRAP1-
interfered cells was dependent on increased ubiquitination. To this aim, the 
respective ubiquitination levels in scramble and TRAP1-inteferred cells 
were analyzed. In figure 13 (panels B and C) is shown that both proteins are 
more ubiquitinated in sh-TRAP1 transfectants; accordingly, increased levels 
of ubiquitinated F1ATPase accumulated upon TBP7 interference (Figure 13, 
panel D).   
                              
 
Figure 13: TRAP1 and TBP7 regulate the levels of 
specific mitochondrial substrates. A) The levels of 18 
Sorcin and F1ATPase in shTRAP1 and scrambled stable 
clones were analyzed by Western Blot analysis with the 
indicated antibodies. B) and D) Scrambled and sh-TRAP1 
HCT116 clones (or HCT116 cells upon 48 h  transfection 
with siRNA specific for TBP7) were treated with 1 µM 
MG132 for 24 h before harvesting, immunoprecipitated with 
the indicated antibodies, subjected to SDS-PAGE and 
immunoblotted using mouse monoclonal anti-Ub antibody. 
Three independent experiments were performed, with similar 
results. C) Scrambled and sh-TRAP1 HCT116 clones were 
transfected with an expression vector containing the 18-
Sorcin-Myc expression vector and analyzed as described in 
Materials and Methods. E) TRAP1, TBP7, F1ATPase and 
Sorcin expression in human CRCs. Total cell lysates from 
four human CRCs (T) and the respective non-infiltrated 
peritumoral mucosas (M) were analyzed as described in 
Materials and Methods. 
A 
 
RESULTS 
 40 
  
 
 
3.2.5 TRAP1 interacts with the translational apparatus on ribosomes 
As discussed above, it’s well known that de novo folding in 
eukaryotes starts cotranslationally (55), with the help of a specialized 
chaperone machinery that is physically and functionally linked to ribosomes 
(and to ribosome bound nascent polypeptides) (56, 57), coupling folding to 
translation and to degradation of misfolded- newborn polypeptides via UPS 
(16, 17). Considering that my previous results show that TRAP1 doesn’t 
affect  protein stability and post- translational degradation, even if involved 
B 
C 
D 
E 
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in ubiquitin dependent quality control,  I decided to test the hypothesis that 
TRAP1 could be linked to the translational apparatus, being involved in 
cotranslational quality control via ubiquitin, given its interaction with the 
regulatory proteasomal subunit TBP7. I obtained very preliminary data that 
give an indication about TRAP1 implication in this physiological process. 
The first hypothesis that I wanted to test was to verify the physical 
association between TRAP1 and the ribosomes; Western blot analysis of 
purified ribosomes shows that a fraction of TRAP1 is present in ribosomal 
pellet, with the presence of the specific ribosomal marker L3 (Fig.14, panel 
A). To confirm the association of TRAP1 with the translational apparatus, I 
performed coimmunoprecipitation experiments to verify the physical 
interaction of TRAP1 with the elongation factor eEF1A, identified as a 
putative TRAP1 interactor by mass spectrometry analysis; coIp experiments 
show that TRAP1 and eEF1A are physically interacting in HCT116 cells 
(Fig 14, panel B). These preliminary observations suggest that TRAP1 
could be one of the chaperones associated to the translational machinery 
involved in cotranslational protein quality control; it remains to evaluate if 
TRAP1 could play this function in concert with TBP7, thus linking 
cotranslational protein quality control and ubiquitination.  
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Figure 14: TRAP1 and the translational apparatus. A) Ribosomes from HCT-116 cells 
were isolated by centrifugation through a sucrose cushion as described in Materials and 
Methods. Equivalent amounts of supernatant and ribosomal-containing pellet were 
subjected to immunoblot analysis with the indicated antibodies. B) Interaction between 
TRAP1 and EF1A. Total HCT 116 lysates were immunoprecipitated with anti EF1A 
antibody and subjected to SDS PAGE, then immunoblotted with the indicated antibodies.  
 
  
A 
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4 DISCUSSION 
TRAP1 was identified by our group as a molecular chaperone 
iperexpressed in osteosarcoma cells adapted to mild oxidative stress (4). For 
its well demonstrated  mitochondrial localization and cytoprotective effect 
against antiblastic agents, we and others demonstrated for this molecular 
chaperone a role in protection against apoptosis acting in concert with the 
other components of mitochondrial transition pore (6, 7). 
Despite its well defined and accepted role in protection from apoptosis, less 
is known about the molecular pathways in which TRAP1 is involved neither 
about its interactors. For this reason, a mass spectrometry (LS/ MS) analysis 
was performed to identify putative “ligands” of TRAP1, and among all we 
further characterized two proteins identified as Sorcin and TBP7. 
Sorcin is a Calcium binding protein identified as overexpressed in many 
tumor cell lines and involved in calcium homeostasis and chemoresistance 
development (8, 9, 10). Our group identified for the first time a novel low 
molecular weight Sorcin isoform that interacts with TRAP1 and is localized 
in the mitochondrial matrix; moreover, Sorcin is involved in protection from 
apoptosis acting in concert with TRAP1 (39). The role of this Calcium 
binding protein in the protection from apoptosis and its interaction with 
TRAP1 allowed us to include these proteins in a well charachterized 
network of mitochondria -localized molecular chaperones: as described and 
summarized by Altieri et al (45), this pathway antagonizes CypD-dependent 
pore-forming properties, and oxidative cell death in tumors, potentially via 
ATPase-directed protein (re)folding (Fig.15) . For its ubiquitous differential 
expression in cancer, as opposed to normal tissues, this mitochondrial 
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chaperone network is considered a potentially attractive target for cancer 
therapy. 
 
Figure 15: Cytoprotective network in mitochondria involving TRAP1 and Sorcin. The 
interaction between TRAP1 and Sorcin is crucial in cancer cells in regulating calcium 
homeostasis, counteracting ROS production and inhibiting PTP opening, thus conferring 
resistance to apoptosis and to antiblastic agents (46). 
 
My PhD project mainly focused on the study and characterization of 
TRAP1-TBP7 interaction. TBP7 is an AAA-ATPase subunit of the 
proteasome regulatory particle, previously identified as a synphylin- 
interacting protein and probably involved in the pathogenesis of Parkinson’s 
disease (58). In my PhD thesis, I demonstrated for the first time that TRAP1 
and TBP7 interact in the endoplasmic reticulum (ER), an organelle crucial 
for protein quality control. TRAP1 and TBP7 interference sensitizes 
HCT116 cells to apoptosis induced by thapsigargin, an ER stress inducer; in 
addition, TRAP1 interference causes a dramatic increase of BiP levels upon 
thapsigargin treatments. Moreover, TRAP1 and/or TBP7 interference 
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induces a significant increase of cellular ubiquitination: in particular, this 
accumulation of ubiquitin levels is not detectable in mitochondrial fraction, 
where TBP7 is absent. These phenotypes are selectively rescued by a 
TRAP1 deletion mutant (Δ1-59) that lacks mitochondrial targeting sequence 
(MTS) and is able to bind TBP7; the rescue doesn’t occur after 
overexpression of a mitochondrial TRAP1 mutant (Δ101-221), which is 
unable to bind TBP7. Furthermore, the overexpression of a TBP7 mutant 
(ΔTBP7), which disrupts TRAP1-TBP7 interaction, causes an accumulation 
of ubiquitinated proteins similar to that caused by TRAP1 or TBP7 
interference. These results show that the ER localization of TRAP1 is 
essential to perform its function of protein quality control in concert with 
TBP7, and that this interaction is crucial in maintaining protein homeostasis, 
without affecting the proteasomal function. TRAP1 regulates the levels of 
two specific mitochondrial nuclear-encoded proteins, 18 Sorcin and the  β-
subunit of  F1ATPase complex, whose expression decreased in shTRAP1 
cells, as a consequence of their elevated ubiquitination levels. All these 
observations open interesting questions about the new discovered role of ER 
localized TRAP1 in controlling protein ubiquitination through TBP7 
interaction. We hypothezise that when a protein is misfolded or damaged, it 
is controlled by a series of molecular chaperones that try to refold it; if this 
is not possible, the damaged protein is directed, in most cases, to 
ubiquitination and proteasomal degradation. These mechanisms are 
prevalently controlled on endoplasmic reticulum, where a wide number of 
molecular chaperones, inside the lumen and just outside the ER, controls the 
folding state of the new translated polypeptides, protecting them, or 
destining them to degradation (59). The ubiquitin-proteasome system (UPS) 
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is crucial in the elimination of damaged proteins; in fact the presence of 
proteasome associated to the outer face of ER, where both TRAP1 and 
TBP7 are located, is well demonstrated (60). An accumulation of misfolded 
proteins triggers ER stress that, in turn, elicits an Unfolded Protein 
Response (UPR), leading to: i) the immediate overexpression of the luminal 
chaperone BiP, ii) a translational block and iii) the transcription of stress- 
responsive genes (24). The fact that TRAP1 interference induces an increase 
in BiP expression suggests that shTRAP1 cells are subjected to an higher 
stress level. It is reasonable to think that this elevated stress condition is 
induced by the accumulation of ubiquitinated proteins, escaped from the 
quality control exherted by TRAP1 and TBP7 on ER. The increase in BiP 
expression could represent a compensatory response to fight against the 
high levels of misfolded and potentially toxic proteins accumulated in 
absence of TRAP1, supporting the emerging idea of a “chaperones 
compensation”. The finding that two specific mitochondrial proteins, Sorcin 
and F1ATPase, are more ubiquitinated in absence of TRAP1 and TBP7 
arises the question of mitochondrial proteins quality control, a still poorly 
characterized issue. Mitochondrial proteins are controlled, in their 
compartment, by mitochondrial proteases, that eliminate misfolded proteins; 
there are no evidences of the presence of proteasome in mitochondria, even 
if ubiquitin ligases have recently been found in these organelles, thus 
suggesting  that many mitochondrial damaged proteins could be 
ubiquitinated inside mitochondria, then retrotranslocated and degraded by 
the proteasome, as recently supposed for  the mitochondrial inner membrane 
protein UCP (34). The identification of TRAP1/TBP7-specific “substrates” 
strongly contributes to the complex study of mitochondrial protein quality 
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control, and supports a role of the cytosolic UPS  in controlling the levels 
and/or  the quality of proteins destined to mitochondria. In fact, recent 
findings demonstrate that a pre-import control could by exherted on 
mitochondria-destined proteins, in association with ubiquitin proteasome 
system, that targets damaged or mistargeted nuclear encoded mitochondria-
destined  proteins to prevent their import into the organelle and the 
accumulation in mitochondria of damaged products (36). We suppose that 
this pre-import control could be located at ER, that is in close proximity to 
mitochondria and harbours a rich machinery of chaperones- including 
TRAP1- that controls the correct folding and targeting of new translated 
proteins. Supporting this hypothesis there are very recent evidences showing 
that protein targeting and degradation are coupled for elimination of 
mislocalized proteins; this mechanism has been specifically demonstrated 
for membrane proteins translated at ER site that, when are inappropriately 
released to the cytosol, become substrate of the ubiquitin-proteasome 
pathway. This process seems to be controlled by an HSP70 client protein, 
Bag6, a molecule that links targeting and ubiquitination pathways (61). 
Finally, the finding that TRAP1-dependent regulation of mitochondrial 
substrated is conserved in CRCs tumor specimens confirms the presence of 
a conserved network that regulates tumor growth and maintainance of the 
malignant phenotype, thus providing a novel molecular target for treatment 
of human CRCs. 
The importance of protein quality control machinery in cellular survival 
and, in particular, in the development of malignant phenotypes was the main 
reason to select TBP7 to study TRAP1 network. Protein quality control is a 
basic cellular phenomenon through which aberrant proteins become 
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eliminated. The quantity and severity of misfolded proteins can overwhelm 
the capacity of the PQC system and may lead to protein aggregate 
accumulation; misfolded proteins that cannot be degraded tend to be more 
toxic to the cells. Tumorigenesis is regulated by several mechanisms 
including signalling, transcription and DNA replication; in  breast cancer, 
recent discoveries show that a cytoplasmic protein quality-control pathway 
is implicated in the suppression of breast cancer cell growth, suggesting a 
new role for quality-control mechanisms in suppressing cells with malignant 
potential (62). Furthermore, Kajro and collegues reported the intriguing 
observation that iperexpression of the cytoplasmic protein quality-control 
ubiquitin ligase, CHIP (carboxy terminus of Hsp70-interacting protein), 
suppresses tumorigenesis and metastatic cellular phenotypes in cultured 
breast cancer cells (63). These studies raise the unexpected possibility that 
quality-control pathways may have a role in tumour progression. Molecular 
chaperones are strictly involved in quality control mechanisms, especially in 
cytoplasm and in endoplasmic reticulum, even if in a recent paper Altieri et 
al (64) suggest that perturbation of mitochondrial chaperones triggers an 
UPR response similar to that induced by ER stress; nevertheless, these data 
confirm the close link between mitochondria and ER, strongly supporting 
the emerging idea of a structural and functional crosstalk between the two 
compartments. 
Our final model (Fig. 16) supports the idea of a close correlation between 
mitochondria and endoplasmic reticulum in quality control of mitochondria 
targeted proteins. We speculate that Sorcin and F1ATPase (and, in a similar 
way, other mitochondrial proteins subjected to TRAP1 and TBP7 control) 
are translated in proximity of mitochondria, on ribosomes associated to the 
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outer side of the ER, where TRAP1 and TBP7 are located. If these neo-
synthesized proteins are damaged, they will be not imported into 
mitochondria, but sequestered by TRAP1 with an attempt to refold or repair 
them; if this attempt fails, the substrates are ubiquitinated, recognised by the 
regulatory subunits of proteasome to which TBP7 belongs, and delivered to 
the proteolitic core for degradation. We still have to analyze whether  this 
process could happen in proximity of MAMs, reticular membranes 
physically linked to mitochondria. Furthermore, future approaches will 
elucidate if the quality control of these mitochondria-destined proteins 
happens in a co-translational way, when they are still attached to ribosomes, 
or after release of the polypeptides from the translational machinery. Very 
preliminary data obtained in the last part of my PhD work indicate the 
association of TRAP1 to ribosomes and to members of the translational 
machinery (in particular, the elongation factor EF1A), thus suggesting that 
TRAP1 quality control could happen in a very preliminary phase of a 
protein’s life, soon after synthesis or co-translationally. If these data will be 
confirmed, TRAP1 could be functionally and physically included into 
ribosome associated chaperone machinery, whose members are well known 
in yeast (HSP70 family members), but remain still unknown in higher 
eukaryotes (65). 
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Figure 16: Crosstalk between ER and mitochondria in quality control of 
mitochondrial destined proteins. TRAP1 forms a supra-molecular complex with TBP7 on 
the outside of the ER, in a cellular compartment of tight ER–mitochondria contact sites, 
where proteasomes are also present. This TRAP1/TBP7 complex is involved in the control 
of protein stability and intracellular protein ubiquitination of mitochondria-destined 
proteins. These two proteins, each with independent but related functions, help to judge 
whether a protein can be repaired and reach the final mitochondrial destination or, if 
damaged, needs to be degraded through the ubiquitin- proteasome system. 
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Background. Protein homeostasis is a highly complex network of molecular interactions governing the
health and life span of the organism. Molecular chaperones, mainly heat shock proteins (HSP) and other stress-
inducible proteins abundantly expressed in multiple compartments of the cell, are major modulators of protein
homeostasis. TRAP1 is a mitochondrial HSP involved in protection against oxidant-induced DNA damage and
apoptosis. It was recently described as a component of a mitochondrial pathway selectively up-regulated in
tumor cells which antagonizes the proapoptotic activity of cyclophilin D, a mitochondrial permeability
transition pore regulator, and is responsible for the maintenance of mitochondrial integrity, thus favoring cell
survival. Interestingly, novel TRAP1 antagonists cause sudden collapse of mitochondrial function and selective
tumor cell death, suggesting that this pathway may represent a novel molecular target to improve anticancer
therapy. Preliminary data suggest that TRAP1 may be a valuable biomarker in ovarian cancers: in fact, TRAP1
levels are signiﬁcantly higher in cisplatin-resistant ovarian tumors and ovarian carcinoma cell lines.
Conclusions.While major advances have been made in understanding the genetics and molecular biology of
cancer, given the considerable heterogeneity of ovarian cancer, the introduction of novel targeted therapies and
the consequent selection of treatments based on the molecular proﬁle of each tumor may have a major impact
on the management of this malignancy and might contribute to building a new era of personalized medicine.© 2009 Elsevier B.V. All rights reserved.Contents
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A highly conserved and functionally interactive network of
intracellular “chaperones” disaggregate, refold and renature mis-ca e Biotecnologie Mediche,
ini 5, 80131 Napoli, Italy. Fax:
).
ll rights reserved.folded proteins following different environmental, physical and
chemical stress. Heat shock proteins (HSPs), and other HSP-
controlled cellular responses limit the damage caused by stress,
thus facilitating cellular recovery. The major HSPs interact with
components of the apoptotic pathways and promote cell survival by
preventing mitochondrial outer membrane permeabilization and
subsequent cytochrome c release, caspase activation and apopto-
some assembly [1]. As a result of protein misfolding, protein
aggregation, or disruption of regulatory complexes, inappropriate
178 M. Landriscina et al. / Gynecologic Oncology 117 (2010) 177–182activation of signaling pathways could occur in several pathophys-
iological conditions, mainly during acute or chronic stress. Conse-
quently, the levels of HSPs are elevated in many cancers, and HSP
overexpression results in a poor prognosis in terms of patient
survival and response to therapy in speciﬁc cancer types [2,3].
Indeed, elevated HSP expression in malignant cells plays a key role
in protecting against the spontaneous apoptosis associated with
malignancy as well as the apoptosis generated by therapy, mechan-
isms which may underlie the role of HSPs in tumor progression and
resistance to treatment [3,4].
The 90-kDa heat shock proteins (HSP90), which are integrally
involved in cell signaling, proliferation, and survival, are ubiquitously
expressed in cells. Many proteins in tumor cells are dependent upon
the HSP90 protein folding machinery for their stability, refolding, and
maturation [5]. Thus, HSP90 has emerged as a promising target for the
treatment of cancer [6]. HSP90 exists as a homodimer, containing
three domains. Interestingly, while the N-terminal domain contains
an ATP-binding site that binds the natural products geldanamycin and
radicicol, a second ATP-binding site in the C-terminus of HSP90 has
been identiﬁed which not only binds ATP, but also cisplatin (CDDP),
novobiocin, epilgallocatechin-3-gallate and taxol [7], all well-known
HSP90 inhibitors and powerful antitumor agents.
Several lines of evidence suggest a direct correlation between
HSP27 overexpression and resistance to chemotherapy in several
human malignancies, such as ovarian cancer, head and neck cancer,
esophageal squamous-cell carcinoma, and leukemia [3]. Similarly,
HSP70 and HSP27 are emerging as predictors of resistance to
chemotherapy and shorter disease-free survival in breast cancer [3,8].
The molecular mechanisms involving HSPs in resistance to cancer
therapies can be explained in several ways: (i) as molecular
chaperones they can confer cytoprotection by more efﬁciently
repairing the damaged proteins resulting from cytotoxic drug
administration; (ii) protecting cancer cells against apoptosis [9], (iii)
protecting the microvasculature inside tumors, because HSP27 is
found in endothelial cells [10], and (iv) enhancing DNA repair [11].
In such a perspective, neutralizing HSPs is therefore an attractive
strategy for anticancer therapy. Up to now, the only inhibitors to have
been developed are against HSP90 and they are now under clinical
evaluation However, an inhibitor of HSP70 or other HSPs would be
very useful in cancer therapy alone and in combination with the
above-mentioned inhibitors of HSP90. Indeed, several reports suggest
that HSP70 or HSP27 antisense constructs have chemosensitizing
properties and may even kill cancer cell lines in the absence of
additional stimuli [12,13]. Interestingly, the cytotoxic effect of HSP70
down-modulation is particularly strong in transformed cells yet
undetectable in normal, non transformed cell lines or primary cellsFig. 1. Examples of signaling pathways and target molecules altered in ovarian cancer.
Panel A. Regulation of tumor cell mitochondrial homeostasis by a Hsp90/TRAP1/
cyclophilin D network. TRAP1 antagonists include novel agents (known and/or
unknown) directed to mitochondria which induce apoptosis by disabling the
cytoprotective pathway (for details see the text and Ref. [22]). CypD, cyclophilin D.
Panel B. Regulation of cell proliferation and apoptosis in cisplatin chemosensitive/
chemoresistant human ovarian cancer cells. Examples of target molecules undergoing
quali-quantitative activation (green/grey) or inhibition (red/white). (A) Cisplatin
treatment induces cell cycle arrest through a p53-dependent up-regulation of cell cycle-
regulatory proteins, such as p21, and of pro-apoptotic proteins (green/grey colors). This
activates programmed cell death pathways, (i.e. activation of the caspases). In these
cells, cell survivalmediators such as Akt, are downregulated or are in their inactive state.
Prohibitin may also play a role in inhibiting cell cycle progression through the Rb-E2F
pathway by binding to Rb. (B) In the presence of low levels of p53 (upon ubiquitination
and/or inactivation) pathways involving Akt and other proteins with pro-survival/
cytoprotective roles are in an active state despite the presence of cisplatin. Overall,
failure to activate apoptosis in response to chemotherapeutic agents is a major cause of
uncontrolled cell proliferation and chemoresistance. Panel C. Key role of heat shock
proteins (HSPs) in the regulation of cell survival and apoptotic pathways. Most HSPs
function as inhibitors of crucial molecules in the apoptosis pathway such as JNK, Cyt C,
caspase-3 and other proteins with cytoprotective roles. Meanwhile, Hsp27 and Hsp90
can also promote the function of AKT in maintaining cell survival.[14]. This body of evidence suggests that targeting HSPs is one of the
most promising approaches to anticancer therapy.TRAP1 as a candidate biomarker in cancer
TRAP1 function
TRAP1 (TNF receptor-associated protein 1) is a mitochondrial
heath shock protein 75 with antioxidant and antiapoptotic functions
[15,16]. Several lines of evidence suggest that TRAP1 is part of a
complex network involved in protecting cells against oxidative stress
and apoptosis. Indeed, TRAP1 and HSP90 were recently described as
components of a mitochondrial pathway selectively up-regulated in
tumor cells which antagonizes the proapoptotic activity of cyclophilin
D (CypD), a regulator of the mitochondrial permeability transition
179M. Landriscina et al. / Gynecologic Oncology 117 (2010) 177–182pore and responsible for the maintenance of mitochondrial integrity,
thus favoring cell survival (Fig. 1A) [17]. Interestingly, our group
recently demonstrated that stable and transient transfectants con-
taining high TRAP1 levels (i) are more resistant both to H2O2-induced
DNA damage and to the apoptosis induced by CDDP and other
apoptotic stressors; (ii) inhibit the release of apoptosis-inducing
factors from mitochondria upon CDDP treatment; (iii) interfere with
caspase 3 activation; (iv) contain higher reduced glutathione levels
than control cells, which probably contributed to their oxidant-
resistant phenotype [16].
TRAP1 and cancer drug-resistance
Based on previous comparisons between various tumoral and
normal tissues, our group and other Authors proposed TRAP1 as a
candidate cancer biomarker. Our group is one of the ﬁrst to
demonstrate the up-regulation of TRAP1 [18] in human osteosarcoma
cells chronically adapted to grow in mild oxidizing conditions [19].
Speciﬁcally, TRAP1 mRNA expression is concomitantly increased in
oxidant-adapted cells as well in tumor cells resistant to 5-ﬂuorouracil
and platin derivatives, thus further supporting the correlation
between resistance to oxidative stress and chemoresistance [20]. In
addition, we recently demonstrated that TRAP1 is responsible for a
multi-drug resistant phenotype in human colorectal carcinoma cells
[21] since TRAP1 overexpression induces resistance to 5-ﬂuorouracil,
oxaliplatin and irinotecan, three agents widely used in the treatment
of human colorectal cancer [22]. Conversely, the inhibition of TRAP1
ATPase activity either by using a mitochondria-directed ATPase
peptidomimetic Shepherdin [17] or by stable transfection of a
dominant-negative amino-terminal TRAP1 deletion mutant, increases
the sensitivity to apoptosis induced by oxaliplatin and irinotecan in
wild type colon cancer cells and in cells resistant to the single agents
[21]. Finally, we further supported the role of TRAP1 as a cancer
biomarker, by demonstrating that TRAP1 expression is increased in
62% of colorectal carcinomas examined [21]. Taken together, these
results suggest that TRAP1 may be proposed as a novel molecular
target to overcome drug resistance. This hypothesis is further
supported by studies showing that TRAP1 and other proteins involved
in the activation of cell growth and signal transduction pathways,
such as MAPK and other targets involved in VEGF signaling, were
upregulated in nasopharyngeal carcinoma [23].
TRAP1 and ovarian cancer
Few data are available suggesting a role of TRAP1 in ovarian
cancers. In such a perspective, resistance to tumor necrosis factor-α
(TNFα)-mediated apoptosis in ovarian cancer-derived cells has been
observed [24]. However, the relevance of these studies to the
heterogeneity of ovarian cancer has yet to be established. Further-
more, in previous studies aiming to understand the molecular basis
for the failure of CDDP-based chemotherapy, a gene expression
comparison between CDDP-sensitive and CDDP-resistant ovarian
tumor cell lines, by mRNA differential display, highlighted TRAP1,
HSP27 and HSP70 as the most signiﬁcant up-regulated genes in
resistant cells [24]. Furthermore, transient transfection with HSP27
expression vectors made the sensitive cell more resistant, while
transfection with the speciﬁc antisense oligonucleotides made the
ovarian tumor cell line more sensitive [25]. These results are in
agreement with the direct correlation between HSP overexpression
and resistance to chemotherapy in several human malignancies (see
previous chapter in this review). Recent proteomic approaches
identiﬁed other redox regulatory proteins, such as peroxiredoxins,
thioredoxin-2, and several HSPs such as tumor-associated protein in
ovarian serous cystadenocarcinoma [26].
Another study was performed to identify the mechanisms
underlying progesterone's growth suppressive and immunomodula-tory effects in endometrial cancer. Expression analysis demonstrated
a signiﬁcant effect of progesterone on a number of genes, including
cell signaling, DNA remodeling, apoptotic, tumor-suppressor, and
transcription factors. Speciﬁcally, a consistent modulation of cyto-
kines was demonstrated: pro-inﬂammatory genes such as TNFalpha,
IL-1beta, and MCP-1/MCAF-1 were down-regulated and anti-
inﬂammatory genes such as TRAP1 and SMAD4 were induced [27].
Furthermore, a CDDP-resistant ovarian carcinoma cell line exhibited
a 20-fold level of drug resistance (PE01CDDP), compared to the
parental PE01 line. Microarray analysis revealed 51 genes whose
mRNA increased by at least 2 fold in PE01CDDP cells relative to
PE01, including TRAP1 [28]. Finally, other studies suggest that
expression levels of certain proteins in ovarian cancers are estrogen-
regulated and this could help to identify patients who would beneﬁt
from endocrine therapy. Interestingly, TRAP1 expression is increased
in estrogen receptor-positive ovarian cell lines while TRAP1 up-
regulation by estrogen is reversed by the anti-estrogen tamoxifen.
These studies also aimed to explore the predictive value of estrogen-
regulated gene changes as indicators of sensitivity in ovarian cancer
patients treated with the aromatase inhibitor letrozole [29].
Signiﬁcant differences in expression levels of TRAP1 were observed
between tumors from CA125 responsive/stable patients as opposed
to tumors from patients whose disease was progressing, using serum
levels of CA125 as an indicator of response. Aromatase expression in
the ovarian cancers also differed between these 2 groups of patients
[29].
Taken together, the identiﬁcation of TRAP1 as a potential target in
ovarian cancer may provide an opportunity to improve the treatment
options in this tumor through customized clinical trial designs, and
important therapeutic advances for patients with this invalidating
malignancy.
Major issues in the clinical management of advanced
ovarian cancer
The majority of patients with epithelial ovarian cancer are
diagnosed with locally-advanced or metastatic disease (FIGO stages
III and IV), making this the gynaecologic cancer associated with the
highest morbidity in the western world. While surgery is a
fundamental component of initial therapy, most patients cannot be
cured by surgery alone, due to residual microscopic and macroscopic
peritoneal implants or distant metastases. However, ovarian carcino-
ma is a chemosensitive tumor and is one of the malignancies for
which the strategy of delivering cytotoxic pharmaceutical agents
produced more favorable clinical beneﬁts. Numerous chemothera-
peutics have been shown to induce objective responses following
surgery, and current treatment with combination chemotherapy
results in clinical complete remission in the majority of patients with
locally-advanced ovarian cancer. Indeed, median progression-free
survival (PFS) ranges from 16 to 21 months and median overall
survival (OS) from 24 to 60 months, depending upon the volume of
disease at the time chemotherapy is started [30]. Consequently, 5-
year survival rates have increased from 30% in the 1960s to almost
50% in the current decade. However, there are a considerable number
of patients who relapse after initial chemotherapy and all of themwill
ultimately succumb to their disease. Median survival following
relapse is approximately 2 years [31].
Platin derivatives are the backbone of chemotherapy in ovarian
cancer. Therefore, from this point of view, the identiﬁcation of TRAP1
as the target gene involved in platin-derived chemoresistance
becomes even more interesting. Initial studies employed CDDP in
combination with cyclophosphamide, and therefore, this doublet
became the reference regimen for subsequent studies until the GOG
111 trial showed the PFS and OS superiority of CDDP and paclitaxel
[32,33]. At present, the combination of carboplatin and paclitaxel is
considered the standard of care, since two large non-inferiority trials
Table 1
HSP90/TRAP1 antagonists under preclinical/clinical evaluation.
Pharmaceutical
agents
Target domain Human cancer models References
Geldanamycin HSP90 ATP-binding
N-terminal domain
Pancreas carcinoma,
rhabdomyosarcoma,
[42-44,
51,52]
Geldanamycin
Analogs
HSP90 ATP-binding
N-terminal domain
17AAG Prostate, breast, ovarian
and hepatocellular
carcinoma, melanoma,
neuroblastoma,
glioblastoma, advanced
solid malignancies
[42,45-46,
53-54,
55-61]
Radicicol n.a. [42-44]
PU-H71 Hepatocellular and breast
carcinoma
[53,62]
BIIB021 Multidrug-resistant tumor
cells
[63]
SNX-2112 Multiple myeloma [64]
17-DMAG Cervical, gastric, colon
hepatocellular and
pancreas carcinoma,
melanoma, multiple
gynecologic cancer cell
types
[53,56,
65-69]
IPI-504 Multiple myeloma,
pancreas and HER-2
positive breast carcinoma
[70-72]
Shepherdin Mitochondrial
HSP90/TRAP1
complex
n.a. [17,47-48]
Gamitrinibs HSP90 ATP-binding
N-terminal domain
(mitochondria-
directed)
n.a. [49]
Novobiocin HSP90 ATP-binding
C-terminal domain
Drug-resistant human
tumors
[7,73]
Epigallocatechin-
3-Gallate
(EGCG)
HSP90 ATP-binding
C-terminal domain
Kidney, prostate, breast
and pancreas carcinoma
[7,74-78]
n.a., not available.
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toxicity with at least equivalent efﬁcacy–over its CDDP counterpart
[34,35]. While these studies clearly suggest that platin-based
combination chemotherapy represents an improvement in the
treatment of advanced ovarian cancer, most patients still die from
their disease. Thus, an important challenge in the management of
ovarian cancer is the development of novel strategies to improve the
efﬁcacy of chemotherapeutic regimens, both for induction chemo-
therapy and for patients at the time of relapse.
Several studies have tried to increase the efﬁcacy of the
carboplatin/paclitaxel doublet, with no success. After exposure to
platin derivatives, various agents have been tested with disappointing
activity or relevant critical toxicities. Topotecan, gemcitabine and
pegylated liposomal doxorubicin came into common use due to their
reproducible activity and reasonable therapeutic index [36]. However,
the addition of the latter three agents into the ﬁve-arm GOG 182 trial
did not prove advantageous over the carboplatin/paclitaxel doublet
as ﬁrst-line chemotherapy [37]. When used as short–term consolida-
tion or maintenance after initial platinum-based induction therapy,
only paclitaxel showed improvement in PFS [38].
A relevant issue in ovarian cancer therapy is the management of
patients who recur after platin-based chemotherapy. It is well
recognized that tumors which have responded to platinum-based
regimens might respond a second or third time to this class of agents
[39]. The probability of such a response is closely related to the
duration of the platinum-free interval, which is the time from
completion of the last regimen and the documentation of disease
progression. In platinum-sensitive recurrence (i.e., evidence of
disease N6 months since the last platinum treatment), two random-
ized phase III trials documented the favorable impact of the re-
challenge of platinum-based combination therapy (platin/paclitaxel
or platin/gemcitabine) compared to single-agent platinum [40,41]. By
contrast, the outcome of patients with early recurrence after platin-
based chemotherapy (i.e., evidence of disease b6 months since the
last platinum treatment) is generally worse since the clinical activity
of platinum derivative re-challenge or other chemotherapeutic regi-
mens is poor. Thus, it is critical to characterize novel molecular
markers able to predict a condition of resistance to platin derivatives
and develop novel strategies to overcome drug resistance and
improve the outcome for this subset of patients.
TRAP1: a novel therapeutic molecular target in
ovarian carcinoma?
The results reported above support the working hypothesis that
TRAP1 could be a novel molecular target in ovarian carcinoma. This is
supported by two major observations: (i) platin-based therapies are
at present the most successful in the advanced setting of this disease
and (ii) the up-regulation of TRAP1 expression in human CDDP-
resistant ovarian carcinomas and ovarian cancer cell lines suggest that
TRAP1 is involved in CDDP resistance [24,28] and thus may be
regarded as a novel biomarker of drug-resistance in this malignancy.
Furthermore, the mitochondrial heat shock protein TRAP1 is a critical
component of a mitochondrial pathway involved in protecting tumor
cells from apoptosis and favoring drug-resistance [17]. This hypoth-
esis would indicate that targetedmolecular strategies mainly aimed at
inhibiting the pro-survival activity of the TRAP1/HSP90 pathway may
improve the efﬁcacy of anticancer treatments by decreasing drug
resistance. Thus, it is tempting to speculate that elucidation of the
exact molecular mechanisms that govern TRAP1-mediated regulation
of cell survival and drug-resistance in ovarian cancer may provide
novel diagnostic tools for drug-resistance assessment, andmay lead to
an improvement in ovarian cancer treatment by providing the
rationale to develop new therapeutic strategies.
In such a context, it is signiﬁcant that several agents which target
the TRAP1/HSP90 pathway are under preclinical/clinical evaluationin several human malignancies (Table 1). A derivative of geldanamy-
cin, 17AAG, has been proposed for clinical use in cancer patients for its
ability to block the HSP90 pathway, by binding the regulatory pocket
in the N-terminal domain of HSP90 [42]. 17AAG has shown signiﬁcant
antitumor activity in vitro and in animal models and, thus, has entered
clinical testing in cancer patients [43]. Down-regulation of client
proteins (i.e., Raf-1, cdk4 and Akt, see also Figs. 1B and C as an
example) has been reported in lymphocytes at well-tolerated doses of
17AAG [44] and early evidence of therapeutic activity has been
described in human solid tumors by using 17AAG alone or in
combination with paclitaxel [45,46]. However, recent reports suggest
that 17AAG is unable to accumulate in mitochondria [17,47]: hence,
HSP90 inhibition as well as cytochrome c release cannot occur, and
apoptosis is therefore not activated. Recently, it has been reported
that the mitochondria-directed ATP binding peptidomimetic shep-
herdin induces the disruption of TRAP1/HSP90 interaction and favors
CypD release and the consequent opening of the mitochondrial
permeability transition pore [17]. Furthermore, we have recently
shown that the inhibition of TRAP1 activity by shepherdin rescues the
resistance to apoptosis induced by oxaliplatin and irinotecan in
colorectal carcinoma cells resistant to the single agents [21]. The
advantage of using shepherdin to block ATP binding and ATPase
activities, compared to the widely used pharmacological ATPase
inhibitors 17AAG, geldanamycin and radicicol [17,47,48], depends on
the speciﬁcity of its effects. In fact, shepherdin is directed to
mitochondria due to the Antennapedia sequence, where TRAP1 and
181M. Landriscina et al. / Gynecologic Oncology 117 (2010) 177–182HSP90 are active in protecting against apoptosis. Since TRAP1 (i) is
present only in mitochondria, while HSP90 is also localized in the
cytoplasm, and (ii) shows an ATP binding afﬁnity higher than that of
HSP90 (KM 33 μM vs. 100 μM, respectively), the efﬁciency and
selectivity of blocking TRAP1 ATPase activity by shepherdin in
mitochondria becomes highly relevant [15]. These data also suggest
that strategies aimed at inhibiting TRAP1 function, based on novel
TRAP1 ATPase antagonists, may induce sudden collapse of mitochon-
drial function and apoptosis, thus improving the efﬁcacy of anticancer
treatments.
Recently, gamitrinibs, a novel class of small molecules, have been
described. These agents are designed to selectively target HSP90 in
human tumor mitochondria and have been shown to accumulate in
the mitochondria of human tumor cell lines and to inhibit HSP90
activity by acting as ATPase antagonists [49]. Taken together, these
results suggest that TRAP1 may be regarded as a novel molecular
target to overcome drug resistance in ovarian cancer and TRAP1
antagonists deserve to be evaluated at preclinical and clinical levels as
pharmacological tools potentially able to restore/improve the
sensitivity of cancer cells to antiblastic agents. Such studies would
provide critical information for the understanding of the molecular
mechanisms involved in the resistance to anticancer agents in ovarian
cancer and would be extremely useful when designing novel
therapeutic strategies based on the combination of traditional
chemotherapeutic agents and TRAP1-speciﬁc antagonists with the
aim of rescuing drug-resistance and improving clinical outcome.Concluding remarks
Nowadays, great clinical interest is focused on novel molecular-
targeted tumor-speciﬁc agents and on the design of multi-target
strategies based on the simultaneous inhibition of several tumor-
speciﬁc pathways, with the aim of reversing drug-resistance and
improving antitumor activity. In such a context, molecular chaper-
ones and stress responsive proteins may be potential molecular
targets for improving the cytotoxic effects of drug therapies and
overcoming drug resistance. These studies, although still prelimi-
nary, will also provide critical information for the understanding of
the molecular mechanisms involved in resistance to molecular-
targeted agents.
At the cellular and molecular levels, ovarian cancers are remark-
ably heterogeneous. At least 15 oncogenes have been implicated and
at least seven signaling pathways are activated in N50% of ovarian
cancers, such as the PI3K–Akt–PTEN pathway, and these are potential
targets for anticancer therapeutics [50]. Examples of target molecules
and signaling pathways altered in ovarian cancer are shown in Fig. 1.
Given the heterogeneity of this disease, increases in long-term
survival might be achieved by translating recent insights at the
molecular and cellular levels into personalized individual strategies
for treatment and by optimizing early detection. Our studies on TRAP1
and other predictive biomarkers will provide proof-of-principle of
target modulation, could be used for patient selection, and will be
essential in the development of novel molecular-targeted therapies
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ve deletion mutant sensitized tumor cells to apoptotic
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as a novel molecular target in localized and metastatic
te cancer (4), and some other tumors (5), whereas
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le is known about TRAP1 signal transduction. Kang and
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etwork selectively active in mitochondria of tumor
s. Other studies suggested an involvement of this chap-
in cell adhesion and synaptic morphology through the
lation of N-cadherin expression (8). Starting from this
d information, a proteomic analysis of TRAP1 coimmu-
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her characterize the TRAP1 network and evaluate pro-
teractors relevant for TRAP1 role in multidrug resis-
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al muscle, kidney, and brain, but most abundantly in
c muscle (9). After Ca2+ binding, the overall hydropho-
of the protein increases, and this leads to the transloca-
rom the cytoplasm to cell membranes, resulting in
ependent interaction with other proteins (e.g., the rya-
e receptor; ref. 10). Although several biochemical studies
ailable on the direct binding of Sorcin to both cardiac
dine receptor RyRs (9) and voltage-dependent L-type
m channel CaV1.2 (11, 12), little is known about the
on of this soluble Ca2+-binding protein in chemoresis-
Indeed, intracellular Ca2+ concentration may play a role
development of chemoresistance, as suggested by clin-
als with verapamil, a Ca2+ channel blocker which selec-
enhances drug cytotoxicity in MDR cell lines (13). Thus,
tudies, aimed at investigating the regulatory role of Ca2+
ol resistance, have suggested that chemoresistant cells
s higher levels of the Ca2+-binding protein Sorcin and
tiapoptotic Bcl2, compared with the parent cell line
oth these proteins have previously been implicated in
resistance, in part due to their ability to modulate
vels. Other reports suggest a correlation between Sor-
d the multidrug-resistant MDR1/P-glycoprotein: it has
hown that the knockdown of Sorcin induces the upre-
on of MDR1 in HeLa cells (15); by contrast, a direct
ation between Sorcin and multidrug resistance overex-
on has also been reported in human gastric cancer cell
nd vincristine-resistant gastric cancer cells (16–18).
, recent studies aimed at evaluating changes in gene
ssion profile in oral squamous cell carcinoma and
mall cell lung cancer identified a cDNA homologous
cin expressed only in tumors, apparently responsible
g resistance and poor prognosis (19, 20).
s study shows for the first time that TRAP1 and a Sor-
form with an electrophoretic motility of 18 kDa inter-
mitochondria, and that the result of this interaction
erve as an additional or alternative indirect route by
both proteins can regulate apoptosis and chemoresis-
in colorectal carcinoma cells.
rials and Methods
icals, cell cultures, constructs, short hairpin
and small interfering RNAs
P, FU, and IRI and all reagents were purchased by
-Aldrich unless otherwise specified. MG-132 was pur-
d by Merck Chemicals Ltd-Calbiochem; shepherdin
ntrol scrambled peptides were synthesized by PRIMM
orted in ref. (7).
an Saos-2 osteosarcoma and HCT-116 colon carcino-
lls were purchased from the American Type Culture
tion (ATCC) and cultured in DMEM containing 10% fe-
ine serum, 1.5 mmol/L glutamine, and 100 U/mL pen-
and streptomycin. Cell lines are routinely monitored in
boratory by microscopic morphology check. Authenti-
of cell lines has been checked before starting this
<1 year ago, through standardized techniques by eval-
, respectively, the haplotype in Saos-2 cells (HLA A2,
lowed
in ea
r Res; 70(16) August 15, 2010
American Association Copyright © 2010 
cancerres.aacrjournals.oDownloaded from 16, and Bw47) and the presence of a mutation in co-
of the ras proto-oncogene in HCT-116 cells, according
CC product description.
-length TRAP1 cDNA was cloned in pRc-CMV vector
ogen; ref. 21). cDNAs for 22- and 18-kDa sorcin iso-
were cloned in pRc-CMV or p-cDNA 3.1 vectors each
ng HA or Myc epitopes at the COOH terminus, respec-
Small interfering RNAs (siRNA) of TRAP1 and Sorcin
purchased from Qiagen. For knockdown experiments,
s were diluted to a final concentration of 20 nmol/L
ansfected according to the manufacturer's protocol.
1-stable interference was achieved by transfecting
116 cells with TRAP1 (TGCTGTTGACAGTGAGC-
CGGTCCCTGTACTCAGAAATAGTGAAGCCACAGATG-
TCTGAGTACAGGGACCGGGCTGCCTACTGCCTCGGA)
ambled (sequence containing no homology to known
alian genes) short hairpin RNAs (shRNA) (Open
tem).
escence microscopy
analysis of immunofluorescence was performed with a
al laser scanner microscopy Zeiss 510 LSM (Carl Zeiss
imaging GmbH), equipped with Argon ionic laser (Carl
Microimaging GmbH) whose λ was set up to 488 nm, a
laser whose λ was set up to 546 nm, and an immersion
jective, 63 ×/1.4 f.
ransfection experiment in cultured HCT116 cells were
8-kDa Sorcin and mitochondria-targeted red fluores-
protein (p-mitoRFP) expression vectors.
omic analysis of TRAP1 coimmunoprecipitation
lexes
is and immunoprecipitation procedures. TRAP1 com-
were isolated from Saos-2 osteosarcoma cell total
ts by affinity purification. Stable cells expressing
1-HA were lysed and then incubated onto anti-HA
e–conjugated antibody overnight under gentle stirring.
were collected by centrifugation (3,000 rpm for
utes*), extensively washed with lysis buffer supplemen-
ith 150 mmol/L NaCl to eliminate nonspecific bound
ns. Elution of the desired protein complexes was per-
d by competition with HA peptide in elution buffer.
luted proteins were precipitated in methanol/chloro-
and then loaded onto a 10% SDS-PAGE. The gel was
d with colloidal Coomassie blue (Thermo Scientific).
n bands were excised from the gel, reduced, alkylated,
igested with trypsin (22).
spectrometry analysis and protein identification
tide mixtures extracted from the gel were analyzed
nochromatography tandem mass spectrometry (MS/
n a CHIP MS Ion Trap XCT Ultra equipped with a
ary 1100 high-performance liquid chromatography
and a chip cube (Agilent Technologies). Peptide
is was performed using data-dependent acquisition
e MS scan (mass range from 400–2,000 m/z) fol-
by MS/MS scans of the three most abundant ions
ch MS scan. Raw data from nanochromatography
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n database using the in-house MASCOT software
x Science).
oxicity assays
ptosis was evaluated by cytofluorimetric analysis of
in V and 7-amino-actinomycin D–positive cells by
the FITC-Annexin V/7-amino-actinomycin D kit
an Coulter). Stained cells were analyzed by “EPICS
ow Cytometer (Beckman Coulter). Ten thousand events
ollected per sample. Positive staining for Annexin V
ll as double staining for Annexin V and 7-amino-
mycin D were interpreted as signs of, respectively,
and late phases of apoptosis (23). In specific experi-
, HCT-116 wild-type (WT) or HCT sh-TRAP1 cells
transiently cotransfected with pRc-CMV (mock) or
a Sorcin constructs and pEGFP-F (Clontech) and,
urs later, treated with 10 μmol/L, FU, IRI or l-OHP.
nduced apoptosis was evaluated by propidium iodide
g. The transfection vector pEGFR-F, which encodes
farnesylated-enhanced green fluorescent protein
-F), was used as a repoter vector both to monitor
ection efficiency and as a cotransfection marker.
iments were performed at least thrice using three
tes for each drug concentration.
noblot analysis
al cell lysates were obtained by homogenization of
ellets in cold lysis buffer [20 mmol/L Tris (pH 7.5)
ining 300 mmol/L sucrose, 60 mmol/L KC1, 15
/L NaC1, 5% (v/v) glycerol, 2 mmol/L EDTA, 1%
Triton X-100, 1 mmol/L phenylmethylsulfonyl fluo-
2 mg/mL aprotinin, 2 mg/mL leupeptin, and 0.2%
deoxycholate] for 1 minute at 4°C and further son-
for an additional 30 seconds at 4°C. Mitochondria
purified using the Qproteome Mitochondria Isolation
iagen) according to the manufacturer's protocol. Mi-
drial subfractionation was performed according to
and colleagues (24). Briefly, 150 μg of mitochondria
ed from HCT-116 cells were swollen with hypotonic
m to break the outer mitochondrial membrane,
g intact the inner mitochondrial membrane. The
n mitochondria were pelleted by centrifugation;
pernatant contained the soluble proteins released
the inner mitochondrial membrane; and the pellet
e mitoplast fraction. Immunoblot analysis was per-
d as previously reported (2). Specific proteins were
ed by using the following mouse monoclonal anti-
s from Santa Cruz Biotechnology: anti-TRAP1
557), anti-Sorcin (sc-100859), anti-cMyc (sc-40),
OX4 (sc-58348), anti–cytochrome c (sc-13156), anti-
n (sc-8035), and anti–glyceraldehyde-3-phosphate de-
genase (GAPDH; sc-69778). The rabbit polyclonal
n-SOD was purchased from Upstate Biotechnology,
nti–F1-ATPase (sc-16690) was from Santa Cruz Bio-
ology. Anti-Sorcin polyclonal antibody was a kind
om Prof. E. Chiancone, University of Rome “La
za”, Rome, Italy.
tentio
MS/M
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cancerres.aacrjournals.oDownloaded from uantitative reverse transcription-PCR analysis
al RNA was extracted using the Trizol Reagent (Invitro-
The following primers used were as follows: TRAP1,
rd 5 ′ -GACGCACCGCTCAACAT -3 ′ , reverse 5 ′ -
TCAAACATGGACGGTTT-3′; Sorcin 22 kDA (transcript
ward 5′-CGCAGTCTGCAGCATGGCG-3′, reverse 5′-
CGGCAAGTCTCCAGGT-3′; Sorcin 18 kDa (transcript
ward 5′-GGCCACTCTGCAAGAAGGCA-3′, reverse 5′-
GGAGCCCCTCCATACT-3′ ; GAPDH, forward 5′-
GCTGAGAACGGGAA-3′, reverse 5′-GCATCGCCC-
GATTTT-3′. Reaction conditions were 95°C for 10 min-
ollowed by 35 cycles of 30 seconds at 95°C, 30 seconds
C, 5 minutes at 72°C, and 7 minutes at 72°C.
tical analysis
paired Student's t test was used to establish the sta-
l significance between different levels of apoptotic cell
in cell lines overexpressing 18-kDa Sorcin or TRAP1, or
ch Sorcin and/or TRAP1 expression had been knocked
compared with the respective mock-transfected con-
tatistically significant values (P < 0.05) are reported
Tables.
lts
is a mitochondrial TRAP1 interactor
ishing for partners” strategy combined with mass spec-
tric procedures was carried out to identify TRAP1 pro-
artners specifically interacting with the bait. Previous
s from our group showed that TRAP1 gene expression
sed upon adaptation of human osteosarcoma cells to
ic mild oxidizing conditions and a phenotype resistant
2– or cisplatin-induced DNA damage and apoptosis
nerated upon transfection with TRAP1 (21). Therefore,
osteosarcoma cells were stably transfected with the
AP1 construct or the empty vector as control. Total
n lysates were incubated with anti-HA–conjugated aga-
eads and the retained samples were eluted by compe-
with HA peptide. The sample and the control were
nated by 10% SDS-PAGE. The entire lanes from the
re cut into slices, and each gel slice was submitted
identification procedure (25). The resulting peptide
res were directly analyzed by mass spectrometry (liquid
atography/tandem mass spectrometry, LC-MS/MS)
entified by the MASCOT protein database search. Pro-
dentified in the control and the sample lanes were dis-
, whereas those proteins solely identified in the sample
bsent in the control were selected as putative TRAP1
ctors. Among the putative TRAP1 binding partners,
l mitochondrial proteins, mainly components of the
rane carrier family, were identified. Other interactors
e cytoskeleton proteins as tubulin and some actin iso-
, as well as proteins involved in cell remodeling, as pre-
y suggested by Kubota and colleagues (8), protein
thesis, posttranslational modifications and cell cycle
tion, as previously described (26). We focused our at-
n on a protein of ∼18 kDa identified as Sorcin by LC-
S analysis. No trace of this protein could be observed in
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ied showed an electrophoretic mobility corresponding
olecular mass slightly lower (18 kDa) than that re-
in the Swiss Prot databank (22 kDa).
group is involved in the study of molecular mechan-
nvolved in chemoresistance of colorectal cancers (3).
fore, TRAP1/Sorcin interaction was confirmed in
16 (Figs. 1A and 2A) and HT-29 (data not shown) colon
oma cells by coimmunoprecipitation experiments
either anti-TRAP1 (Fig. 1A) or anti-Sorcin (Fig. 2A)
dies. As shown in Fig. 1A, Western blot analysis using
orcin antibodies revealed two specific bands in total ly-
from HCT-116 cells. Because TRAP1 is almost com-
y localized in mitochondria, a subfractionation of
ysates was performed and revealed that the 22-kDa
band is present only in the cytosolic fraction, whereas
wer molecular weight (LMW) protein with an electro-
tic motility of ∼18 kDa is localized in the mitochondria
A). Interestingly, we observed that TRAP1 interacts
cally with the 18-kDa Sorcin isoform (Fig. 1A). Accord-
ions was assessed by using the listed antibodies specific for the submitocoimmunoprecipitation analyses using mitochondrial
s confirmed the specific interaction between TRAP1
purifi
TRAP
r Res; 70(16) August 15, 2010
American Association Copyright © 2010 
cancerres.aacrjournals.oDownloaded from e LMW Sorcin (Supplementary Fig. S1). The identifica-
f the 18-kDa Sorcin as specific to the mitochondrial
rtment and the finding that it interacts with TRAP1
ochondria were both unexpected because Sorcin has
reviously described as a cytosolic protein, with no de-
n its specific organelle localization. The finding of two
isoforms with different electrophoretic mobilities and
ecific interaction of TRAP1 with the LMW isoform was
r confirmed by immunoblot analysis of immunopreci-
s from HCT-116 cells transfected with either 22- or 18-
orcin expression vectors (Fig. 1B). These results agree
uantitative reverse transcription-PCR (RT-PCR) analy-
RNA purified from HCT-116 cells showing the pres-
of two independent transcripts encoding for two
isoforms, namely variants a and b (data not shown),
reported in the BLAST databases (Supplementary Fig.
nally, fluorescence microscopy analysis shows that the
sorcin isoform (a) colocalizes with mitoRFP (b) in mi-
ndria (Fig. 1C). To further characterize the submito-
rial compartments involved in the interaction, we
ial compartments.1. TRAP1 interacts with Sorcin within the mitochondria. A, total cell lysates from HCT-116 cells were fractionated in the cytosolic (CYTO) and
ndrial (MITO) fractions, separated by SDS-PAGE and immunoblotted with mouse monoclonal anti-TRAP1, anti-Sorcin, and anti-tubulin antibodies.
total cellular extracts incubated with protein A/G-Sepharose without antibodies; IP, immunoprecipitation with the corresponding antibodies.
-116 were transfected with expression vectors specific for the 22- or 18-kDa Sorcin isoforms carrying, respectively, HA or Myc epitopes at the COOH
s. Total cell lysates, and TRAP1 and Sorcin immunoprecipitates were analyzed by SDS-PAGE and immunoblotted with anti-TRAP1 antibodies.
nsfection experiment in HCT116 cells with pcDNA 3.1 Myc plasmid expressing 18-kDa sorcin cDNA (a) or mitochondria-targeted red fluorescence
(mitoRFP) plasmid (p-mitoRFP; b). Fluorescence microscopy shows that the chimeric sorcin protein (a) colocalizes with the fluorescent protein
itochondria (b). c, merge. Scale bar, 2 μm. D, mitochondria prepared from HCT-116 cells were swollen with hypotonic medium to break the outer
ndrial membrane, keeping the inner mitochondrial membrane intact as described in Materials and Methods. The swollen mitochondria wereed mitochondrial subfractions and showed that
1/Sorcin binding occurs in the mitoplast fraction,
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ria (Fig. 1D; ref. 24). These results agree with the sub-
ondrial localization of TRAP1.
teraction between Sorcin and TRAP1 is specific
equires the NH2-terminal domain of TRAP1
binding specificity between the two proteins was
med using protein lysates from HCT-116 cells in
TRAP1 expression was notably decreased by shRNAs
AP1). Indeed, in these cells, coimmunoprecipitation
is failed to detect the interaction between TRAP1
MW Sorcin (compare coimmunoprecipitation analy-
Fig. 2A and B) due to the very low intracellular
levels after RNA interference (compare TRAP1 pro-
vels in the lanes of total lysates in Fig. 2A and B). As
usly shown, TRAP1 has a mitochondrial targeting se-
e located at the NH2 terminus of the protein (26). To
which TRAP1 domain was involved in TRAP1/Sorcin
ction, we performed the same coimmunoprecipita-
xperiments with protein lysates obtained from
16 cells transfected either with a mutant of TRAP1
ich the first 100 amino acids at the NH2-terminal end
fused to the myc tag (Fig. 2C), or with the ΔN mu-
acking the NH2-terminal domain of TRAP1 and car-
an HA epitope at the COOH terminus (Fig. 2D). The
indicate that Sorcin binding requires the NH2 ter-
of TRAP1 protein (Fig. 2C) and that the interaction
en these two proteins is lacking when the first 100
the le
protei
-116 cells were transfected with a mutant TRAP1 construct lacking 100 amino a
for amino acids 101 to 604 fused to cMyc epitope at the COOH terminus (ΔN-M
acrjournals.org
American Association Copyright © 2010 
cancerres.aacrjournals.oDownloaded from acids are deleted (Fig. 2D). This also agrees with
tosolic localization of this TRAP1 deletion mutant
not shown).
rocal regulation of TRAP1 and Sorcin
then sought to characterize the regulation that oc-
etween the two proteins upon their binding. To this
e measured the levels of each protein by overexpres-
r downregulating either Sorcin and/or TRAP1, re-
vely. Figure 3A shows that a decreased expression
LMW Sorcin isoform is detected in mitochondria
TRAP1 HCT-116 colon carcinoma cells compared
WT cells. Because TRAP1 has chaperone activity
the only member of the HSP90 family with mito-
rial localization (26), and considering that Sorcin is
of a canonical mitochondrial localization sequence,
pothesized that TRAP1 might be involved in Sorcin
ort to mitochondria. With this aim, we showed that
ansfection of TRAP1 expression vectors in cells with
ow amount of TRAP1 (sh-TRAP1) restores mitochon-
evels of LMW Sorcin to those observed in WT cells
A). The fact that the “low Sorcin” phenotype in sh-
1 cells is rescued upon TRAP1 transfection suggests
olvement of TRAP1 in the mitochondrial transport
LMW Sorcin isoform. As a control, interference of
HSP90 or HSP70 by specific siRNAs did not affect
vels of Sorcin (data not shown). Conversely, TRAP1
n levels decrease in colorectal carcinoma cells upon2. Characterization of TRAP1 domains involved in the interaction with Sorcin. Protein lysates from different cells (see below) were
precipitated with the indicated antibodies, analyzed by SDS-PAGE, and immunoblotted with the listed antibodies. No Ab, total cellular extracts
ed with protein A/G-Sepharose without antibodies; IP, immunoprecipitation with the corresponding antibodies. A, WT HCT-116 cells.
-116 cells in which TRAP1 expression was stably decreased by shRNA (sh-TRAP1). C, HCT-116 cells were transfected with a mutant TRAP1
ion vector containing cDNA sequences coding for amino acids 1 to 100 at the NH2 end, fused to cMyc epitope at the COOH terminus (N100-Myc).cids at the NH2 end and containing cDNA sequences
yc).
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Published OnlineFirst July 20, 2010; DOI:10.1158/0008-5472.CAN-10-1256ent downregulation of Sorcin expression by specific
s (Fig. 3B). These results show a reciprocal regula-
etween TRAP1 and Sorcin. Previous data suggest
his calcium-binding protein could be involved in
gulation of the gene expression of MDR1 in HeLa
15). The subcellular fractionation analysis by Western
hown in Fig. 3C and D indeed suggests that Sorcin's
onal role could be to contribute to TRAP1 protein
ty. In fact, the decreased TRAP1 expression observed
Sorcin interference (Fig. 3C, lane 2) is prevented by
etreatment of colon carcinoma cells with the protea-
inhibitor MG132 (Fig. 3C, lane 4). The same results
obtained using purified mitochondrial lysates (Fig.
present the mean of three independent experiments.n agreement with posttranslational regulatory me-
ms, we confirmed that mRNA levels of TRAP1 were
(0.5 m
role o
r Res; 70(16) August 15, 2010
American Association Copyright © 2010 
cancerres.aacrjournals.oDownloaded from ffected by Sorcin interference, thus excluding tran-
onal regulation (Supplementary Fig. S3).
1/Sorcin interaction is prevented upon Ca2+
tion
known that Sorcin may modulate the cytoplasmic re-
f Ca2+, mainly from smooth endoplasmic reticulum in
ns (27). We therefore evaluated whether TRAP1/Sorcin
ction could be modulated by chelating free Ca2+ with
ne glycol tetraacetic acid. As shown in Supplementary
, binding between the two proteins is greatly decreased
presence of 0.1 mmol/L ethylene glycol tetraacetic
eing completely abolished at a higher concentration3. TRAP1/Sorcin reciprocal regulation. A, total cell lysates from WT HCT-116, sh-TRAP1, or sh-TRAP1 cells transfected with TRAP1 full-length
ct were fractionated in the cytosolic (CYTOSOL) and mitochondrial (MITO) fractions as described in Materials and Methods, separated by
GE, and immunoblotted with mouse monoclonal anti-TRAP1 and anti-Sorcin antibodies, and rabbit polyclonal anti-F1 ATPase antibodies. Note
densitometric band intensities of LMW Sorcin in mitochondria of indicated cell populations are 1 (WT), 0.21 (sh-TRAP1 cells), and 0.92
P1+TRAP1), respectively. Three independent experiments were performed with similar results. B, total cell lysates from HCT-116 cells transfected
nspecific siRNA as a control (line 1) or two independent siRNAs of Sorcin (lines 2 and 3) were separated by SDS-PAGE and immunoblotted
use monoclonal anti-TRAP1, rabbit polyclonal anti-Sorcin, and mouse monoclonal anti-GAPDH antibodies. Note that densitometric band intensities
P1 or 22-kDa Sorcin are indicated by numbers by assuming protein levels of the controls (WT cells) are equal to 1. Three independent
ents were performed with similar results. C and D, TRAP1 and Sorcin immunoblot analysis of total cell lysates (C) and mitochondrial fractions (D)
CT-116 cells transfected with siRNA-negative control (lines 1 and 3) or siRNA of Sorcin (lines 2 and 4), and cultured in the presence of the
ome inhibitor MG-132 (250 nmol/L) for 48 h (lines 3 and 4), or the inhibitor-free solvent (lines 1 and 2). Note that densitometric band intensities for
or 18-kDa Sorcin are indicated by numbers by assuming protein levels of the respective control (mock-transfected cells) are equal to 1.mol/L) of the Ca2+ chelator. This suggests a regulatory
f Ca2+ in TRAP1/Sorcin binding.
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ance and are coupregulated in human
ctal carcinomas
previously showed the role of TRAP1 in the resis-
of colon carcinoma cells to FU-, l-OHP–, and IRI-
d apoptosis (3), and data are available on Sorcin in-
ent in multidrug resistance in gastric cancer cell
(16). Here, we confirm an analogous role of Sorcin
g resistance in HCT-116 colon carcinoma cells ex-
to the same three drugs. Indeed, HCT-116 were
ed for 48 hours in the presence of FU, IRI, or
, and evaluated for the rate of apoptotic cell death.
nsitivity to each drug is expressed as a ratio between
nduced and vehicle-induced apoptosis (Table 1). In-
ngly, protection by the 18-kDa Sorcin isoform toward
ogrammed cell death induced by FU, l-OHP, and IRI
erved (Table 1). To study the functional effects of
/Sorcin interaction on the protection from apopto-
evaluated the rates of apoptotic cell death in colo-
carcinoma HCT-116 cells treated with l-OHP upon
ent (siRNA) or stable (shRNA) downregulation of
and/or Sorcin gene expression. As shown in Table
silencing of either TRAP1 or Sorcin by siRNA en-
d drug-induced apoptosis. However, TRAP1/Sorcin
e knockdown did not induce any additional effect
ll death (Table 2), thus suggesting that the two pro-
concomitantly contribute to cytoprotection by inter-
and working together in a common pathway.
dingly, in parallel experiments, drug-induced cell
was evaluated in sh-TRAP1 HCT-116 cells transfected
he 18-kDa Sorcin isoform (Table 1). Interestingly, al-
HCT-116 cells overexpressing the 18-kDa Sorcin iso-
ar
lorect
le totic ecta
ck) or 18-kDa Sorcin c FP-F
Apoptosis (% ± SD) Ratio (±SD)
-1
eh
0 μ
0 μ
0 μ 1 6.7 ±
-1
eh
mpared with mock-transfected cells.
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cancerres.aacrjournals.oDownloaded from , and IRI, the downregulation of TRAP1 abolishes this
osis-resistant phenotype, further supporting the hy-
sis that Sorcin and TRAP1 cooperate in protecting
cell death and that the cytoprotective activity of Sor-
quires TRAP1 to be functioning (Table 1).
as recently shown that shepherdin, a mitochondria-
ed peptidomimetic, induces programmed cell death
rupting a cytoprotective pathway involving TRAP1,
vely active in tumor cell mitochondria (7). We have
usly shown that, indeed, this network is activated
on carcinoma cells (3). Here, we show that Sorcin
erence by siRNAs does not increase sensitivity to
erdin-induced apoptosis either in the presence or
ce of TRAP1 (Supplementary Table S1). Again, these
s suggest an interdependent activity on the part of
proteins, which interact to protect cells from mito-
rial apoptosis.
ed on the evidence that TRAP1 and Sorcin coo-
in inducing an apoptosis-resistant phenotype in
ctal carcinoma cells, we sought to evaluate TRAP1
orcin expression in human colorectal carcinomas.
stingly, we observed a concomitant upregulation
th Sorcin isoforms and TRAP1 protein levels in
f our series of 41 human colorectal carcinomas,
parallel increase in TRAP1 and Sorcin mRNA ex-
on levels evaluated by semiquantitative PCR analy-
igure 4 shows the protein and mRNA levels of
1 and Sorcin in three tumor specimens and in
spective normal noninfiltrated mucosas, chosen as
entative analytic results of our series. A parallel
ulation of TRAP1 and Sorcin was observed in co-
al carcinoma cells resistant to FU, l-OHP, and IRIe characterized by a reduced sensitivity to FU, (data not shown).cell ected CMV1. Rates of apop
ated r IRIcell death in color
onstructs and pEGl carcinoma
vector treApopt
 for C
 onrgs transiently transf
with FU, l-OHP, oosis (% ± SD) Ratio
1.4
Cancer Res; 7
 ancer Research
 November 30, 2011with pRc-(±SD) P
.004*
0(16) August 15, 20Mock 18-kDa Sorcin16 cells
icle 1.9 ± 0.2 2.4 ± 0.3
mol/L FU 9.6 ± 0.9 1.2 3.3 ± 0.4 ± 0.4 05.0 ± 1.4 .008*
mol/L l-OHP 10.5 ± 1.1 5.5 ± 1.3 1.9 ± 0.6 0.8 ± 0.4 0.008*
mol/L IRI 2.7 ± 1.2 3.4 ± 0.5
16 shRNA TRAP11.5 ± 0.5 0icle 2.2 ± 0.3 2.6 ± 0.2
mol/L FU 1.5 ± 0.9 2.1 4.3 ± 0.5 ± 1.00 μ 2 9.7 ± 2 9.3 n.s.*
0 μmol/L l-OHP 24.9 ± 0.8 11.3 ± 2.2 25.1 ± 0.4 9.6 ± 1.0 n.s.*
0 μmol/L IRI 28.3 ± 0.9 12.9 ± 2.5 31.4 ± 0.7 12.1 ± 1.3 n.s.*
E: Ratios are calculated between rates of apoptosis in drug- and vehicle-treated cells. P values indicate the statistical signif-
ce between the ratios of apoptosis in Sorcin- and mock-transfected cells. Apoptotic rates are calculated based only on sorted
FP-F–positive cells.
reviation: n.s., not significant.10 6583
Discu
Thi
work
Using
pitatin
teract
had be
findin
tion o
the or
tionat
main
major
18-kD
fractio
teract
more
Sor
impor
Consis
role o
prelim
drial l
Fig. S2
shown
naling
of Ca2
quent
meos
contri
pertur
the cy
to LM
lular c
in-dep
mech
(i.e., t
of Sor
The
led us
no can
into t
be tra
a mec
tently
of Sor
on the
the lev
by shR
ter tra
sion v
TRAP
isms,
teaso
invest
in the
Table
recta
OHP
down AP So e
expre
siRNA
Con ±
10 μ
OHP
± ± 0
30 μ
OHP
siRNA
Con ±
10 μ
OHP
± ± 1 03
30 μ
OHP
siRNA
Con ±
10 μ
OHP
± ± 2 03
30 μ
OHP
siRNA
Con ±
10 μ
OHP
± ± 2 .*
30 μ
OHP
shRNA
Con ±
10 μ
OHP
± ± 1 01
30 μ
OHP
shRNA in
Con ±
10 μ
O
± ± 1 .†
3
O
NOT
in d
stat
indu
neg
Abb
*Co
tran
†Compared with shRNA TRAP1 transfected cells.
Landriscina et al.
Cancer Res; 70(16) August 15, 20106584
American Association Copyright © 2010 
cancerres.aacrjournals.oDownloaded from 
Published OnlineFirst July 20, 2010; DOI:10.1158/0008-5472.CAN-10-1256ssion
s article provides evidence of a new mitochondrial net-
involving TRAP1 and the Ca2+-binding protein Sorcin.
mass spectrometry analysis of TRAP1 coimmunopreci-
g proteins, we identified Sorcin as a novel TRAP1 in-
or. To our knowledge, this is the first time that Sorcin
en found to associate to a mitochondrial protein. This
g prompted us to investigate the subcellular localiza-
f Sorcin because none of the previous data described
ganelle compartmentalization of this protein. Cell frac-
ion experiments clearly indicate the occurrence of two
Sorcin isoforms: the 22-kDa isoform, quantitatively the
Sorcin band, is found in the cytosol, whereas the LMW
a isoform is specifically localized in the mitochondrial
n. According to this finding, we show that TRAP1 in-
s with the LMW Sorcin isoform within mitochondria,
specifically in mitoplasts (Fig. 1).
cin is a Ca2+-sensitive protein, interacting with many
tant regulatory proteins involved in Ca2+ homeostasis.
tent with these features, the existence of a functional
f Ca2+ in the interaction between Sorcin and TRAP1 is
inarily shown by the interference of Sorcin mitochon-
ocalization upon Ca2+ depletion (see Supplementary
). Although the role of Ca2+ in mitochondria is widely
, little is known about the role of Ca2+ in TRAP1 sig-
. Because Sorcin is highly sensitive to the modulation
+ levels, the interaction with TRAP1 and the conse-
import of Sorcin into mitochondria, in which the ho-
tasis of calcium is strictly controlled (28), might
bute to defending the Ca2+-sensitive protein against
bations of Ca2+ levels, most frequently observed in
tosolic compartment. The selective binding of TRAP1
W Sorcin could also be dependent on the same subcel-
ompartmentalization of both proteins. However, more
th analysis is required to characterize the molecular
anisms involved in TRAP1/LMW Sorcin interaction
he effects of different protein structure/conformation
cin isoforms on the interaction with TRAP1).
interaction of Sorcin with a mitochondrial chaperone
to investigate how the Ca2+-binding protein, which has
onical mitochondria-targeting sequence, is imported
hese organelles and to analyze whether Sorcin might
nslocated into the mitochondrial compartment through
hanism involving its interaction with TRAP1. Consis-
with this assumption, we found that the localization
cin in the mitochondria of human cells is dependent
presence and abundance of TRAP1 (Fig. 3A). In fact,
els of 18-kDa Sorcin decrease upon TRAP1 knockdown
NAs, whereas a rescue of this phenotype is achieved af-
nsfection of colon carcinoma cells with TRAP1 expres-
ectors. Conversely, Sorcin interference might affect
1 protein stability through posttranslational mechan-
as suggested by preliminary experiments with the pro-
me inhibitor MG132 (Fig. 3B–D). Although further2. Rates of apoptotic cell death in colo-
l carcinoma HCT-116 cells treated with l-
upon transient (siRNA) or stable (shRNA)
regulation of TR
ssion1 and/or rcin genApoptosis
(% ± SD)
Ratio
(± SD)
P-negative control
trol 2.6
mol/L l- 5.90.2
0.4 2.3 .3mol/L l- 23.6 ± 1.2 9.1 ± 1.2Sorcin
trol 1.1
mol/L l- 7.50.1
0.5 6.8 .2 0.0mol/L l- 19.0 ± 1.4 17.3 ± 3.1 0.013TRAP1
trol 1.6
mol/L l- 21.30.2
1.4 13.3 .9 0.0mol/L l- 28.0 ± 1.2 17.5 ± 3.3 0.014TRAP1/Sorcin
trol 1.7
mol/L l- 15.90.3
1.1 9.3 .8 n.smol/L l- 28.6 ± 1.3 16.8 ± 4.5 n.s.*TRAP1
trol 2.4
mol/L l- 20.20.2
1.2 8.4 .3 0.0mol/L l- 27.3 ± 0.7 11.4 ± 1.3 0.007TRAP1/siRNA Sorc
trol 2.6
mol/L l- 17.70.2
1.0 6.8 .0 n.sHP
0 μmol/L l-
HP
32.4 ± 1.5 12.5 ± 1.6 n.s.†
E: Ratios are calculated between rates of apoptosis
rug- and vehicle-treated cells. P values indicate the
istical significance between the ratios of apoptosis
ced by l-OHP in transfected cells and the siRNA-
ative control.
reviation: n.s., not significant.
mpared with either siRNA Sorcin or siRNA TRAP1-
sfected cells.
igation is necessary to clarify the mechanism involved
regulation of TRAP1 expression by Sorcin in this regard,
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Published OnlineFirst July 20, 2010; DOI:10.1158/0008-5472.CAN-10-1256portant to underline that our findings are in line with pre-
tudies indicating that the suppression of Sorcin induced a
increase in the expression ofMDR1 (15), thus indicating a
this protein in regulatorymechanisms of gene expression.
ptosis is the essential response induced in tumor cells by
chemotherapeutic agents. Several mechanisms are in-
in resistance to chemotherapeutic agents in tumor cells
mong others, we recently studied, at a preclinical level,
le of TRAP1 in inducing a chemoresistant phenotype in
colorectal carcinoma (3), whereas a possible involve-
of this mitochondrial chaperone in ovarian cancer has
uggested (30). Other studies have identified TRAP1 as a
mitochondrial survival factor differentially expressed in
ed and metastatic prostate cancer compared with nor-
ostate. Targeting this pathway could be explored as novel
ular therapy in patients with advanced prostate tumors
rcin has been implicated in chemoresistance and cancer
l. In fact, high levels of this protein have been reported in
r cell lines and vincristine-resistant gastric cancer cell
16–18). Furthermore, Sorcin expressionmight be respon-
or drug resistance and poor prognosis in non–small cell
mors (19, 20). The results reported here suggest that the
usly described role of Sorcin in chemoresistance and cell
al may be dependent on its interaction with TRAP1 and
ement in TRAP1 mitochondrial antiapoptotic network.
our knowledge, this study is the first evidence of a role
by Sorcin in resistance to FU, IRI, and l-OHP, three anti-
agents that represent the backbone of human colorec- regula
antitative RT-PCR (C). B, densitometric analysis of TRAP1 and 18- and 22-kDa S
are expressed as fold increases, by assuming protein levels of the controls (M) a
acrjournals.org
American Association Copyright © 2010 
cancerres.aacrjournals.oDownloaded from and/or TRAP1 sensitizes human HCT-116 colon cancer
anticancer compounds that induce apoptosis, suggest-
at targeting the TRAP1/Sorcin network directly in mito-
ria may represent a novel therapeutic strategy for
ctal tumors. Indeed, it is very well established that regi-
combining FU with IRI or l-OHP are equally effective as
ne treatment for advanced colorectal carcinoma (31),
hieve a response rate of 30% to 50% and an overall sur-
f 14 to 20 months (32). Thus, the development of novel
gies able to counteract multidrug resistance to improve
icacy of systemic chemotherapy is a major issue in the
l management of colorectal cancer patients. In such a
ctive, our results suggest that the TRAP1/Sorcin path-
eserves to be further evaluated as a potential molecular
in human colorectal carcinoma for the clinical develop-
of mitochondria-targeting agents. Indeed, a derivative of
amycin, 17AAG, is at present under clinical investiga-
cancer patients due to its ability to block the HSP90/
1 pathway, by binding the regulatory pocket in the NH2-
al domain of HSP90 (33), whereas other small mole-
(e.g., shepherdin, gamitrinibs) have been designed to
vely accumulate in the mitochondria of human tumor
argeting the HSP90/TRAP1 network and acting as
e antagonists (34). Finally, the clinical validation of
biomarkers predictive of resistance/sensitivity to spe-
hemotherapy regimens is urgently required in human
s. Thus, the novel preliminary finding of a parallel up-
tion of TRAP1 and Sorcin in human colorectal cancerscinoma therapy (31). Interestingly, RNAi knockdown of highlights the existence of a functional link between the two
4. TRAP1 and Sorcin protein and mRNA levels in human colorectal carcinomas. A and C, protein (A) and mRNA (C) levels of TRAP1, and 18
-kDa Sorcin in three colorectal tumors (T), and the corresponding noninfiltrated peritumoral mucosas (M) analyzed by immunoblot (A) andorcin isoforms in the immunoblot analysis reported in A. All the
re equal to 1.
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Published OnlineFirst July 20, 2010; DOI:10.1158/0008-5472.CAN-10-1256ns, suggesting the opportunity to further characterize
two polypeptides as candidate biomarkers to predict
sponse of colon cancer patients to antiblastic treat-
and personalize individual therapeutic strategies.
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E-mail address: giuseppe.dalessio@unina.it (G. D’AThe data presented here show for the ﬁrst time that the protein known as ‘‘ribonuclease (RNase)
inhibitor’’ (RI or RNH1) is present not only in the cell cytosol, but also in mitochondria, the central
organelles in cell redox homeostasis. This ﬁnding directly correlates with the reported ability of RI to
protect the cell from oxidative stress, with its sensitivity to oxidation and reactivity as a reactive
oxygen species scavenger. While this study was carried out we also surprisingly discovered the pres-
ence of RI in the cell nucleus. We deem that these data open new views in the investigation on the
cellular role(s) of the RI.
Structured summary:
RI physically interacts with ATP synthase sub Alpha mitochondrial, Stress 70 Protein, Mitochondrial,
Calcium-binding mitochondrial carrier protein Aralar 2 ADP/ATP Translocase 2 Elongation factor Tu
and Cytochrome b-c1 complex Sub 2 by anti bait coimmunoprecipitation (View interaction)
PARP and RI colocalize by cosedimentation (View interaction)
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The label of ‘‘ribonuclease (RNase) inhibitor’’ (RI, also termed
RNH1) to a ubiquitous protein of about 50 kDa, acidic, very abun-
dant in the cell cytosol, with a high content of Cys residues, con-
sisting of 15 Leu repeats (LRR), has been for more than half a
century certainly correct. RI inhibits the great majority of the
extracellular RNases from the vertebrate superfamily, bound by
RI with very high afﬁnity and catalytically neutralized. The struc-
ture of RI, free or complexed to an RNase, has been determined
[1,2]. Extensive reviews have been published on RI structure and
function [3,4].
However, the physiological role of this protein has not been
conclusively deﬁned. It has been proposed that the role of RI in
the cell is that of a ‘‘sentry’’, to protect its cytosolic RNA from extra-chemical Societies. Published by E
clease; ROS, reactive oxygen
containing 0.2% Gelatin and
ansition pore; ANT, ADP/ATP
horesis in sodium dodecyl-
lessio).cellular RNases that may enter that compartment [5]. This hypoth-
esis is based on the following evidence: RI resistant RNases, such as
bovine seminal RNase [6] and onconase [7], are cytotoxic; non-
cytotoxic RNases, strongly inhibited by RI, become cytotoxic when
they are engineered into relatively RI-resistant RNases [8]; cells
manipulated to increase the RI levels become more resistant to
RNase cytotoxicity [5,8,9].
In contrast with the ‘‘sentry’’ hypothesis, it has been reported
that the removal of RI from cells, obtained through RNA silencing,
does not render these cells sensitive to non-cytotoxic RNases [10].
Moreover, cytotoxic RNases have been described [11] that bind RI
with high afﬁnity [12]. On the other hand, data have been accumu-
lating on a different research line. Hofsteenge and co-workers have
early reported that in cultured cells an oxidative insult with H2O2,
a general oxidant, or with diamide, a thiol speciﬁc oxidant, engen-
ders a severe cellular loss of RI as a protein [13]. More recently, it
has been reported that cells over-expressing RI becomemore resis-
tant to H2O2 stress [14], and that RI has a strong scavenging activ-
ity on reactive oxygen species (ROS) [15]. These data, and those
from a parallel investigation of the effects of oxidants and anti-
oxidants on normal and RI deprived cells, has led to the proposal
that RI plays the physiological role of a defensive system against
oxidative stress [16]. Furthermore, in cells stressed with arsenitelsevier B.V. All rights reserved.
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tivation of tRNAs and translational arrest [17,18].
The data presented here, collected through biochemical and
mass spectrometric analyses, as well as inspections by immunoﬂu-
orescence at the subcellular level, support the hypothesis of a key
physiological role of RI in redox homeostasis. They show for the
ﬁrst time that RI is present and reactive as a ROS scavenger not
only in the cell cytosol, but also in mitochondria, the organelles
central in the cell redox homeostasis. Furthermore, they have en-
abled us to illustrate how RI is surprisingly abundant also in the
cell nucleus.
These data and conclusions do not provide a complete, exhaus-
tive picture of the physiological signiﬁcance of RI in the cell, but
certainly open the way to completely novel approaches to the
investigation of the cellular role of the RI.
2. Materials and methods
2.1. Cell culture and extracts
HeLa and HCT cells were cultured in DMEM supplemented with
10% bovine fetal serum in standard conditions. Cell viability was
assessed with the Trypan Blue exclusion method. Cell extracts
were prepared in 1% NP-40 in Phosphate Buffered Saline (PBS) with
protease and phosphatase inhibitors (Roche). Surnatants were col-
lected after centrifugation at 18 000g for 30 min 4 C, then stored
at 80 C. In some experiments, cells were transfected at 80% con-
ﬂuence with Metafectene–Pro (Biointex) coated plasmid DNA, and
incubation lasted o/n to allow expression of the recombinant pro-
tein. Cytosolic and nuclear extracts were prepared as described
[19]. Cytosolic and mitochondrial fractions were prepared with
the Qproteome Mitochondria Isolation Kit (Qiagen). Protein con-
centration was measured by the Bradford method (Bio-Rad).
2.2. Immunoprecipitation and mass spectrometry analyses
The sequence encoding human RI was ampliﬁed with GoTaq
DNA polymerase (Promega) using the following primers:
50-GGGGGAATTCAATGAGCCTGGACATCC-30 (forward);
50-GGGGGGTCGACTCAGGAGATGACCCTC-30 (reverse);
bearing EcoRI and SalI restriction sites, respectively, at 50 ends, and
the plasmid pTRP-cRI as a template [20]. The ampliﬁed fragment
was then directionally inserted into the EcoRI/SalI sites of
p3xFlag-CMV-7.1 to facilitate selection of immune complexes with
M2 Anti-Flag Afﬁnity Gel (SIGMA). Lysates of HeLa cells transfected
with p3xFlag-CMV-7.1 or the recombinant p3xFlag-RI (about 2 mg)
were challenged with M2 Anti-Flag Afﬁnity Gel, the immune com-
plexes were separated in 10% polyacrylamide gel electrophoresis in
sodium dodecyl-sulfate (SDS–PAGE) and stained with colloidal
Coomassie Blue (Invitrogen). Relevant protein bands and the corre-
sponding gel slices from control immunoprecipitation were
excised and processed for liquid chromatography and tandem
mass spectrometry (LC/MS/MS) analyses, performed on an LC/
MSD Trap XCT Ultra equipped with a 1100 nanoHPLC system and
a chip cube (Agilent Technologies, Palo Alto, CA). Raw data were
used to query a non-redundant protein database using in-house
MASCOT software (Matrix Science, Boston, MA).
2.3. Western blotting
Cell lysates were separated in 8% or 10% SDS–PAGE, then blot-
ted on PVDF membranes (Bio-Rad) using HEP-1 electroblot appara-
tus (OWL) at 2.5 mA/cm2. After blocking, membranes wereincubated o/n with relevant primary antibodies, then washed
and incubated with secondary peroxidase-linked antibodies. Light
emission in the presence of Immobilon Western Chemilumines-
cent HRP Substrate (Millipore) was detected with the ChemiDoc
system (Bio-Rad).
2.4. Antibodies
Antibodies used in these analyses were: anti-RI rabbit poly-
clonal antibodies, a kind gift of Dr. Guo-Fu Hu, Department of
Pathology, Harvard Medical School, Boston, USA; an alternative
anti-RI monoclonal antibody (anti-RNH1 M07, Abnova); anti-
PARP-1 C2-10 monoclonal antibody (Enzo) directed to poly-
ADP-ribose polymerase as nuclear marker. Antibodies anti-GAPDH,
directed to glyceraldehyde-P dehydrogenase as cytosolic marker,
6C5 anti-tubulin, COX4 monoclonal antibody, and goat polyclonal
antibody anti-B23 as a nucleolar marker, were from Santa Cruz
Biotechnology. Alexa Fluor 488 goat anti-rabbit (Molecular
Probes). Peroxidase-linked secondary antibodies were anti-mouse
IgG (Fc speciﬁc) or anti-rabbit IgG goat polyclonal antibodies
(Sigma).
2.5. Immunoﬂuorescence and confocal microscopy
Cells growing on glass cover slips (in medium containing or not
250 nM Mitotracker Red as a mitochondrial dye, according to the
manufacturer’s protocol) were ﬁxed for 20 min in PBS containing
4% paraformaldehyde (Sigma), washed two times in 50 mM NH4Cl,
then with PBS GS (PBS containing 0.2% Gelatin and 0.075% Saponin,
from Sigma) and incubated in humidiﬁed atmosphere with the rel-
evant antibodies at room temperature. Cells were then washed
with PBS GS and incubated in humidiﬁed atmosphere at room tem-
perature with the secondary antibodies and with tetramethylrhod-
amine isothiocyanate (TRITC)–phalloidin as a dye speciﬁc for
microﬁlaments (Sigma), as indicated. As a negative control, cells
were also stained with secondary antibodies alone (not shown).
Nuclei were stained with DNA intercalants Hoechst 33258 or
DRAQ5 (Bio status, Alexis Corporation), as indicated. Cells were ﬁ-
nally mounted in 50% glycerol in PBS and analyzed with a Zeiss
LSM 510 Meta confocal microscope. The lambda of the argon ion
laser was set at 488 nm, those of the two HeNe lasers were set
one at 546, the other at 633 nm. Fluorescence emission was re-
vealed by BP 505–530 band pass ﬁlter for Alexa Fluor 488, by BP
560–615 band pass ﬁlter for TRITC–phalloidin or Mitotracker Red
and by 615 long pass ﬁlter for DRAQ5. Nuclei stained with Hoechst
33258 were acquired as non-confocal images by mean of a light
detector and 352/461 nm ﬁlter (UV light). Double- and triple stain-
ing immunoﬂuorescence images were acquired separately in the
green, red and infra red channels and then saved in TIFF format
to prevent the loss of information. They had been acquired with
a resolution of 1024  1024 pixels with the confocal pinhole set
to one Airey unit.
3. Results
3.1. Searching for proteins interacting with RI
We have designed co-immunoprecipitation experiments to
identify proteins interacting with RI in the cellular environment,
as a new approach to the understanding of its biological role. To
this end, lysates from HeLa cells transfected with the recombinant
vector p3xFlag-RI or control vectors, were challenged with anti-
Flag M2 afﬁnity Gel, then bound proteins were analyzed by SDS–
PAGE and stained with Coomassie Blue. The outcome revealed, in
addition to Flag-RI, a number of protein bands absent in the control
Table 1
Mitochondrial proteins speciﬁcally interacting with RI, the RNase/angiogenin inhib-
itor in HeLa cell lysates as identiﬁed by mass spectrometry. Peptides corresponding to
proteins listed in the table were totally absent in control immunoprecipitation.
Swiss-
Prot #
Protein MW Peptides
P38646 Stress 70 Protein Mitochondrial 73 680 8
Q9UJS0 Calcium-binding mitochondrial carrier
protein Aralar 2
74 176 10
P25705 ATP synthase sub Alpha mitochondrial 59 751 12
P49411 Elongation factor Tu 49 542 13
P22695 Cytochrome b-c1 complex Sub 2 48 443 5
P05141 ADP/ATP Translocase 2 32 895 9
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mass spectrometry analysis. The results (see Fig. S1) show that a
relevant group of interacting proteins belongs to the mitochondrial
inner membrane or matrix (see Table 1), suggesting that, in addi-
tion to the cytosolic compartments, RI appears to reside also inside
mitochondria.
3.2. RI is localized in mitochondria
We then tried a direct biochemical approach to detect the
presence of RI in mitochondria. The mitochondrial and cytosolic
fractions of transfected HeLa and HCT cells were analyzed byFig. 1. Subcellular localization of RI in HCT and HeLa cells transfected with p3xFlag or c
Western blotting with anti-Flag antibody (a-Flag), is detected not only in the cytosolic (c
anti-tubulin (a-tubulin) and anti-COX4 (a-COX4) antibodies as markers for cytosolic and
RI in HCT and HeLa cells is shown, revealed by Western blotting with anti-RI polyclonal
COX4) antibodies. 40 lg of each lysate were analyzed.Western blotting to identify 3xFlag-RI. The results (Fig. 1A and B)
show that a substantial amount of recombinant RI is associated
to the mitochondrial fractions. In addition, endogenous RI is re-
vealed by speciﬁc antibodies in the mitochondrial fractions of
untransfected cells (Fig. 1C), while an unrelated control antiserum
was unable to produce the signal (not shown).
To conﬁrm this ﬁnding, we performed an immunoﬂuorescence
confocal analysis of HeLa cells. The results (see Fig. 2) show that
endogenous RI largely colocalizes with mitochondria stained with
Mitotracker Red. As expected, RI is also present in the cytosol and,
surprisingly, also in the nuclear matrix.
3.3. Evidence of RI localization in the nucleus
We have validated the presence of RI in the nucleus by probing
HeLa cells nuclear extracts and cytosolic lysates with polyclonal
anti-RI antibodies. The results of Western blottings, shown in
Fig. 3, conﬁrm the presence of RI in the cell nucleus. The signal gen-
erated by a monoclonal anti-RI antibody in confocal immunoﬂuo-
rescence analyses (see Fig. 4A–C) is consistent with the results
shown in Figs. 2, 3 and 4D–G, in which the RI nuclear localization
is revealed by speciﬁc polyclonal antibodies. In confocal immuno-
ﬂuorescence analyses, both antibodies show the same very intense
and diffuse staining pattern of the nucleus, with the exception of
regions corresponding to nucleolar areas, identiﬁed by an antibodyontrol vector (mock). (A) Recombinant RI, revealed by SDS–PAGE 10% followed by
) but also in the mitochondrial (m) fractions. (B) The same lysates were blotted with
mitochondrial fractions, respectively. (C) The subcellular localization of endogenous
antibodies. Filters were re-blotted with anti-tubulin (a-tubulin) and anti-COX4 (a-
Fig. 2. Confocal microscopy showing signiﬁcant mitochondrial localization of endogenous RI in HeLa cells. Red: mitochondria stained with Mitotracker Red; green: a-RI
followed by Alexa ﬂuor 488-conjugated goat anti-rabbit IgG antibody; yellow: merge. Bars: 5 lm.
Fig. 3. Evidence of RI localization in the nucleus. Western blot analyses with anti-RI
polyclonal antibodies. Lanes 1 and 2: 2.5 or 5 lg of HeLa cells nuclear extracts; in
lanes 3 and 4: 2.5 or 5 lg of cytosolic lysates. The blot was re-probed with anti PARP
and anti-GAPDH antibodies as markers for nuclear and cytosolic extracts,
respectively.
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shown).
4. Discussion
The result of our work uncover novel, previously unnoticed sub-
cellular localizations of RI. We have established that RI, known as a
cytosolic protein, is also present in the cell nucleus and mitochon-
dria. Association of RI with proteins of the mitochondrial inner
membrane and matrix place this protein in a major environmentof ROS production. The ability of RI to protect genome integrity
and cell viability from oxidative stress injury is documented in
the literature, and correlates well with the sensitivity to oxidation
and the in vitro activity as ROS scavenger of the protein [14–16].
Singh et al. have shown that apoptosis induced in HeLa cells by
H2O2 induced oxidative stress, depends on ROS generated in mito-
chondria [21]. HeLa cells on the other hand show increased resis-
tance to H2O2 induced mortality when RI is overexpressed [14].
The evidence reported here provides a new direct basis, through
experimental methodologies distinct from the others so far
proposed on the role of RI as a ROS scavenger. Interesting to note
protein ADP/ATP Translocase (ANT), co-immunoprecipitated with
RI, is a regulative component of the mitochondrial permeability
transition pore (MPTP), which plays a pivotal role in mitochondrial
induced cell death [21]. Oxidative stress promotes glutathione-
mediated oxidation of ANT cysteine residues located in matrix-
facing loops, resulting in Ca++ binding of the protein and activation
of MPTP [22]. Thus, we are tempting to speculate that ANT-
associated RI could act as a shield against ROS induced, GSH med-
iated oxidation of the nucleotide transporter. Oxidation of RI leads
to the formation of intramolecular disulﬁde bridges with an all-
or-none pattern, and to its rapid degradation in the cell [13]. We
have observed some degradation of endogenous RI in mitochon-
drial lysates (see Fig. 1C), a ﬁnding consistent with the hypothesis
that RI is easily oxidized in mitochondria due to the ROS rich
environment.
The identiﬁcation of RI in the nucleus is surprising; its role in
this cellular compartment is unknown. In immunoprecipitation
Fig. 4. Confocal microscopic analysis of HeLa cells. (A) Green ﬂuorescence associated with monoclonal anti-RI antibody. (B) Blue ﬂuorescence associated with Hoechst
staining, acquired as non-confocal images. (C) Merge between (A) and (B). RI is evident in the nuclear matrix, absent in nucleoli. Bars: 20 lm. (D) Green ﬂuorescence
associated with polyclonal anti-RI antibodies. (E) Nuclear blue ﬂuorescence after staining with DRAQ5. (F) Red ﬂuorescence after staining with TRITC-conjugated phalloidin.
(G) Merge between (D), (E) and (F). Bars: 10 lm.
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cept the nuclear pore membrane glycoprotein 210 (accession num-
ber Q8TEM1). This ﬁnding is in line with the observation that the
recombinant 3xFlagRI, perhaps due to the extension of 28 residues
at the amino end, does not enter the nucleus (not shown). While
the protein appears abundant in the nuclear matrix, it seems deﬁ-
nitely excluded from nucleoli. It can be assumed that in the reduc-
ing nuclear environment RI is in the thiol form, thus able to bind
and inhibit RNases, such as angiogenin. As angiogenin accumulates
in HeLa nucleoli, where it plays a key role in rRNA biogenesis [23],
the absence of RI, a powerful inhibitor of the enzyme, from the
nucleolar areas, would be consistent with this role of angiogenin.
In conclusion, the observations reported in this study offer new
evidence supporting the role of RI as a scavenger of ROS, and raise
intriguing new questions about its signiﬁcance and interactions in
the nucleus, thus opening new lines of investigation for an
advancement in the knowledge of RI functions in cell biology.
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TRAP1 and the proteasome regulatory particle
TBP7/Rpt3 interact in the endoplasmic reticulum and
control cellular ubiquitination of specific
mitochondrial proteins
MR Amoroso1, DS Matassa1, G Laudiero1, AV Egorova2, RS Polishchuk2, F Maddalena3, A Piscazzi4, S Paladino5,6, D Sarnataro5,6,
C Garbi5, M Landriscina*,4 and F Esposito*,1
Tumor necrosis factor receptor-associated protein-1 (TRAP1) is a mitochondrial (MITO) antiapoptotic heat-shock protein. The
information available on the TRAP1 pathway describes just a few well-characterized functions of this protein in mitochondria.
However, our group’s use of mass-spectrometric analysis identified TBP7, an AAA-ATPase of the 19S proteasomal subunit,
as a putative TRAP1-interacting protein. Surprisingly, TRAP1 and TBP7 colocalize in the endoplasmic reticulum (ER), as
demonstrated by biochemical and confocal/electron microscopic analyses, and interact directly, as confirmed by fluorescence
resonance energy transfer analysis. This is the first demonstration of TRAP1’s presence in this cellular compartment. TRAP1
silencing by short-hairpin RNAs, in cells exposed to thapsigargin-induced ER stress, correlates with upregulation of BiP/Grp78,
thus suggesting a role of TRAP1 in the refolding of damaged proteins and in ER stress protection. Consistently, TRAP1 and/or
TBP7 interference enhanced stress-induced cell death and increased intracellular protein ubiquitination. These experiments led
us to hypothesize an involvement of TRAP1 in protein quality control for mistargeted/misfolded mitochondria-destined proteins,
through interaction with the regulatory proteasome protein TBP7. Remarkably, expression of specific MITO proteins decreased
upon TRAP1 interference as a consequence of increased ubiquitination. The proposed TRAP1 network has an impact in vivo, as
it is conserved in human colorectal cancers, is controlled by ER-localized TRAP1 interacting with TBP7 and provides a novel
model of the ER–mitochondria crosstalk.
Cell Death and Differentiation advance online publication, 7 October 2011; doi:10.1038/cdd.2011.128
Tumor necrosis factor receptor-associated protein-1 (TRAP1)
was initially identified as a TNF-receptor-associated protein
and is a member of the heat-shock protein-90 (HSP90)
chaperone family.1,2 Through an mRNA-differential display
analysis between oxidant-adapted and control osteosarcoma
cells, our group identified, among other proteins, TRAP1,
whose expression was highly induced upon oxidant adapta-
tion.3 Furthermore, TRAP1 showed antioxidant and antia-
poptotic functions,4 while an involvement of this mitochondrial
(MITO) chaperone in the multi-drug resistance of human
colorectal carcinoma (CRC) cells was also established.5
Little is known about TRAP1 signal transduction: the first
most important finding on TRAP1 function came from studies
by the Altieri’s group, which identified TRAP1 as a member of
a cytoprotective network selectively active in the mitochondria
of tumor tissues.6 The same group has recently proposed
TRAP1 as a novel molecular target in localized andmetastatic
prostate cancer,7 and is now involved in a promising
preclinical characterization of mitochondria-targeted small-
molecule HSP90 inhibitors.8,9 Besides some well-character-
ized TRAP1 functions in mitochondria, during preparation of
this manuscript it was reported that interference by HSP90
chaperones triggers an unfolded protein response (UPR) and
activates autophagy in the mitochondria of tumor cells.10 A
putative role of TRAP1 in endoplasmic reticulum (ER) stress
control was concomitantly suggested by Takemoto et al.,11
even though no evidence regarding the mechanisms involved
was provided in this study.
A proteomic analysis of TRAP1 co-immunoprecipitation
(co-IP) complexes was performed in our laboratory, in order to
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further characterize the TRAP1 network and evaluate protein
interactors relevant for its roles. Among several other
proteins, a novel MITO isoform of Sorcin, a calcium-binding
protein, was identified as a new TRAP1 ‘ligand’ and a
cytoprotective function against apoptosis induced by anti-
blastic agents was recently demonstrated for this protein by
our group.12 In the present paper, we characterize another
new interaction of TRAP1 with TBP7/ATPase-4/Rpt3, an S6
ATPase protein of the proteasome regulatory subunit.13,14
TBP7 was first identified as a novel synphilin-1-interacting
protein,13 so a functional role in Parkinson’s disease was
proposed for this protein. However, not many novel results
became available subsequently on TBP7 function.
Altogether, (i) the absence of TBP7 in mitochondria; (ii) its
still uncharacterized function as a regulatory protein; and (iii)
its association with TRAP1 prompted us to analyze the sub-
cellular localization of TRAP1/TBP7 interaction and to
investigate its functional role. Several studies have described
a function of HSP in the control of gene expression,15,16 and
recent evidence demonstrated the importance of 19S
ATPases in the transcription machinery, as well as their
additional regulatory mechanisms in mammalian transcrip-
tion.17 Therefore, we hypothesized that the TRAP1/TBP7
interaction might have a role in protein quality control and
cellular ubiquitination. Moreover, the finding that the two
proteins directly interact in the ER further supports our
hypothesis, as it is known that misfolding of proteins is tightly
controlled by a large number of molecular chaperones and, if
the quality control fails, they are ubiquitinated and degraded
by the proteasome.18 This paper, for the first time, describes
the presence of TRAP1 on the outer side of the ER and shows
the functional role that TRAP1 has in the quality control
of proteins destined to the mitochondria, and in the regulation
of intracellular protein ubiquitination, through interaction with
TBP7.
Results
TRAP1 and TBP7 colocalize and directly interact in the
ER. The ‘fishing for partners’ strategy combined with mass
spectrometric procedures performed to identify TRAP1
protein partners has already been described elsewhere.12
Among the putative TRAP1-binding partners, we focused
our attention on a protein of about 50 kDa identified by our
LC-MS/MS analysis as S6/TBP7/ATPase-4/Rpt3.19 To con-
firm that this proteasome subunit was indeed a TRAP1-
interacting protein, we performed western blot (WB) and co-IP
analyses in total extracts from HCT116 colon carcinoma cells
(Figure 1A). As TRAP1 is localized in mitochondria, sub-
fractionation of HCT116 cellular extracts was performed.
Surprisingly, WB analysis of sub-cellular compartments failed
to demonstrate the presence of the regulatory protein in
mitochondria, but identified TBP7 both in the cytosol and
microsomal fraction (Figure 1B). Co-IP analyses from ER
fraction confirmed the TRAP1/TBP7 interaction in the ER
(Figure 1C).
The TRAP1/TBP7 molecular interaction was further inves-
tigated by using a fluorescence resonance energy transfer
(FRET) approach in fixed cells (Figure 1D).20 In cells co-
expressing wild-type TRAP1 and TBP7 we found about 12%
of FRET efficiency (Figure 1D) indicating that TRAP1 and
TBP7 are close enough to allow energy transfer. Interestingly
we found FRET exclusively when we bleached ER regions,
which we selected on the basis of their morphological features
(one example in Figure 1D, a–f). Thus, these data indicate that
TRAP1 and TBP7 directly interact with each other and this
interaction occurs specifically in the ER compartments.
Furthermore, according to the biochemical data described
below in the paper (Supplementary Figure 1 and Figure 4H),
we found no FRET between TRAP1 and a mutant form of
TBP7 (Figure 1D).
As it had never been reported previously, we aimed to
further confirm the novel localization of this MITO chaperone
in the ER through electron microscopy (EM) and confocal
microscopy analyses (Figures 1E and F). To further evaluate
whether TRAP1 is associated with the ER membranes, cells
stably expressing TRAP-HA vectors were prepared for
immuno-EM. Labeling with an anti-HA antibody revealed
significant amounts of TRAP1 in mitochondria (Figure 1E, a
and b, arrowheads), as has been reported previously.6 In
Figure 1 TRAP1 and TBP7 interact and colocalize in the ER. (A) Total HCT116 lysates were harvested and immunoprecipitated using anti-TRAP1 and anti-TBP7
antibodies as described under Materials and Methods, separated by SDS-PAGE and immunoblotted using the indicated mouse monoclonal anti-TRAP1 and mouse
monoclonal anti-TBP7 antibodies. No Ab, total cellular extracts incubated with A/G plus agarose beads without antibody; IP, immunoprecipitation using the corresponding
antibodies. (B) Total HCT116 lysates were fractionated into MITO, CYTO and microsomal (ER) fractions as described under Materials and Methods, separated by SDS-PAGE
and immunoblotted using mouse monoclonal anti-TRAP1 and mouse monoclonal anti-TBP7 antibodies. The purity of the fractions was assessed by using mouse monoclonal
anti-tubulin, goat polyclonal anti-CypD, rabbit polyclonal anti-calnexin antibodies specific for the single subcellular compartments. (C) TRAP1 and TBP7 co-IP analysis on the
microsomal fraction (ER), obtained as described under Materials and Methods. WB of immunoprecipitates was performed by using the indicated antibodies. (D) TRAP1/TBP7
direct interaction. FRET was measured by using the acceptor photo-bleaching technique as described under Materials and Methods. The images show the signal of TBP7
(red) and TRAP1 (green) before (a–c) and after photo-bleaching (d–f). The selected ROI for bleaching was indicated. Energy transfer efficiency was measured in cells
transiently co-transfected with TRAP1 and either TBP7 or its mutant form (DTBP7-Flag), and is expressed in % as mean of three independent experiments. Error bars:±S.D.;
*Po0.0001. (E) ER Distribution of TRAP1 in HCT116 cells (EM). Cells expressing TRAP-HA vector were fixed and prepared for immuno-EM (see Materials and Methods).
Labeling with the anti-HA antibody revealed significant amount of TRAP1 in mitochondria (a, b, arrowheads). In addition, TRAP1 was distributed throughout the elongated
membrane profiles (a, arrows) that on the basis of their ultrastructural features (such as attached ribosomes) can be attributed to the rough ER compartment, and detected
along the nuclear envelope (b, arrows). The density of immuno-gold labeling (in arbitrary units; average±S.D.) in mitochondria (MITO), ER and endosomes (as a negative
control) is reported in the lower histogram. (F) ER TRAP1/TBP7 colocalization (confocal microscopy). Immunofluorescence shows colocalization of TBP7 with TRAP1 and with
the ER protein calnexin. In Panel-1, a double immunofluorescent staining is shown for TRAP1 (green) and TBP7 (red). In Panel-2, a double immunofluorescent staining is
shown for calnexin (green) and TBP7 (red). In cells expressing the Myc-tagged TRAP1 construct (red) the protein co-distributes to a great extent with endogenous calnexin
(green, Panel-3). (G and H) Biochemical characterization of TRAP1/TBP7 ‘topology’ in the ER. WB of HCT116 microsomal fractions treated with 0.4 mg/ml or 4 mg/ml
proteinase-K (pt K)±1% NP-40 for 20min on ice (G) or with 100mM Na2CO3 (pH 11.3) for 30min (H) as described under Materials and Methods. Specific proteins were
revealed using the indicated antibodies. (H): S, supernatant; P, pellet
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addition, we found that TRAP1 was distributed throughout the
elongated membrane profiles (Figure 1E, a, arrows) that on
the basis of their ultrastructural features (such as attached
ribosomes) can be attributed to the rough ER compartment.
Moreover, gold particles – indicating TRAP1molecules –were
detected along the nuclear envelope (Figure 1E, b, arrows),
considered to be part of the ER membrane network. A careful
examination of the density of immuno-gold labeling (in
arbitrary units; average±S.D.) over different intracellular
membranes allowed us to demonstrate that indeed TRAP1
was enriched in mitochondria (2.53±0.34) as it has already
been reported. However, significant labeling density was also
calculated for ER membranes (1.02±0.22) as shown in
Figure 1E. Taken together, the EM observations are in line
with the above results showing association of TRAP1 with the
ER (Figures 1A–C). Accordingly, immunofluorescence con-
focal microscopy analysis showed colocalization of TBP7 with
TRAP1 and with the ER protein calnexin, thus confirming ER
localization further (Figure 1F).
Altogether, these findings demonstrate that the interaction
between TRAP1 and TBP7 occurs in the ER, but are unable to
reveal a detailed localization in this context. To further
evaluate the ‘topology’ of TRAP1 and TBP7 in the ER, a
biochemical assay based on protease digestion was per-
formed. Figure 1G shows that both proteins are sensitive to a
proteinase-K digestion, whereas calnexin, a well-known ER-
resident protein, is undigested. These approaches allowed us
to demonstrate that TRAP1 and TBP7 are located on the
outside of the ER. Moreover, alkaline treatment of ER
fractions to remove peripheral membrane proteins allowed
us to demonstrate that both TRAP1 and TBP7 are loosely
associated to ER membranes (Figure 1H).
TRAP1 interference sensitizes CRC cells to TG-induced
ER stress. We therefore investigated the functional role of
the TRAP1/TBP7 interaction. Several data suggest that
ER stress, worsened by the high ROS concentrations in this
sub-cellular compartment, is controlled by networks of
molecular chaperones.21 Considering the previously
described protective role of TRAP1 against several
stresses, including oxidative stress through its antioxidant
functions,4,22 we hypothesized that the TRAP1/TBP7
interaction constituted an additional control to check the
state/folding of proteins damaged in the ER. In order to
induce protein misfolding in the ER, we induced ER stress by
using thapsigargin (TG), a well-known agent that mobilizes
Ca2þ from the ER.23 As a marker of ER stress we analyzed
the expression of BiP/Grp78, a major ER chaperone protein
essential for protein quality control in the ER, as well as a
central regulator of the UPR.24 Figure 2 shows that BiP
mRNA expression is strongly increased, upon TG treatment,
in TRAP1-interfered cells as compared with the respective
control (Figures 2a and b). Interestingly, a rescue of this
phenotype is achieved upon TRAP1 re-addition (Figure 2b).
These results demonstrate that TRAP1 knockdown
sensitizes cells to TG-induced ER stress, thus suggesting
an involvement of this protein in ER stress response, as
reported recently.10,11
We and other groups have previously demonstrated the
protective roles of TRAP1 against cell death induced by
several agents.4,6 Therefore, we addressed whether TRAP1-
interfered cells become more sensitive to apoptosis, as a
possible and expected consequence of increased ER
stress, and whether TBP7 might have a role in this process.
Table 1 shows that TRAP1 and TBP7 interference sensitized
HCT116 cells to TG-induced apoptosis. Noteworthy, a similar
result was observed upon cell treatment with oxaliplatin, a
genotoxic agent (Table 1). Taken together, all these observa-
tions confirm the well-known role of TRAP1 in the protection
against stress-induced cell death and highlight a new role for
regulatory proteasome proteins in apoptotic control.
TRAP1/TBP7 control of intracellular protein ubiquiti-
nation. We then hypothesized that, if the level of protein
damage upon ER stress is too severe to be counteracted/
repaired by TRAP1 refolding, increased protein degradation
might occur, and increased ubiquitination levels of
intracellular proteins could be observed. Indeed, tight
regulation of protein ubiquitination by TRAP1/TBP7 does
occur: in fact, a low-ubiquitin (Ub) signal is observed in
TRAP1-containing cells, whereas TRAP1 interference
strongly increases general protein ubiquitination levels
(Figure 3).
The control of ubiquitination of intracellular proteins by
TRAP1/TBP7 is a general phenomenon as it is present in total
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Figure 2 BiP mRNA levels in sh-TRAP1 stable clones. (a) Semi-quantitative
RT-PCR analysis of BiP/Grp78 mRNA expression in sh-TRAP1 stable clones with
respect to scrambled transfectants after 12-h treatment with 1mM TG. As control,
the levels of GAPDH transcript were analyzed. (b) Real-time RT-PCR analysis of
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different BiP/Grp78 levels under the indicated conditions
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extracts (Figure 3a). Interestingly, both TRAP1 and TBP7
seem to have a critical role in the regulation of protein
ubiquitination. In fact, upon transfection of TRAP1 expression
vectors in sh-TRAP1 stable transfectants a rescue of the high-
Ub ‘phenotype’ is observed (Figure 3a). Sub-cellular fractio-
nation allowed us to demonstrate that this regulatory role
is more evident in the post-mitochondrial (PM) fraction
(cytosolþmicrosomes), where TRAP1/TBP7 control is parti-
cularly necessary given the abundance of proteins translated,
but often damaged. Conversely, the same regulation is not
observed in MITO extracts even after re-transfection of
TRAP1, likely because TBP7 is absent in these organelles
(Figure 3b). These results confirm that TRAP1 function in the
regulation of protein ubiquitination requires the presence of
TBP7. Additionally, increased cellular levels of ubiquitinated
proteins, very similar to those obtained in cells transiently
transfected with TRAP1 siRNAs, were observed upon TBP7
siRNA transfection (Figure 3c), thus confirming the role of
TBP7 in this regulation. Altogether, these results demonstrate
that the TRAP1/TBP7 interaction is a useful and important
checkpoint in which these two proteins concomitantly work to
judge whether a protein can be repaired and reach the final
destination or, if the damage is too severe, it needs to be
degraded. Furthermore, despite the block of proteasome
activity by MG132 treatment, the experiments shown in
Figure 3 demonstrate that the regulation of protein ubiquitina-
tion by TRAP1 is not due to inhibition of proteasome function,
as it is observed also in the absence of the inhibitory drug
(Figure 3a). Indeed, this finding was confirmed by assaying
the proteasome’s activity in vitro using fluorescent substrates
and extracts from scrambled- and TRAP1- or TBP7-interfered
cells. The results shown in Figure 3d demonstrate that neither
TRAP1 nor TBP7 interference inhibits the proteasome’s
function.
More importantly we asked whether the control of protein
ubiquitination by TRAP1/TBP7 requires TRAP1 MITO locali-
zation. To address this issuewe generated theD1–59 deletion
mutant of TRAP1 (in which the first 59 aa containing the MITO
targeting sequences (MTS2) were removed from the N-
terminus) yielding a TRAP1mutant defective for MITO import,
but still able to bind to TBP7 (Supplementary Figure 1 and
Figures 4a and b). Interestingly, transfection of this mutant in
sh-TRAP1 stable clones rescued the heavy Ub levels present
in TRAP1-interfered cells (Figure 4c). Conversely, another
TRAP1 deletion mutant (D101–221) was generated that
keeps the MTS (Supplementary Figure 1) and, thus, is able
to localize into mitochondria, but is unable to bind to TBP7,
which, as shown previously, is absent in the MITO fraction.
Transfection of the D101–221 mutant in sh-TRAP1 cells
showed no changes in protein ubiquitination levels (Figures
4d–f). These experiments provide proof of concept that the
relevant amount of TRAP1 present in the ER fractions (see
the EM qualitative/quantitative analyses shown in Figure 1e)
is indeed involved in the regulation of protein ubiquitination
through its binding to TBP7, whereas MITO TRAP1 does not
influence Ub levels, according to the phenotype generated by
the D101–221 TRAP1 deletion mutant. Finally, we demon-
strated that transfection of the TRAP1 D1–59 mutant
decreased the BiP/Grp78 mRNA levels present in sh-TRAP1
clones upon TG-induced ER stress. Figure 4g shows that a
rescue of BiP/Grp78 mRNA levels is obtained upon transfec-
tion of the D1–59 mutant, whereas the D101–221 TRAP1
mutant with MITO localization not only is unable to counteract
ER stress, but even further increased BiP/Grp78 levels.
Strikingly, a TBP7deletionmutant (SupplementaryFigure 1),
unable to bind to TRAP1 (Figure 4h), yields, upon transfection
in HCT116 cells (scrambled), a strong Ub pattern undistin-
guishable from the phenotype of sh-TRAP1 stable transfec-
tants (Figure 4i), likely acting as dominant negative over the
endogenous TBP7 protein’s function.
Quality control of specific mitochondria-destined
proteins by TRAP1/TBP7. Once we demonstrated the
contribution of TRAP1/TBP7 to the regulation of ER stress/
apoptosis, with the consequent modulation of intracellular
protein ubiquitination, we hypothesized that TRAP1 could be
involved in a general control of protein stability. To this aim,
pulse–chase experiments were performed in scrambled and
sh-TRAP1 stable transfectants. However, a comparable
pattern of degraded proteins is still observed 72 h after
Met/Cys chase (Figure 5a). This unchanged overall protein
stability led us to hypothesize that TRAP1 could be involved
in the control of protein folding/stability for selective proteins,
likely those directed to mitochondria. To evaluate this
hypothesis, the levels of F1ATPase, a nuclear-encoded
MITO protein and a potential TRAP1 interactor as suggested
by MS analysis,12 were analyzed in cells in which TRAP1
expression was lowered by short-hairpin RNA (shRNA)
interference. Interestingly, protein levels decreased
in TRAP1 stably interfered cells (Figure 5b and
Supplementary Figure 2), whereas a rescue was obtained
upon re-addition of the D1–59 TRAP1 mutant but not by the
D101–221 TRAP1 mutant (Supplementary Figure 3). These
findings confirm that the regulation of the observed
Table 1 Rates of apoptotic cell death in CRC HCT116 cells treated with 1mM
TG for 24 h or with 10mM oxaliplatin (l-OHP) for 48 h upon transient (siRNA) or
stable (shRNA) downregulation of TRAP1 or TBP7
Apoptosis (%±S.D.)
Ratio (±S.D.) P-valueVehicle
Scramble
Vehicle 3.5±0.3
TG 5.0±0.2 1.4±0.2
l-OHP 11.2±0.4 3.2±0.4
siRNA TRAP1
Vehicle 4.7±0.2
TG 21.5±.0.4 4.6±0.3 o0.0001
l-OHP 55.5±0.6 11.8±0.7 o0.0001
shRNA TRAP1
Vehicle 3.5±0.4
TG 24.2±.0.5 6.9±1.1 0.001
l-OHP 31.8±0.4 9.1±1.3 0.002
siRNA TBP7
Vehicle 5.2±0.2
TG 15.7±0.3 3.0±0.2 o0.0001
l-OHP 55.1±0.6 10.6±0.5 o0.0001
Ratios are calculated between rates of apoptosis in drug- and vehicle-treated
cells. The P-values indicate the statistical significance between the ratios of
apoptosis in siRNA-transfected cells and the respective scrambled controls.
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Figure 3 Ub levels in HCT116 cells. (a) Total cell lysates from sh-TRAP1 and scrambled HCT116 stable clones were transfected with either an HA-tagged Ub vector
(Ub-HA) or with TRAP1 expression vectors; treated with 1mM MG132 for 24 h; harvested 48 h after transfection; and subjected to immunoblot using rabbit polyclonal anti-HA
antibodies. The same filter was re-probed using mouse monoclonal anti-GAPDH antibodies for normalization of cell lysates. Three independent experiments were performed, with
similar results. (b) Sub-cellular fractionation was obtained from sh-TRAP1 and scrambled HCT116 stable transfectants treated as described in panel a. The extracts from the PM
fraction (microsomesþCYTO fraction) and mitochondria (MITO, see Materials and Methods) were separated by SDS-PAGE and immunoblotted using a rabbit polyclonal anti-HA
antibody to detect Ub levels. The purity of fractions was verified by using mouse monoclonal anti-COX IV or mouse monoclonal anti-GAPDH antibodies. Three independent
experiments were performed, with similar results. (c) HCT116 cells were co-transfected with a Ub-HA vector and an siRNA negative control (scramble), or with siRNAs specific for
TRAP1, TBP7, or both (as indicated) and total cell lysates were harvested after 48 h from transfection. Total lysates were subjected to SDS-PAGE and immunoblotted using rabbit
polyclonal anti-HA antibodies to detect total Ub levels. The same filter was re-probed using mouse monoclonal anti-GAPDH antibodies for normalization of cell lysates, and using
mouse monoclonal anti-TRAP1 and mouse monoclonal anti-TBP7 antibodies. (d) Proteasome activity is not affected by TRAP1 and TBP7 silencing. Total cellular extracts were
prepared after 48 h of transfection with specific siRNA for TRAP1, TBP7 or Sorcin, as control, or with an siRNA negative control (scramble), and incubated in the presence of assay
buffer and the fluorogenic substrate Suc-LLVY-AMC, as described under Materials andMethods. Samples were analyzed in triplicate using an excitation wavelength of 360 nm and
an emission wavelength of 450 nm to detect chymotryptic proteasome activity. The data represent the mean of three independent experiments
Figure 4 The TRAP1/TBP7 interaction in the ER is required for control of protein ubiquitination and ER stress. (a and d) Sub-cellular localization of D1–59-Myc/D101–221-HA
mutants. HCT116 cells were transfected with theD1–59-Myc (a) orD101–221-HA (d) TRAP1 mutants; sub-fractionated into MITO, CYTO and microsomal (ER) fractions (a), or MITO
and PM (cytosolþmicrosomes) fractions (d), as described under Materials and Methods; separated by SDS-PAGE; and immunoblotted using the indicated antibodies to verify the
expression of mutants and the purity of fractions. For details on procedures for generation of the mutants see Materials and Methods. (b, e) Interaction between D1–59-Myc/D101–
221-HA mutants and TBP7. HCT116 cells were transfected with D1–59-Myc (b) or D101–221-HA (e) TRAP1 mutants, harvested and immunoprecipitated using anti-Myc or anti-HA
antibodies as described under Materials and Methods. Immunoprecipitates were separated by SDS-PAGE and immunoblotted using the indicated antibodies. No Ab, total cellular
extracts incubated with A/G plus agarose beads without antibody; IP, immunoprecipitation with the corresponding antibodies. Three independent experiments were performed, with
similar results. (c) Ubiquitination levels upon transfection of the D1–59-Myc TRAP1 deletion mutant. Total lysates from HCT116 scrambled, sh-TRAP1 stable clones and sh-TRAP1
cells transfected with theD1–59-Myc TRAP1mutant were subjected to immunoblot analysis usingmousemonoclonal anti-Ub antibodies to detect total ubiquitination levels and with an
anti-GAPDH antibody for normalization of cell lysates. Three independent experiments were performed, with similar results. (f) Ubiquitination levels upon transfection of theD101–221-
HA TRAP1 deletion mutant. HCT116 scramble, sh-TRAP1 and sh-TRAP1 cells transfected with theD101–221-HA TRAP1mutant were sub-fractionated in PM (microsomesþCYTO
fraction) and MITO fractions as described under Materials and Methods. Total lysates from the same cells were used as controls (left panel). Protein lysates were subjected to
immunoblot analysis using mouse monoclonal anti-Ub antibodies to detect total ubiquitination levels. The purity of fractions was verified using mouse monoclonal anti-GAPDH (left and
right panels) and mouse-monoclonal anti-COX IV (middle panel) antibodies. Three independent experiments were performed, with similar results. (g) Real-time RT-PCR analysis of
BiP/Grp78 mRNA expression in scrambled and sh-TRAP1 HCT116 cells exposed to 1mM TG for 12 h (same as in Figure 2b) and in sh-TRAP1 HCT116 cells transfected with the
D1–59-Myc or D101–221-HA TRAP1 mutant, as indicated, before treatment with TG. The P-values indicate the statistical significance between the BiP/Grp78 levels under the
indicated conditions. (h) Interaction between TRAP1 and the DTBP7-Flag deletion mutant. HCT116 cells were transfected with the DTBP7-Flag deletion mutant, harvested and
immunoprecipitated using anti-TRAP1 antibodies as described under Materials and Methods. Immunoprecipitates were separated by SDS-PAGE and immunoblotted using the
indicated antibodies. No Ab, total cellular extracts incubated with A/G plus agarose beads without antibody; IP, immunoprecipitation with the corresponding antibodies. Three
independent experiments were performed, with similar results. The arrow indicates theDTBP7-Flag mutant band. (i) Ubiquitination levels upon transfection of theDTBP7-Flag deletion
mutant. Total lysates from HCT116 scrambled cells transfected withDTBP7-Flag mutant were subjected to immunoblot analysis using mouse monoclonal anti-Ub antibodies to detect
total ubiquitination levels and with mouse monoclonal anti-HSP60 antibodies for normalization of cell lysates. Three independent experiments were performed, with similar results
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phenomena occurs in the cytosolic (CYTO) compartment
and support our model. Accordingly, the protein levels of p18
Sorcin, another MITO protein, recently identified by our group
as a novel MITO Sorcin isoform interacting with TRAP1,12
decreased upon TRAP1 interference (Figure 5b, arrow). Of
note, under the same experimental conditions, no differences
were observed in the protein levels of the higher mobility p22
Sorcin isoform, which shares high homology with p18 Sorcin,
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but is not a MITO protein, neither is a TRAP1 ‘partner’
(Figure 5b).12 Therefore, we hypothesize that the decreased
expressions of F1ATPase and p18 Sorcin in the
mitochondria of TRAP1-interferred cells were dependent on
increased ubiquitination. To this aim, the respective
ubiquitination levels in scrambled- and TRAP1-interfered
cells were analyzed. Figures 5c and d show that both
proteins are more ubiquitinated in sh-TRAP1 transfectants.
Accordingly, increased levels of ubiquitinated F1ATPase
were induced upon TBP7 interference (Figure 5e).
Finally, we evaluated whether the TRAP1/TBP7 interaction
and the relative effects on protein levels would have an impact
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immunoblotted using rabbit polyclonal anti-Sorcin, mouse monoclonal anti-TRAP1, goat polyclonal anti-F1ATPase antibodies. The same filter was re-probed using mouse
monoclonal anti-GAPDH antibodies for normalization of cell lysates. The arrow indicates the MITO 18-kDa Sorcin isoform band. (c) Scrambled and sh-TRAP1 HCT116 clones
were transfected with an expression vector containing the cDNA of p18 Sorcin fused to a c-Myc epitope at the C-terminus (Sorcin-Myc) and treated with 1 mM MG132 for 24 h
before harvesting. Lysates were immunoprecipitated using mouse monoclonal anti-Myc antibodies and analyzed by immunoblot analysis using mouse monoclonal anti-Ub
antibodies. The membrane was re-probed using an anti-Myc antibody to control transfection efficiency. (d) Scrambled and sh-TRAP1 HCT116 clones were treated with 1mM
MG132 for 24 h before harvesting, immunoprecipitated with an-anti F1ATPase antibody, subjected to SDS-PAGE and immunoblotted using mouse monoclonal anti-Ub and
goat polyclonal anti-F1ATPase antibodies. Three independent experiments were performed with similar results. (e) HCT116 cells were co-transfected with a Ub-HA vector and
an siRNA negative control (scramble), or with siRNAs specific for TBP7; treated with 1 mMMG132 for 24 h before harvesting; immunoprecipitated using a goat polyclonal anti-
F1ATPase antibody; subjected to SDS-PAGE; and immunoblotted using mouse monoclonal anti-Ub and goat polyclonal anti-F1ATPase antibodies. Three independent
experiments were performed, with similar results
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in vivo. To this aim, we analyzed our tissue collection of CRCs,
previously characterized for TRAP1 and Sorcin expression by
immunoblot analysis.12 We observed that all CRCs over-
expressing the 18-kDa Sorcin isoform (11/59 cases) shared
the concomitant upregulation of TRAP1. Therefore, we
analyzed for TRAP1, Sorcin, F1ATPase and TBP7 expres-
sion the 11 Sorcin-overexpressing tumors and, as controls,
other 14 CRC specimens. Figure 6 reports the immunoblot
analysis of the four proteins in four tumor samples represen-
tative of our tumor collection, whereas the expression profile
of the four genes in 25 CRCs is reported in Supplementary
Table 1. Remarkably, the majority of the p18 Sorcin- and
TRAP1-positive tumors showed upregulation of TBP7 (9/11
cases) and F1ATPase (8/11 cases). By contrast, among eight
tumors with low expression of TRAP1, all showed low levels of
TBP7 and p18 Sorcin and 7/8 showed low expression of
F1ATPase. w2-Test demonstrated a positive statistical corre-
lation between the expression levels of TRAP1 and those of
Sorcin, F1ATPase and TBP7 (Supplementary Table 1).
Discussion
TRAP1 was identified by our group as one of the proteins
involved in and important for the homeostasis of osteosarco-
ma cells adapted to mild oxidative stress.4 The control of the
protein folding environment in sub-cellular organelles, such as
mitochondria, is important for adaptive homeostasis and may
participate in human diseases, but the regulators of this
process are still largely elusive. During the preparation of this
manuscript, Altieri et al.10 demonstrated that selective
targeting of HSP90 chaperones in mitochondria of human
tumor cells triggered compensatory autophagy, and an
organelle UPR enhanced tumor cell apoptosis initiated by
death receptor ligation, and inhibited tumor growth in mice
without detectable toxicity. These results reveal a novel role of
HSP90 chaperones in the regulation of the protein folding
environment in mitochondria of tumor cells.
Starting from the above observations and in agreement with
Altieri’s results, here we demonstrate an additional role of
TRAP1 in protein quality control, acting on the outside of the
ER. This TRAP1 function requires TBP7, a protein of the 19S
proteasome regulatory subunit. As demonstrated by mass
spectra analysis, this AAA-ATPase is a novel TRAP1-
interacting protein whose role is determinant in the quality
control of proteins. In fact, the interference of either TRAP1 or
TBP7 proteins resulted both in the induction of apoptosis in
response to both TG-induced ER stress or oxaliplatin
treatment, and in increased intracellular protein ubiquitination,
which was selectively rescued by re-addition of TRAP1.
Interestingly, TRAP1/TBP7 regulation of cellular ubiquitina-
tion is independent of modulation of proteasome function, as
an in vitro assay of proteasome activity shows that TRAP1/
TBP7 interference does not affect proteasome functionality.
The regulatory networks that control the protein folding
machinery in mitochondria are still largely elusive. In this
regard, the demonstration that regulation of protein quality
control by TRAP1 is directed toward MITO proteins, expands
the currently rather limited list of MITO proteasome targets.
It is reasonable to hypothesize that multiple chaperone
networks control the misfolding of proteins addressed to
different sub-cellular compartments. In this study, an addi-
tional ‘pre’-screening for proteins directed to mitochondria is
characterized: if the protein is highly damaged and not
successfully refolded by the chaperone machineries inside
or outside the ER, including TRAP1, it will be identified by the
regulatory proteasome protein, and targeted for degradation.
TRAP1-containing supra-molecular complexes might be
present just outside the mitochondria, and in the cellular
compartment of the tight ER–mitochondria interface (Hayashi
and Su25 and Figure 1e), where proteasomes have also been
identified26 and ensure that among all the proteins translated
in the ER, only undamaged proteins could enter the
mitochondria. Very recently, Takemoto et al.11 suggested
that the MITO chaperone TRAP1 regulates the UPR in the
ER, even though its presence in the ER has not been reported.
Therefore, the demonstration that TRAP1 is present also on
the external side of the ER is an important achievement
strongly supporting its role in protection against stress.
A still unsolved question is the mechanistic link between
TRAP1-dependent MITO adaptive response to stress and
regulation of gene expression. Interestingly, some analyses
have demonstrated the importance of 19S ATPases in the
assembly of the transcription machinery.17 Alternatively, it
could be hypothesized that MITO chaperones may regulate
gene expression by modulating ER stress. In support of this
hypothesis, our results suggest that TRAP1may be involved in
the ER stress response. Furthermore, an interaction between
TRAP1 and Sorcin, a calcium-binding protein, was character-
ized by our group,12 which might contribute to a regulatory role
of the TRAP1 and TRAP1-interacting proteins in ER stress
induced by perturbation of calcium homeostasis (Maddalena
et al., unpublished data) and protein quality control.
We did not observe any strong differences in MITO protein
ubiquitination upon modulation of TRAP1 levels. Quality
control of MITO proteins must be monitored by molecular
chaperones.27 Only very small numbers of MITO proteins are
currently known to be degraded in a proteasome-dependent
manner,28 so a more focused effort to identify such additional
substrates might dramatically expand the list of MITO
proteasome targets. Our results demonstrate that expression
of p18 Sorcin and F1-ATPase is decreased upon
TRAP1 interference as a consequence of their increased
TRAP1-positive TRAP1-negative
M
-F1ATPase 51 kDa
-TRAP1 75 kDa
-TBP7 47 kDa
18 kDa-SORCIN
-GAPDH 34 kDa
Case
T M T M T M T
9 12 6 7
Figure 6 TRAP1, TBP7, F1ATPase and Sorcin expression in human CRCs.
Total cell lysates from four human CRCs (T) and the respective non-infiltrated peri-
tumoral mucosas (M) were separated by SDS-PAGE and immunoblotted using
rabbit polyclonal anti-Sorcin, mouse monoclonal anti-TRAP1, mouse monoclonal
anti-TBP7 and goat polyclonal anti-F1ATPase. The same filter was re-probed using
mouse monoclonal anti-GAPDH antibodies for normalization of cell lysates. For
details on case numbers, refer to Supplementary Figure 1
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ubiquitination. The identification of TRAP1/TBP7-specific
‘substrates’ strongly contributes to the complex study of MITO
protein quality control. One reason for ubiquitination of MITO
proteinsmay be that whenmitochondria-destined proteins are
mistargeted or misfolded, they are identified as aberrant and
recognized by the Ub–proteasome system (UPS) for removal.
This may even support a role of the CYTO UPS in controlling
the levels and/or the quality of proteins destined for
mitochondria. In addition, the presence of TRAP1 on the
outer side of ER and the absence of TBP7 in mitochondria
suggest that TRAP1 functions in these latter organelles are
not directly linked to ubiquitination control, whereas this
control is present in a different compartment and requires
interaction with TBP7. In support of this model are results of
transfection experiments using newly generated TRAP1
mutants, either able to interact with TBP7 and localized in
the ER/cytosol fractions (D1–59) or unable to bind to TBP7 but
imported into mitochondria (D101–221). Indeed, only the
MITO import-defective D1–59 mutant, and not the MITO
D101–221 deletion mutant, rescues the strong Ub levels in
sh-TRAP1-interfered cells. These findings provide proof of
concept that protein quality control depends on the CYTO
interaction between TRAP1 and TBP7. Consistent with these
results is the observation that again only the D1–59 TRAP1
mutant rescues the decreased levels of TRAP1-regulated
proteins (Supplementary Figure 3), as well as the levels of
BiP/Grp78 mRNA upon TG-induced ER stress (Figure 4g). All
these observations are in agreement with still unidentified
proteasome members in mitochondria, even though several
proteases, ATPases and Ub ligases have been identified.29
Furthermore, a functional interplay between MITO and
proteasome activity has been demonstrated, thus suggesting
that both systems are interdependent.30
Remarkably, the finding that the proposed TRAP1 network
is conserved in CRCs is consistent with our model and
provides new insights into the quality control/stability/ubiqui-
tination of proteins in human cancer, a still highly debated
issue. Indeed, the proteotoxic stress generated by accumula-
tion of misfolded proteins and the consequent heat-shock
response is currently under evaluation as a potential antic-
ancer treatment target, as many tumor cells show constitutive
proteotoxic stress and dependence on heat-shock response
because of their rapid rates of proliferation and translation.31
Interestingly, bortezomib, a reversible inhibitor of the 26S
proteasome, is at present a valuable option for the first-line
treatment of multiple myeloma.32 Thus, characterization of
TRAP1, a chaperone upregulated in about 60% of human
CRCs,5 as a protein involved in quality control and in
protection against apoptosis in cancer cells provides a strong
rationale for considering this network as a novel molecular
target for treatment of human CRC.
In summary, a new crosstalk between ER andmitochondria
is suggested and summarized in the workingmodel, as shown
in Figure 7. Our study demonstrates for the first time that
TRAP1
nascent
protein
degraded
protein
PROTEASOME
TBP7
UB
UB
UB
UB
UB
UB
ER
BiP
misfolded
protein 
MITOCHONDRION
p18Sorcin
F1ATPase
Figure 7 Crosstalk between ER and mitochondria, and MITO protein quality control. TRAP1 forms a supra-molecular complex with TBP7 on the outside of the ER, in a
cellular compartment of tight ER–mitochondria contact sites, where proteasomes are also present. This TRAP1/TBP7 complex is involved in the control of protein stability and
intracellular protein ubiquitination of mitochondria-destined proteins. These two proteins, each with independent but related functions, help to judge whether a protein can be
repaired and reach the final MITO destination or, if damaged, needs to be degraded through the Ub–proteasome system
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TRAP1 is also present in the ER of cancer cells where it is
involved in the quality control and intracellular protein
ubiquitination of mitochondria-destined proteins, through
direct interaction (as demonstrated by the FRET analysis
shown in Figure 1d) with TBP7, one of the proteins present in
the regulatory proteasome subunit. Thus, a ‘customs office’
could be hypothesized at the ER/mitochondria interface, with
TRAP1 and TBP7 being the officers at this important
checkpoint. These two officers, each with independent but
related functions, help to judge whether a protein can be
repaired and reach its final MITO destination or, if the damage
is too severe, it needs to be degraded.
Materials and Methods
Cell culture, plasmid generation and transfection procedures.
HCT116 cells were cultured in DMEM supplemented with 10% fetal bovine serum
(FBS) under standard conditions. Full-length TRAP1 and Sorcin expression vectors
were obtained as described previously.12
Mutant D1–59-Myc was generated by using the following primers: D1–59-myc,
forward: 50-ATTAGAATTCATGAGCACGCAGACCGCCGAGG-30, reverse: 30-AT-
TACTCGAGGTGTCGCTCCAGGGCCTTGA-50. PCR-amplified fragments were
gel-purified and cloned in-frame into the pcDNA 3.1 plasmid (Invitrogen, San
Giuliano Milanese, Italy) at the EcoRI and XhoI restriction sites.
Mutant D101–221-HA was generated by using the following primers: TRAP1-
HA, forward: 50-attaGCGGCCGCGCAGCCAACATGGCGCGCGAGCCTGCGGG-
30, reverse: 50-attaTCTAGATTAAGCGTAATCTGGAACATCATATGGGTATCAGT
GTCGCTCCAGGGCCTTGA-30; and D101–221-HA, forward: 50-attaCCGCGGT
CGGCAGCCCCGGGGAGCCT-30, reverse: 50-attaCCGCGGAAACACCTCTTTTTC
TGAGT-30. The PCR products obtained with the primers TRAP1-HA forward and
D101–221-HA reverse were cloned in the pRc-CMV vector (Invitrogen); the PCR
product obtained with the primers DATPase-HA forward and TRAP1-HA reverse
was subcloned in the same plasmid. All clones were sequenced to confirm identity
and PCR fidelity. The plasmid pCMV5L/S6 (TBP7-HA) was a gift from Dr Simon
Dawson (University of Nottingham).
Mutant DTBP7-FLAG was generated by excising a fragment from the full-length
TBP7 expression vector by using EcoRI and BamHI restriction endonucleases. The
fragment was gel-purified and cloned into the corresponding sites of the expression
vector p3x-FLAG.
Transient transfection of DNA plasmids was performed with the Polyfect
Transfection reagent (Qiagen, Milan, Italy). siRNAs of TRAP1 and TBP7 were
purchased from Qiagen (cat. no. S100301469 for TBP7 and cat. no. SI00115150 for
TRAP1). For knockdown experiments, siRNAs were diluted to a final concentration
of 20 nmol/l and transfected according to the manufacturer’s protocol. For control
experiments, cells were transfected with a similar amount of scrambled siRNA
(Qiagen; cat. no. SI03650318). Transient transfections of siRNAs were performed
by using the HiPerFect Transfection Reagent (Qiagen). TRAP1-stable interference
was achieved by transfecting HCT116 cells with TRAP1 (TGCTGTTGACAGT
GAGCGACCCGGTCCCTGTACTCAGAAATAGTGAAGCCACAGATGTATTTCTG
AGTACAGGGACCGGGCTGCCTACTGCCTCGGA) or scrambled (sequence con-
taining no homology to known mammalian genes) shRNAs (Open Biosystems,
Huntsville, AL, USA).
Cell extracts, purification and treatments. Total cell lysates were
obtained by homogenization of cell pellets and tumor specimens in cold lysis buffer
(20mM Tris (pH 7.5), containing 300mM sucrose, 60mM KCl, 15mM NaCl, 5% (v/
v) glycerol, 2 mM EDTA, 1% (v/v) Triton X-100, 1 mM PMSF, 2mg/ml aprotinin,
2 mg/ml leupeptin and 0.2% (w/v) deoxycholate) for 1min at 4 1C and further
sonication for 30 s at 4 1C. For ER stress induction, cells were treated overnight with
1mM TG (Sigma-Aldrich, Milan, Italy) before harvesting.
Mitochondria and ER were purified by using the Qproteome Mitochondria
Isolation kit (Qiagen) according to the manufacturer’s protocol and as described
elsewhere.12 Briefly, HCT116 cells were washed and suspended in lysis buffer,
which selectively disrupts the plasma membrane without solubilizing it, resulting in
the isolation of CYTO proteins. Plasma membranes and compartmentalized
organelles, such as nuclei, mitochondria and ER, remained intact and were pelleted
by centrifugation. The resulting pellet was resuspended in disruption buffer,
repeatedly passed through a narrow-gauge needle (to ensure complete cell
disruption) and centrifuged to pellet nuclei, cell debris and unbroken cells. The
supernatant (containing mitochondria and the microsomal fraction) was re-
centrifuged to pellet mitochondria. The resulting supernatant (microsomal fraction)
was treated with proteinase-K for 20min on ice±NP-40 (Igepal; Sigma-Aldrich)
according to Hassink et al.33 or with 0.1 M Na2CO3 (pH 11.3) for 30min to remove
peripheral ER membrane proteins.34
WB analysis and antibodies. Equal amounts of protein from cell lysates
and tumor specimens were subjected to 10% (v/v) SDS-PAGE and transferred to a
PVDF membrane (Millipore, Temecula, CA, USA). The membrane was blocked
with 5% (w/v) skimmed milk and incubated with the primary antibody, followed by
incubation with an HRP-conjugated secondary antibody. Proteins were visualized
with an ECL detection system (GE Healthcare, Waukesha, WI, USA). The following
antibodies from Santa Cruz Biotechnology (Segrate, Italy) were used for WB
analysis and immunoprecipitation: anti-TRAP1 (sc-13557), anti-Sorcin (sc-100859),
anti-TBP7 (sc-166003), anti-cMyc (sc-40), anti-CypD (sc-82570), anti-VDAC1
(sc-8830), anti-HSP60 (sc-1052), anti-Ub (sc-8017), anti-COX4 (sc-58348),
anti-F1ATPase (ATP5B subunit; sc-58619), anti-tubulin (sc-8035), anti-HA
(sc-805) and anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH; sc-
69778). A rabbit polyclonal anti-calnexin antibody (BD Biosciences, Milan, Italy)
was also used.
RNA extraction and semi-quantitative and real-time RT-PCR
analysis. Total RNA from cell pellets and tumor specimens was extracted by
using the TRIzol Reagent (Invitrogen). For first-strand synthesis of cDNA, 3 mg of
RNA were used in a 20-ml reaction mixture by using a cDNA Superscript II
(Invitrogen). For real-time PCR analysis, 1 ml of cDNA sample was amplified by
using the Platinum SYBR Green qPCR Supermix UDG (Invitrogen) in an iCycler iQ
Real-Time Detection System (Bio-Rad Laboratories GmbH, Segrate, Italy). The
following primers were used: BiP/Grp78, forward: 50-CGTGGATGACCCGTCTGTG-
30, reverse: 50-cTGCCGTAGGCTCGTTGATG-30 (PCR product 308 bp); and GA
PDH, forward: 50-CAAGGCTGAGAACGGGAA-30, reverse: 50-GCATCGCCC
CACTTGATTTT-30 (PCR product 90 bp). Primers were designed to be intron-
spanning. The reaction conditions were 50 1C for 2min; 95 1C for 2 min; followed by
45 cycles of 15 s at 95 1C, 30 s at 60 1C and 30 s at 72 1C. GAPDH was chosen as
an internal control.
For semi-quantitative RT-PCR, the RNA obtained by scrambled and sh-TRAP1
HCT116 cells was retro-transcribed and amplified using specific primers for BiP/
Grp78 and GAPDH by using the Superscript III-One STEP kit (Invitrogen),
according to the manufacturer’s instructions. The following primers were used to
amplify the corresponding transcripts: GAPDH, forward: 50-GAAGGTGAAGGTCG
GAGTC-30, reverse 50-GAAGATGGTGATGGGATTTC-30; and BiP/Grp78, forward:
50-CTGGGTACATTTGATCTGACTGG-30, reverse: 50-GCATCCTGGTGGCTTTCC
AGCCATTC-30. The primers for BiP/Grp78 were a gift from Professor P Remondelli
(University of Salerno, Italy).
Apoptosis assay. HCT116 cells were subjected to downregulation of TRAP1
and TBP7 expression by siRNA transfection. Apoptosis was evaluated by
cytofluorimetric analysis of Annexin-V and 7-amino-actinomycin-D (7-AAD)-
positive cells using the fluorescein isothiocyanate (FITC)–Annexin-V/7-AAD kit
(Beckman Coulter, Milan, Italy). Stained cells were analyzed by using the ‘EPICS
XL’ Flow Cytometer (Beckman Coulter). Ten thousand events were collected per
sample. Positive staining for Annexin-V as well as double staining for Annexin-V and
7-AAD were interpreted as signs of, respectively, early and late phases of
apoptosis.35 Experiments were performed three times using three replicates for
each experimental condition.
Immunofluorescence, confocal microscopy and EM analysis.
HCT116 cells were fixed with 0.1 M phosphate buffer containing 4% (w/v)
paraformaldehyde for 15min, then blocked and permeabilized with 5% (w/v) BSA,
0.1% (v/v) Triton X-100, 10% (v/v) FBS in PBS for 20min at RT before staining with
primary antibodies (for TRAP1, CALNEXIN and TBP7) and the corresponding
secondary TEXAS RED/FITC-conjugated antibodies. Immunofluorescence was
analyzed by confocal laser-scanning microscopy using Zeiss 510 LSM (Carl Zeiss
Microimaging, Go¨ttingen, Germany), equipped with an Argon ionic laser (Carl Zeiss
Microimaging) whose wavelength was set up to 488 nm; a He–Ne laser whose
wavelength was set up to 546 nm; and an oil-immersion  63/1.4 f objective. For
immuno-EM analysis, cells were fixed with a mixture of 4% (v/v) paraformaldehyde
and 0.05% (v/v) glutaraldehyde; labeled with a monoclonal antibody against HA by
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using the gold-enhance protocol; embedded in Epon-812; and cut as described
previously.36 EM images were acquired from thin sections by using an FEI Tecnai-
12 electron microscope equipped with an ULTRA VIEW CCD digital camera (FEI,
Eindhoven, The Netherlands). Thin sections were also used for quantification of
gold particles residing within mitochondria by using the AnalySIS software (Soft
Imaging Systems GmbH, Munster, Germany).
FRET experiments. FRET was measured by using the acceptor photo-
bleaching technique,20 where, upon irreversible photo-bleaching, the donor
fluorescence increase was recorded. Cells on coverslips were fixed;
immunostained with specific anti-TBP7 and anti-TRAP1 antibodies, and
secondary antibodies conjugated, respectively, to Cy3 and Cy5; and mounted in
PBS/glycerol (1 : 1). Images were collected using a laser-scanning confocal
microscope (Zeiss LSM 510 Meta) equipped with a planapo  63 oil-immersion
(NA 1.4) objective lens. Laser lines at 543 and 633 nm were used to excite,
respectively, the fluorophores Cy3 and Cy5. For Cy5 bleaching, the 633-nm He–Ne
laser light with 100% output power was used and pinhole diameters were set to
have 1.0-mm optical slices.
FRET measurements were performed by using the LSM software (LSM Zeiss,
Go¨ttingen, Germany) after photo-bleaching of a selected squared ROI of 6mm2. We
calculated the FRET efficiency on the basis of the following equation:
E¼ (Fluorescence intensity of Cy3 after bleachingFluorescence intensity of
Cy3 before bleaching)/Fluorescence intensity of Cy3 after bleaching.20
As control we measured FRET on cells expressing TBP7 alone labeled with Cy3
in order to ensure that photo-bleaching per se does not affect the fluorescence of
the donor and that photo-conversion does not occur during the photo-bleaching
analysis. We calculated the background raised by the photo-bleaching per se by
bleaching Cy5 in cells negative for this fluorophore. The background value was
subtracted from all samples.
Pulse–chase assay. Pulse–chase analysis was performed as described
elsewhere.37 In brief, HCT116 cells were incubated in cysteine/methionine-free
medium (Sigma-Aldrich) for 1 h followed by incubation in cysteine/methionine-free
medium containing 50mCi/ml 35S-labeled cysteine/methionine (GE Healthcare) for
1 h. After labeling, cells were washed once with culture medium containing 10-fold
excess of unlabeled methionine and cysteine (5mM each) and incubated further in
the same medium for the indicated time periods. Cells were collected at the
indicated time points and separated by 10% SDS-PAGE. Proteins were transferred
onto a PVDF membrane (Millipore) and analyzed by autoradiography. The same
filters were then probed by WB analysis.
Patients. Between May 2008 and May 2011, specimens from both tumor
and normal, non-infiltrated peri-tumoral mucosa were obtained from 59 patients
with CRC during surgical removal of the neoplasm. Samples were divided into
125-mm3 pieces; one specimen was fixed in formalin and used for the
histopathological diagnosis, whereas the others were immediately frozen in liquid
nitrogen and stored at 80 1C for immunoblot analysis. Samples were analyzed
within 30 days after collection and were thawed only once. Express written informed
consent to use biological specimens for investigational procedures was obtained
from all patients.
Statistical analysis. w2-Test was used to establish statistical correlation
between the expression levels of TRAP1 and those of Sorcin, F1ATPase and TBP7
in human CRCs. Statistically significant values (Po0.05) are reported under
section Results.
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